

# Role of EDG-like lysophospholipid receptors in the regulation of the vascular tone

PhD Dissertation

**Péter Tibor Dancs, MD**

Semmelweis University  
Doctoral School of Basic and Translational Medicine



Supervisor: Zoltán Benyó, MD, PhD, DSc

Official Reviewers: Balázs Balogh, PharmD, PhD  
József Kaszaki, MD, PhD, Dr. habil.

Head of the Final Examination Committee:  
Miklós Kellermayer, MD, PhD, DSc

Members of the Final Examination Committee:  
Andrea Fekete, MD, PhD  
Csongor Csekő, MD, PhD

Budapest  
2019

## Table of contents

1. List of abbreviations .....	4
2. Introduction .....	9
2.1. Lysophospholipids: nomenclature, molecular structure and natural analogues .	10
2.1.1. Lysophosphatidic acid (LPA) .....	10
2.1.2. Sphingosine 1-phosphate (S1P) .....	12
2.2. Biosynthesis and degradation of lysophospholipids .....	14
2.3. Lysophospholipid receptors .....	27
2.3.1. G protein-coupled lysophospholipid receptors .....	27
2.3.1.1. EDG receptors .....	28
2.3.1.2. Non-EDG family LPA receptors .....	36
2.3.2. Intracellular lysophospholipid targets .....	39
2.3.2.1. Intracellular actions of LPA .....	39
2.3.2.2. Intracellular actions of S1P .....	40
2.4. Roles of lysophospholipids in physiological and pathological responses .....	42
2.4.1. Lysophospholipids in the nervous system.....	42
2.4.1.1. Neural development and function .....	42
2.4.1.2. Role of lysophospholipids in neural pathologies .....	43
2.4.1.2.1. Multiple sclerosis.....	43
2.4.1.2.2. Ischemia.....	44
2.4.1.2.3. Neuropsychiatric disorders .....	44
2.4.1.2.4. Alzheimer’s disease .....	45
2.4.1.2.5. Fetal hydrocephalus .....	45
2.4.1.2.6. Neuropathic pain.....	46
2.4.2. Lysophospholipids in immune function.....	47
2.4.2.1. Lysophospholipids in immune cell trafficking.....	48
2.4.3. Lysophospholipids in the reproductive system .....	49
2.4.3.1. Female reproduction.....	49
2.4.3.2. Male reproduction .....	51
2.4.4. Lysophospholipids in tumor biology .....	51

2.4.4.1. Cell proliferation, tumorigenesis .....	51
2.4.4.2. Metastasis .....	53
2.4.4.3. Resistance against chemo- and radiotherapy.....	54
2.4.5. Lysophospholipids in the cardiovascular system.....	55
2.4.5.1. Vascular development .....	55
2.4.5.2. Atherosclerosis and atherothrombotic events .....	56
2.4.5.3. Cardiac functions.....	60
2.4.5.4. Regulation of the vascular tone .....	61
3. Aims of the study.....	65
4. Materials and Methods .....	66
4.1. Animals .....	66
4.2. Preparation of Vessels .....	66
4.3. Myography.....	67
4.3.1. Protocol for testing vasoactive effects in precontracted vessels .....	67
4.3.2. Protocol for testing vasoactive effects on resting tone.....	68
4.3.3. Protocol for testing the long-term vasoactive effects of S1P.....	68
4.4. Quantification of Vascular Thromboxane A <sub>2</sub> Release.....	68
4.5. Expression Analysis of LPA and S1P Receptors in VSM.....	69
4.6. Reagents.....	70
4.7. Data Analysis .....	70
5. Results .....	71
5.1. Activation of EDG-like LPA receptors induce endothelium-dependent and - independent changes of the vascular tension .....	71
5.2. Identification of the LPA receptor(s) mediating VPC31143-induced vasoconstriction .....	74
5.3. Identification of the signal transduction pathways of LPA <sub>1</sub> -mediated vasoconstriction .....	76
5.4. Vasoactive effects of S1P depend on the presence of other constrictors.....	80
5.5. Identification of the S1P receptors, mediating the potentiating effect of S1P....	82
6. Discussion.....	84
6.1. Role of LPA receptors in the regulation of the vascular tone.....	84
6.2. Role of S1P receptors in the regulation of the vascular tone.....	89
7. Conclusions .....	91

8. Summary.....	92
9. Összefoglalás.....	93
10. References .....	94
11. Publications .....	149
11.1. Publication directly related to this thesis .....	149
11.2. Publications not related to this thesis.....	149
12. Acknowledgement.....	150

## 1. List of abbreviations

1-AGPAT: 1-acylglycerol 3-phosphate acyltransferase

AA: Abdominal aorta

ABC: Adenosine trisphosphate-binding cassette

AC: Adenylyl cyclase

ACh: Acetylcholine

AD: Alzheimer's disease

ATX: Autotaxin

A $\beta$ :  $\beta$ -amyloid

BAEC: Bovine aortic endothelial cell

C1P: Ceramide 1-phosphate

cAMP: cyclic adenosine monophosphate

CCL2: chemokine ligand 2, also known as MCP1: Monocyte chemoattractant protein-1

CIB1: Calcium and integrin-binding protein 1

COX1: Cyclooxygenase-1

COX2: Cyclooxygenase-2

CPA: Cyclic phosphatidic acid

cPLA<sub>2</sub>: Ca<sup>2+</sup>-dependent intracellular phospholipase A<sub>2</sub>

CTRL: Control

DGPP: Diacylglycerol pyrophosphate

DMSO: Dimethyl sulfoxide

DSS: dextran sulfate sodium

ECL: Extracellular loop

EDG: Endothelial differentiation gene

EGF: Epidermal growth factor

eNOS: Endothelial nitric oxide synthase

ENPP: Ectonucleotide pyrophosphatase/phosphodiesterase

ER: Endoplasmic reticulum

ERK1/2: Extracellular signal-regulated kinase 1/2

GPCR: G protein-coupled receptor

GP-PDE/GDE: Glycerophosphodiester phosphodiesterase

HDAC1/2: Histone H3-histone deacetylase 1/2

HDL: High-density lipoprotein

HEV: High endothelial venule

HIF-1: Hypoxia inducible factor 1

hTERT: The human telomerase reverse transcriptase

HUVEC: Human umbilical vein endothelial cell

IBD: Inflammatory bowel disease

ICAM-1: Intercellular adhesion molecule-1

IgE: Immunoglobulin E

IL-1 $\beta$ : Interleukin-1 $\beta$

iPLA<sub>2</sub>: Ca<sup>2+</sup>-independent intracellular phospholipase A<sub>2</sub>

JNK: c-Jun N-terminal kinase

KLF2: Krüppel-like factor 2

KO: Knockout

LDL: Low-density lipoprotein

LFABP: Liver fatty acid binding protein

LPA: Lysophosphatidic acid

LPAAT: Lysophosphatidic acid acyltransferase

LPC: Lysophosphatidyl-choline

LPhoE: Lysophosphatidyl-ethanolamine

LPP: Lipid phosphate phosphohydrolase

Lyso-PLD: Lysophospholipase D

mm-LDL: Minimally modified low density lipoprotein

mox-LDL: Mildly oxidized low density lipoprotein

MS: Multiple sclerosis

nat-LDL: Native low-density lipoprotein

NF- $\kappa$ B: Nuclear factor kappa-light-chain-enhancer of activated B cells

NHERF2:  $N^+/H^+$  exchange regulatory factor 2

NK cell: Natural killer cell

NMDA: N-methyl-D-aspartate

NO: Nitric oxide

NPP: Nucleotide pyrophosphatase/phosphodiesterase

NUC: Nuclease-like domain

PA: Phosphatidic acid

PAR1: Protease-activated receptor 1

PC: Phosphatidyl-choline

PDE: Phosphodiesterase domain

PDGF: Platelet-derived growth factor

PE: Phenylephrine

PECAM-1: Platelet endothelial cell adhesion marker-1

PG: Prostaglandin

PhoE: Phosphatidyl-ethanolamine

PI3K: Phosphoinositide 3-kinase

PKC: Protein kinase C

PLA<sub>1</sub>: Phospholipase A<sub>1</sub>

PLA<sub>2</sub>: Phospholipase A<sub>2</sub>

PLC: Phospholipase C

PLD: Phospholipase D  
PLD<sub>2</sub>: Phospholipase D<sub>2</sub>  
PPAR $\gamma$ : Peroxisome proliferator-activated receptor  $\gamma$   
PS: Phosphatidyl-serine  
PSNL: Partial sciatic nerve ligation  
PTEN: Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase  
PTX: Pertussis toxin  
RA: Rheumatoid arthritis  
RBC: Red blood cell(s)  
RGD: Arg-Gly-Asp integrin binding motif  
ROCK: Rho kinase  
S1P: Sphingosine 1-phosphate  
SC: Schwann cell  
SK1: Sphingosine kinase type 1  
SK2: Sphingosine kinase type 2  
SM: Sphingomyelin  
SMase: Sphingomyelinase  
SMB: Somatomedin B-like domain  
SP: Substance P  
SPC: Sphingosylphosphorylcholine  
SPL: Sphingosine 1-phosphate lyase  
sPLA<sub>2</sub>: Secreted phospholipase A<sub>2</sub>  
SPP: S1P phosphatase  
TA: Thoracic Aorta  
TGF $\beta$ : Transforming growth factor  $\beta$   
TM: Transmembrane region

TNF $\alpha$ : Tumor necrosis factor  $\alpha$

TP: Thromboxane prostanoid receptor

TRAF2: Tumor necrosis factor receptor-associated factor 2

TRIP6: Thyroid receptor-interacting protein 6

TXA<sub>2</sub>: Thromboxane A<sub>2</sub>

TXB<sub>2</sub>: Thromboxane B<sub>2</sub>

VCAM-1: Vascular cell adhesion molecule-1

VLDL: Very low-density lipoprotein

VSM: Vascular smooth muscle

VSMC: Vascular smooth muscle cell(s)

WT: Wild type

## 2. Introduction

The term lysophospholipid includes two lipid families with numerous members: the glycerophospholipids and the sphingolipids (1). The best-characterized representatives of these two groups are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) respectively.

The first LPA-related publication is from 1957, when Vogt isolated a mixture of lipid nature, which elicited contractions in the intestine of rabbits (2). The exact compound and structure remained however undiscovered that time. It was only in 1978, when Akira Tokumura and his group isolated and identified LPA from soybean lecithin, a new lipid mediator that induced hypertension in rats and other species (3, 4). At the beginning of the 1990s, Tigyi and Miledi identified albumin-bound LPA as an endogenous regulator of cellular functions and proposed that its actions are mediated by plasma membrane receptor(s) (5-8).

Since then, the number of reports on LPA increased rapidly. However, the molecular target of LPA actions was unclear until 1996, when Chun and colleagues identified the first G protein-coupled receptor (GPCR) of LPA, LPA<sub>1</sub> (9). Since that time, five other LPA receptors have been described and confirmed (LPA<sub>2-6</sub>). Moreover, an intracellular receptor of the same mediator has also been reported in 2003 (10).

The first studies with S1P date back to the early 1990s as S1P was established a regulator of cell proliferation, growth, and survival (11, 12). Although the first S1P receptor itself was described already in 1990 by Timothy Hla and his group (13), it took eight years for S1P<sub>1</sub> to be de-orphaned and confirmed as an S1P GPCR in 1998 (14, 15). During the past 20 years, four other S1P receptors were reported (S1P<sub>2-5</sub>).

Interestingly, three of the six LPA and all S1P GPCRs belong to the endothelial differentiation gene (EDG) family of receptors, sharing several similarities in structure and function as well. Studies conducted with human umbilical vein endothelial cells (HUVECs) showed, that the transcription of these genes increases upon the administration of phorbol-12-myristate-13-acetate, a compound that induces endothelial differentiation, hence the name EDG. Subsequently, it was revealed, that the structure of the EDG encoded protein shows great similarity to the GPCRs (13).

Following the early reports, the lysophospholipid field developed rapidly. The application of genetically modified animals gave another boost; hence, both LPA and

S1P became well-established mediators in several physiological and pathological processes (16, 17).

Our workgroup has been investigating the vasoactive actions of both mediators since the late 2000s. Interestingly, the literature available on both lipids is contradictory (see chapter 2.4.5.4.). In case of LPA, we described dual vasoactive effects in isolated murine vessels depending on the presence or absence of the endothelium. On the other hand, S1P, that had a nearly negligible impact on the diameter of vessels applied alone, potentiated the effect of other constrictors.

Our aim was to describe these phenomena and to explore, with the aid of pharmacological and genetic methods, which lysophospholipid receptors and downstream signaling pathways mediate these processes.

In the following, after a summary of our present knowledge on lysophospholipids, their receptors and roles in physiology and pathology, I would like to present our results on the vasoactive effects of these mediators with special attention on the GPCRs involved.

## **2.1. Lysophospholipids: nomenclature, molecular structure and natural analogues**

### **2.1.1. Lysophosphatidic acid (LPA)**


LPA (1-O-acyl-2-hydroxy-sn-glycerol-3-phosphate) was first identified as a key component of “Darmstoff”, a smooth muscle stimulating substance in 1957 (2, 18). This simple, small lipid derives from the plasma membrane. LPA consists of a polar phosphate headgroup, a glycerol backbone and a hydrophobic fatty acid tail. Based on the acyl-group, LPA can be divided into saturated (e.g.: 16:0, 18:0) and unsaturated (e.g.: 16:1, 18:1, 18:2, 20:4) molecular species (Figure 1).

Because the acyl chains can bind to the glycerol backbone in either sn-1 or sn-2 position, sn-1 and sn-2 regioisomers can be differentiated respectively. Yet sn-2 isomers have a short half-life in vivo, as a relative rapid acyl-migration occurs towards the sn-1 position resulting in a 9:1 (sn-1:sn-2) equilibrium ratio (19, 20).

Studies around the millennium revealed the existence of alkyl-ether (21, 22) and alkenyl-ether (23) analogues of LPA (Figure 1). These naturally less abundant forms proved to be weaker agonists than LPA on its GPCRs (24, 25) with an exception: LPA<sub>5</sub>

showed marked preference for 1-O-alkyl-glycerophosphate to acyl-LPA of the same chain length (26).

Cyclic phosphatidic acid (1-acyl-sn-glycerol-2,3-cyclic phosphate, CPA) is also a naturally occurring analogue of LPA, present in blood (27), however its origin is still obscure. CPA also acts as a second messenger, inhibiting the peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) (28). CPA is proved to be a weak agonist of LPA GPCRs (25, 26).



**Figure 1.** A few natural analogues of LPA; LPA 18:1: 1-oleoyl lysophosphatidic acid, AGP 18:1: 1-O-octadecyl glycerophosphate, Alkenyl-GP: Alkenyl glycerophosphate, modified after G. Tigyí (16)

LPA is present in human plasma in a low nanomolar concentration, however in serum it increases to the micromolar range (29, 30). The rank order of LPA species in plasma is 18:2>18:1≥18:0>16:0>20:4, whereas in serum 20:4>18:2>16:0≥18:1>18:0 (31). It is of note that LPA composition of the plasma alters with pregnancy. Palmitoyl-LPA (16:0) becomes the dominant species, although total LPA concentration of the plasma remains unaltered (32). Accumulation of this form is attributed to alteration in lysophospholipase D (lyso-PLD) activity, while the unaltered total LPA concentration may be a result of the increased general metabolism during pregnancy (32).

Considering its hydrophobic nature, LPA binds to carrier proteins in biological fluids as well as intracellularly (33). These bindings may clarify the contradiction between the facts, that, although the plasma concentration of LPA exceeds the  $K_d$  of LPA GPCRs, LPA-induced biological actions are lacking under resting conditions (31).


Albumin is the most abundant carrier of LPA in blood plasma, binding up to three mols of LPA per mol protein. It is noteworthy, that albumin also binds lysophosphatidyl-choline (LPC) and lysophosphatidyl-ethanolamine (LPhoE), although on a different binding site than LPA (33). Albumin is the most widespread carrier of LPA used under laboratory conditions.

Gelsolin is a protein, discovered in 1979, that has intracellular and secretory forms as well. It circulates in human and rodent blood in a concentration of  $250\pm 50$  mg/l. Formerly considered an exclusively actin-binding protein, later proved to be able to bind LPA with nanomolar affinity (33). Lind and colleagues proposed a novel, remarkable yet speculative hypothesis about the role of plasma gelsolin in inflammation (34). In site of injury, activated platelets and leukocytes produce LPA while actin is released upon cell lysis. The actin released from dying cells binds to gelsolin, depleting it, which makes possible for LPA to act in free, unbound form on defense and repair. The same group showed that plasma gelsolin levels decrease dramatically in case of critical tissue damage, as in adult respiratory distress syndrome (34).

Aside of gelsolin another intracellular binding molecule of LPA has been identified: liver fatty acid binding protein (LFABP). This protein binds LPA on two distinct sites, on which other lysophospholipids (e.g. LPC, LPhoE and lysophosphatidyl-glycerol) can be bound with micromolar affinity. Intracellular concentrations of LFABP range from 0.2 to 0.4 mM. Besides hepatocytes and intestinal cells, LFABP is also expressed in the cells of proximal tubules, where it is assumed to play a role in the reabsorption of lysophospholipids (33).

### **2.1.2. Sphingosine 1-phosphate (S1P)**

The first reports of S1P were published in the early 1990s, proposing a role in intracellular calcium mobilization and cell proliferation (12) in cell growth regulation (11) and apoptosis inhibition (35). In contrast to LPA, S1P depicts a single molecular species (2S-amino-1-(dihydrogen phosphate)-4E-octadecene-1,3R-diol, Figure 2). S1P forms a zwitterionic structure at physiological pH, because the amine group of the terminal serine of the sphingosine base is basic at this pH, whilst the terminal esterified phosphate group bears negative charge. Besides this zwitterionic head group, S1P, similarly to LPA, has a long hydrophobic, aliphatic chain at the other side of the sphingosine base (36).



**Figure 2.** Structure of sphingosine 1-phosphate, its precursor sphingosine and its analogue FTY720-phosphate (Fingolimod-phosphate) (37)

Measured with multiple types of individually developed methods, S1P concentrations are estimated to range between 200-400 nM and 500-900 nM in plasma and serum respectively (38-41). Being a lipid with a considerably large hydrophobic tail, S1P traffic in plasma also requires binding molecules. For a long time albumin was postulated to be the sole carrier of S1P, till it has been revealed, that S1P binds predominantly to lipoproteins in a rank order of high-density lipoprotein (HDL) > low-density lipoprotein (LDL) > very low-density lipoprotein (VLDL) > lipoprotein-deficient plasma (mainly albumin) (42, 43). Other sources consider the amount of S1P bound to LDL and VLDL negligible (44). For a half decade, it remained enigmatic, which of the several components of HDL binds S1P, until in 2011 Christoffersen and colleagues reported it to be apolipoprotein M that binds approximately 65% of plasma S1P (45). HDL is not only a simple carrier of S1P, moreover it seems that HDL, which binds approximately 100-200 pmol/mg S1P (42), and S1P form a functional unit with distinct functions and signaling (42, 46, 47). Firstly, the  $K_{d}$ s of S1P for S1P GPCRs are within the 2 to 30 nM range (14, 48), which is markedly lower, than S1P concentrations found in plasma and serum. Based on these facts, it has been suggested that, HDL-binding might prevent full S1P GPCR activation and acts in a protective manner (42, 49). On the other hand, HDL-bound S1P has been reported to have four times longer half-life than that bound to albumin (42, 50), suggesting a protective role for HDL against ectoenzymes degrading S1P (49).

Later it has been revealed, that S1P is at least partly responsible for the anti-atherogenic, and cytoprotective features of HDL (42, 46). S1P inhibits cell migration in rat vascular smooth muscle cells (VSMC) via S1P<sub>2</sub> (51), moreover, HDL-bound S1P

exerts more sustained S1P<sub>1</sub> agonism, than the albumin-bound form, decreasing tumor necrosis factor  $\alpha$  (TNF $\alpha$ )-induced nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B) and intercellular adhesion molecule-1 expression (52). This type of agonism of S1P<sub>1</sub> might involve other structures, which facilitate the docking and entrapment of HDL-bound S1P and prevent endocytosis. However, this aspect of the S1P area requires further investigations, as the role of scavenger receptor class B type 1 occurred in the docking process (53). Besides, the fact, that oxidation of LDL, which is well-known to promote pro-atherogenic features of this particle, decreases the S1P- and reciprocally, elevates the LPC content of LDL, is also in favor of the anti-atherogenic role of S1P (50).

## **2.2. Biosynthesis and degradation of lysophospholipids**

Although both mediators can be synthesized intra- as well as extracellularly the significance of the two sites differs in case of each lipid. While the bulk of S1P is produced intracellularly, with negligible extracellular production, the majority of plasma LPA is formed extracellularly (54-57).

Intracellularly, in mitochondria and microsomes, LPA is an intermediate of phospholipid synthesis, thus it is a product of glycerophosphate acyl transferase, which esterifies glycerol 3-phosphate with acyl-CoA or that of monoacyl-glycerol kinase as well (33).

Extracellular LPA is a result of three stimulus-coupled synthetic pathways (33). In spite of the recent advances in the field of lysophospholipid metabolism, regulation and the amount of contribution to extracellular LPA levels of each pathway are still questions to be resolved (Figure 3).

LPA can be generated from phosphatidic acid (PA) by the action of numerous enzymes. Although PA is a natural component of biological membranes, it can be a product of the cleavage of other phospholipid precursors, such as phosphatidyl-choline (PC), phosphatidyl-ethanolamine (PhoE) or phosphatidyl-serine (PS) by phospholipase D (PLD). Formation of LPA from PA is catalyzed by phospholipase A<sub>1</sub> (PLA<sub>1</sub>) or phospholipase A<sub>2</sub> (PLA<sub>2</sub>) (58, 59). PA specific variants of these two enzymes have been described in human (31, 60, 61), porcine (62) and horse (63) thrombocytes. Depending on the cleaving enzyme, sn-1 and sn-2 regioisomers are produced by PLA<sub>2</sub> and PLA<sub>1</sub> respectively. The ratio of the isomers is approximately constant (19, 20). PLA<sub>2</sub> has



modified LDL (mm-LDL) treatment of human platelets resulted in shape-change, which proved to be mediated by LPA, was however absent in case of the native, unoxidized form (nat-LDL). Analysis of the lipid composition of nat-, mox- and mm-LDL revealed the presence of LPA in the mox- and mm- forms but not in nat-LDL. Thus, LPA generation occurs during oxidation of LDL in a  $\text{Cu}^{2+}$ -dependent manner and LPA is the main prothrombotic mediator in mox-LDL (67, 68). Besides, the LPA generated in this process can also influence the LDL uptake of atherosclerotic plaques via PPAR $\gamma$  activation (33).

Tokumura and colleagues raised first the possibility of LPA generation through lyso-PLD activity in rat plasma in the 1980s (69), which also gained confirmation in rabbit (70) and human (31, 71). The responsible enzyme remained enigmatic until the early 2000s, when two groups independently reported it to be autotaxin (ATX) (72, 73).

ATX was first identified as an autocrine motility factor in human A2058 melanoma cells, which stimulated motility in numerous tumor cell lines in a pertussis toxin (PTX)-dependent manner (74, 75). Besides that, high expression of ATX was found in neuroblastoma, hepatocellular carcinoma, breast cancer, renal cell carcinoma, glioblastoma, non-small cell lung cancer, B cell lymphoma, and thyroid carcinoma cells (75). ATX expression proved to be regulated diversely depending on cell lines. Studies imply the role of epidermal growth factor (EGF), basic fibroblast growth factor, transforming growth factor beta (TGF $\beta$ ), v-Jun,  $\beta$ -catenin, Wnt-1,  $\alpha_6\beta_4$  integrin, and Epstein-Barr virus infection in this process (76-82).


The crucial role of ATX in mammals is well emphasized by the fact, that mice deficient in ATX die around embryonic day 9.5 due to fatal vascular defects in embryo proper and yolk sack (83). This phenotype is interestingly recapitulated by  $\text{G}\alpha_{13}$  knockout (KO) mice (84-86). ATX KO embryos also showed severe deficiency in neural tube formation and closure (83). Absence in expression of hypoxia inducible factor 1 (HIF-1) and its positive regulator Akt proved to have a role of high significance in neural tube malformations (75). It is of note, that ATX null embryos have abnormal lysosome formation in the visceral endoderm cells of the yolk sack (87). Morpholino oligonucleotide studies in zebrafish revealed a direct role of ATX in the formation of left-right asymmetry (88).

Since ATX heterozygous mice show 50% plasma LPA levels of that in wild types (WT), it has been established, that the bulk of LPA in biological fluids originates from ATX-mediated production (83). Multiple types of precursor lysophospholipids (LPC, LPhoE, LPS), of which LPC is the most abundant, can serve as substrate to ATX, which cleaves the phosphate group, thus forms LPA.

ATX has been identified as a member of the mammalian ectonucleotide pyrophosphatase/phosphodiesterase family (ENPPs or NPPs), which includes seven enzymes designated ENPP 1-7. All members of the family are capable of pyrophosphate bond hydrolysis, while ATX is unique by also having a lyso-PLD activity (72, 73, 89).

ATX is a rigid, multidomain structure glycoprotein of 125 kDa, consisting of five domains (89) (Figure 4). It includes two N-terminal somatomedin B-like (SMB1 and SMB2) domains, a central phosphodiesterase (PDE) domain, a lasso-loop domain, and a C-terminal nuclease-like (NUC) domain. Protein-protein interaction among the SMB domains and the PDE domain, an N-linked glycan and an interdomain disulfide bridge between the PDE and NUC domains, furthermore the fact, that the lasso-loop wraps tightly around the NUC domain maintain a high structural rigidity for the catalytic PDE domain (90, 91). Similarly to the other members of the family ATX has a conserved amino acid residue at Thr<sup>210</sup> as the substrate binding site and two proximal Zn<sup>2+</sup> ions contribute to the lytic activity (91). Unlike any other ENPP, ATX has a deep, hydrophobic lipid binding pocket of 15 Å, situated inside the catalytic domain (91). This pocket is suitable for the acceptance of mono- but not of diacyl phospholipids (91). Later on, it turned out, that the lack of a 18 amino acid sequence made the formation of this pocket possible, which is absent in every other ENPP (90, 91). Conversely, insertion of this sequence did not alter the pyrophosphatase activity of ATX but significantly alleviated its LPC hydrolysis (91). It is noteworthy, that ENPP 6 hydrolyses LPC to LPA, while having the 18 amino acid sequence, although it is possible that LPC binds to ENPP6 in a different orientation (89). ATX has one other feature, missing in other ENPPs, is having a tunnel close to the catalytic domain, which forms a so-called T-junction with the substrate binding pocket to which SMB1 also contributes (90, 91). The function of this tunnel is still ambiguous. A remarkable hypothesis suggests that it could be an exit-site for LPA generated by ATX, releasing its product directly to its cognate receptors on the cell surface (91). In support of this

hypothesis, ATX has a relatively flat surface around the opening of the tunnel which can attach to biological membranes (89). In spite of this appealing hypothesis, the idea of this tunnel being an entry-site for the substrate LPC has also been suggested (89). Further investigations are required to clarify the role of this unique structure.



**Figure 4.** Autotaxin, a: Domains of ATX, b: Crystal structure of ATX while binding LPC, c: Schematic presentation of the active site, the hydrophobic pocket and the tunnel, d: Spherical model of ATX binding LPC; modified after W. H. Moolenaar and A. Perrakis


ATX is known to bind to activated platelets through  $\beta_3$  integrin receptors (54). This interaction is attributed to the SMB domains, especially to SMB2, which although involves the canonical integrin binding motif (Arg-Gly-Asp (RGD)), it seems, ATX binds  $\beta_3$  integrins at a distinct site (90). Besides, ATX binds to chemokine-activated lymphocytes via  $\alpha_4\beta_1$  integrin (92). The detailed properties of this attachment is still elusive, however the PDE domain contains a canonical  $\alpha_4\beta_1$  binding motif (Leu-Asp-Val). Considering the fact, that integrins are not only sole binding molecules but can promote intracellular signaling pathways, it is a conceivable assumption that ATX could mediate LPA-independent effects through integrins (89). Purification of ATX with heparin column chromatography revealed that ATX is able to bind heparin and heparan sulfate (89, 93), allowing this versatile enzyme to have further interactions with the cell surface and the components of the extracellular matrix.

Regulation of ATX activity is a field still flooded with questions. In vitro assays show ATX a relatively slow enzyme, which does not correlate to the rapid changes of LPA levels in biological fluids (89).  $\beta_3$  integrin interactions emerged as potent regulators, as overexpression of this kind of integrin in Chinese hamster ovary cells resulted in markedly increased LPA production (89). Feedback regulation of ATX is also present in vitro by LPA and S1P (89), however this possibility seems to play a minor role in vivo (58).

Unlike to that of LPA, generation of S1P cannot be taken out of context, and should be described together with the production of other sphingolipids (Figure 5). De novo synthesis of sphingolipids occurs in the endoplasmic reticulum (ER), where ceramide is formed via multiple reactions with a rate-limiting step catalyzed by serine palmitoyltransferase (94). Ceramide can be phosphorylated by ceramide kinases to ceramide 1-phosphate (C1P) or can be converted to sphingosine by ceramidase. Sphingosine is the direct precursor of S1P. The reaction is catalyzed by two kinases called sphingosine kinase type 1 and 2 (SK1 and SK2 respectively), which are discussed below in detail. Conversely, ceramide can be formed from membrane sphingomyelin (SM) by sphingomyelinases (SMases), while sphingomyelin synthase catalyzes the inverted reaction. Ceramide can also be transformed to complex glycosphingolipids, which are highly abundant in biological membranes. As seen above, S1P synthesis can

start either de novo or form membrane lipids and since nearly every reaction is reversible structural and mediator sphingolipids can rapidly transform to each other.

It is of interest, while S1P and C1P elicit primarily mitogenic effects (95, 96), ceramide and sphingoid bases have mostly pro-apoptotic impacts (97), making the regulation of their balance fundamental in view of the cell life-cycle. The entire network of these thoroughly regulated processes is described in literature as the “sphingolipid rheostat” (Figure 5).



**Figure 5.** Sphingolipid biosynthetic and degradation pathways after Pitson (98)

SK1 and SK2 are the two enzyme isoforms that catalyze the formation of S1P from its direct precursor sphingosine. Although, the two isoforms have overlapping functions, and each can compensate the absence of the other, highlighted by reports of mice deficient in either of the two enzymes display no obvious phenotypical alteration (99-101), SK1/SK2 double KO mice die in utero due to severe disruption in angiogenesis, neurogenesis and neural tube closure (101).

Both SKs have splice variants. SK1 has three of them (named SK1a, -b and -c), which differ at their N-termini. SK1b has an additional 14 amino acid residue in comparison with SK1a, one of which is a cysteine, a putative palmytoilation site, which might give an explanation to its constitutive localization to the plasma membrane. The role of SK1c, which has an 86 amino-acid long additional residue at its N terminus, requires further investigation (57, 102). SK2 has two confirmed splice isoforms (SK2a and -b), of which SK2b possesses an additional 36 amino acid-long residue and shows higher abundance in a broad range of human tissues. The existence if a third SK2 splice variant is reported, however awaits further confirmation (57, 103, 104). It is of note, that SK2 contains a 116 amino acid-long insert in its central part, close to the sphingosine binding site, which alteration might explain the wider spectrum of artificial substrates utilized by this enzyme (105).

Despite of their importance in sphingolipid metabolism, crystal structure of both SKs have not been clarified yet, our knowledge of their structure, motifs and residues are based on homology studies with other lipid kinases, mainly diacylglycerol kinases and ceramide kinase. SKs cloned from different species contain five conserved regions (named C1-C5), which seem to be of grave importance in substrate binding and catalysis (106). Inhibitor and homology studies revealed multiple motifs in C1-C3, that are critical for nucleotide binding, whilst C5 is assumed to be involved in the catalysis of the nucleotide transfer (98). Since C4 is not conserved in diacylglycerol kinases and ceramide kinase, it appears to have a role in sphingosine binding (107, 108). Investigation with the selective SK1 inhibitor PF-543 clarified the sphingosine binding hydrophobic site, named “J-tunnel” due to its shape, which shows only slight differences in SK2 (47). More in-depth reviews on the structure of SKs are available (47, 98).

Albeit the two SKs catalyze the same reaction, they exhibit considerable differences in subcellular localization and regulation by external stimuli. SK1 normally localizes in the cytoplasm. Cytokine or growth factor mediated activation of the extracellular signal-regulated kinase 1 and 2 (ERK 1 and 2 respectively) results in phosphorylation at Ser226, activation and relocalization of SK1 to the plasma membrane (109). Translocation of SK1 occurs via interactions with the calcium and integrin-binding protein 1 (CIB1), which reaches out to SK1 in a calcium-dependent manner at a site

previously assumed to bind calmodulin (110, 111). Notwithstanding the active translocation of SK1 is CIB1-dependent, its retention is mediated by the interaction with plasma membrane phospholipids PS and PA (98). S1P produced by membrane-bound, activated SK1 either can be exported to the extracellular space, where it can bind to S1P GPCRs, or activates intracellular targets, such as tumor necrosis factor receptor-associated factor 2 (TRAF2) and thus activates NF- $\kappa$ B, exerting pro-survival signals (112). In most cases, ERK-mediated activation of SK1 is transient, as protein phosphatase 2A dephosphorylates SK1 at phospho-Ser225 (113). Several agonists have been associated with SK1 translocation including platelet-derived growth factor (PDGF) (114), nerve growth factor (115), insulin-like growth factor (116), TNF $\alpha$  (109), immunoglobulin E (IgE) (117), LPA (118), and phorbol-esters (109, 119). Besides, numerous protein-protein interactions have been revealed which regulate SK1 activity.  $\delta$ -catenin (120), Lyn kinase (121), Fyn kinase (122), and eukaryotic elongation factor 1A (123) have been reported to activate, while SK-interacting protein (124), aminoacylase 1 (125), platelet endothelial cell adhesion marker-1 (PECAM-1) (126), and four-and-a-half LIM only protein-2 (127, 128) inhibit it.

SK2 activity is also rapidly increased by several agonists, such as TNF $\alpha$  (129), interleukin-1 $\beta$  (IL-1 $\beta$ ) (129), EGF (130), and Fc $\epsilon$ RI cross-linking (122). Although the SK1 ERK regulatory site Ser225 is not conserved in SK2, it seems, that ERK1/2-mediated phosphorylation has an activator effect on SK2, however the putative site of this action is either Ser351 or Thr578 or both (131).

SK2 is generally most abundant in cytoplasm and the nucleus, though serum starvation and protein kinase C (PKC) activation are reported to facilitate its relocalization to the ER (132, 133). Molecular mechanism of this transport is still obscure; however, the N-terminus of the kinase appears to have a role in it (134). S1P produced by ER-bound SK2 is rapidly transformed to ceramide due to the high abundance of the degrading enzyme S1P phosphatase and ceramide synthase in ER (132, 135, 136).

SK2 contains nuclear localization and export signals regulating its translocation into and out of the nucleus, of which the latter is activated by protein kinase D-dependent phosphorylation at either Ser383 or Ser 385 (133, 135).

It is of note, that SK2 has been reported to induce apoptosis in an S1P-independent manner. SK2 contains a BH3 domain, which may be involved in interaction with B-cell lymphoma-extra large, release of cytochrome c and caspase-3 activation (137).

As seen before, regulation of SK2 is quite complex, and albeit a considerable knowledge is already available, the bulk of the work of deciphering involved processes remains to be done. This is well emphasized by the findings, where phosphoproteome analysis of cultured HeLa cells and murine liver tissue conceded at least five new phosphorylation sites on SK2 (Ser351, Ser363, Ser368, Ser378 and Ser448) of yet elusive function and significance (138-140).

As both types of SK localize intracellularly, the bulk of S1P is also produced there, however more and more studies indicate, that SKs can be released to the extracellular environment (141). Constitutive (57, 142) as well as heat stress- (143) and oxidized LDL immune complex-induced (144) secretion of SK1 has been reported. On the other hand, caspase-cleaved forms of SK2 are released from several types of cells during apoptosis (145). Besides, ATX-mediated cleavage of sphingosylphosphorylcholine (SPC) has been described (146), which thus leads to extracellular S1P generation, however the amount of S1P produced this way is limited due to low plasma SPC concentrations (147).

Although S1P is present in plasma at high nanomolar concentrations (38-41), S1P levels are extremely low in most tissues, what generates an *in vivo* S1P gradient between plasma and tissues (148). For a long period, platelets were proposed to be the major source of plasma S1P. S1P is stored in these blood constituents in large amounts (38, 149), which is also supported by the fact, that thrombocytes are devoid one of the major S1P degrading enzyme S1P lyase (SPL) (149, 150). Furthermore, upon stimulation by thrombin (151), or shear stress (152), platelets release S1P in a PKC dependent manner (149, 151). In contrast with this, mice deficient in nuclear factor erythroid 2, a major transcriptional regulator in megakaryocyte development and platelet production (153), had normal plasma S1P levels, however had virtually no circulating thrombocytes (154). Pappu and colleagues demonstrated in 2007, that plasma (but not lymph) S1P predominantly derives from hematopoietic sources, primarily from red blood cells (RBCs) (154). Consistently with this, RBCs are reported to lack all intracellular S1P metabolizing enzymes, which allows the storage of S1P in

high concentrations (155). According circulating hypotheses, RBCs may release S1P on a constant basis, producing a basal S1P level, whereas platelets do it in an activation-dependent manner, generating high S1P concentrations in the local environment (49). Thereafter, studies revealed that every cell is capable of S1P production by sphingomyelin metabolism (156), and that endothelial cells also contribute significantly to plasma S1P levels (157).

Since plasma S1P is primarily produced intracellularly and is impermeable to the plasma membrane due to its polar head, S1P requires transporters to be able to act in the extracellular environment. Numerous members of the adenosine triphosphate-binding cassette (ABC)-type transporter family have been proposed to be responsible for S1P release, including ABCC1 (158), ABCA1 (159), ABCG1 (160) and ABCA7 (161, 162). Despite supportive pharmacological results, these findings gained no confirmation in *in vivo* studies (163). Interestingly, Spinster2 (Spns2) was identified in zebrafish, was shown to be a transporter of S1P and analogue Fingolimod (FTY720). Thus far, it is the only S1P transporter molecule, which was confirmed *in vitro* as well as *in vivo* (164, 165).

Similarly to its synthesis, degradation of LPA can occur in three distinct pathways (33). Dephosphorylation of LPA by phosphatases leads to monoacyl-glycerol, while removal of the fatty acid chain by lysophospholipases results in the formation of glycerol 3-phosphate. LPA can be converted to PA by acyltransferases.

Phosphate headgroup of LPA can be hydrolyzed by lipid phosphate phosphohydrolases (LPPs) of which three isoforms have been described: LPP1 and its splice variant LPP1a, LPP2 and LPP3 (166). Since the crystal structure of LPPs has not been yet clarified, our information on its orientation, structure, and mechanism of action lay predominantly on the analysis of related enzymes chloroperoxidase and phosphatidyl-glycerophosphate phosphatase B from *Escherichia coli*. All members of the LPP family are integral membrane proteins with six transmembrane regions. Both the amino- and carboxy-termini are located intracellularly, whilst the three conserved catalytic domains face the extracellular space. Two of the three catalytic domains (C1 and C2) can be found in the second extracellular loop, while the remaining one (C3) on the third. C1 contributes to substrate recognition, at the same time the other two mediate the phosphotransferase reaction (33, 166). Although functional as monomers, LPPs tend

to form homo- and heterooligomers (166). Nevertheless, LPP1 hypomorph mice exhibit increased concentration and elongated half-life of plasma LPA, overexpression of the same enzyme did not alter LPA levels (166). LPP3 also binds to integrins, but in contrast with ATX, on its RGD motif. The integrins recognized by LPP3 are  $\alpha_v\beta_3$  and  $\alpha_5\beta_1$  (166). Consistently with this, LPP1, which lacks RGD, showed no ability to integrin binding (166). Transgenic mice and in vitro studies indicate a significant role for LPPs in physiological and pathological functions as vascular development and permeability regulation, fur and hair growth, cell cycle modulation, and fertility (166, 167). Considering the actions of ATX in tumor biology, lower expressions of LPPs could be expected in various tumors. In accordance with that, LPP1 and LPP3 expressions are considerably reduced in breast, lung, and ovarian cancer. In contrast, LPP2 showed elevated expression in these types of tumors (166). A feasible explanation to that could be the role of LPP2 in cell cycle regulation, i.e. LPP2 facilitates premature S-phase entry thus enhances tumor growth (166).

LPA is hydrolyzed to glycerol 3-phosphate by lysophospholipases, of which LPA specific species has been isolated from rat brain (168).

The third pathway of LPA degradation is PA synthesis by acyl-transferases. These proteins belong to the 1-acylglycerol 3-phosphate acyltransferase (1-AGPAT) or lysophosphatidic acid acyltransferase (LPAAT) family of five isoenzymes, labeled LPAAT $\alpha$ - $\epsilon$  or 1-AGPAT 1-5 (33). Based on the facts, that LPAAT $\alpha$  and LPAAT $\beta$  have the highest catalytic activity, and LPAAT $\alpha$  favors LPA as acyl acceptor the most, these two enzymes assumed to be responsible for the bulk of the intracellular LPA degrading process (33).

Metabolism of the alkyl-, alkenyl- and cyclic analogues of LPA is still poorly understood. A serine hydrolase, KIAA1363 (169) and diacylglycerol kinases (170) assumed to be involved in intracellular alkyl-LPA generation. CPA is synthesized in mammalian cells by phospholipase D2 (PLD2) (28) or ATX (16). However, the in vivo relevance of the latter is disputed (16). It is of note, that two recently discovered members of the glycerophosphodiester phosphodiesterase family (GP-PDEs or GDEs), GDE4 and GDE7 cleave 1-O-alkyl-sn-glycero-3-phosphocholine and LPC, thus generate alkyl- and acyl forms of LPA, respectively (171).

Extracellular degradation of S1P is also catalyzed by LPPs, which are discussed in detail in context with LPA. This reaction leads to dephosphorylation of S1P. Since LPPs act extracellularly, they have the most direct influence on plasma S1P levels and thus S1P signaling on GPCRs among S1P metabolizing pathways (166).

Intracellular dephosphorylation of S1P is mediated by S1P phosphatases (SPPs). SPP1 and SPP2 are sphingoid base-specific phosphatases located in the ER. SPP2 is expressed in embryonic mouse kidney, where it mediates S1P levels along with SKs, thus influences kidney development. SPP1 is proposed to have a role in formation of ceramide and other sphingolipids in the ER. Since SPP1 is located intracellularly, extracellular S1P requires transporters to reach the enzyme. ABC-type transporters are assumed to serve this function (56).

S1P can be irreversibly metabolized by the intracellular enzyme SPL (56). During the reaction, the sphingoid base is cleaved at position C2,3, resulting in formation of heaxadecenal and ethanolamine phosphate, which products can enter further lipid synthetic processes. Even though SPL is a ubiquitously expressed enzyme, there are reports of its role in ischemia, radiation and chemical injury of tissues (56). Besides, SPL has been shown to be regulated by PDGF signaling (56).

It is of note, that mice deficient in SPL die around weaning age, exhibiting anemia, myeloid cell hyperplasia, and pathological abnormalities of the lung, heart, urinary tract, and bone (56). Accumulation of long chain bases and ceramide in neurons and vital organs as well as cytotoxic concentrations of S1P may be involved in these phenotypic alterations. Moreover, high plasma triglyceride levels and absence of adipose tissue found in SPL KO mice surmise abruptions in global lipid metabolism (56). This is supported by reports, describing SPL product ethanolamine phosphate being essential for functioning of sterol regulatory element-binding proteins and that SPL KO mice showed changes in expression of PPAR $\gamma$  target genes, which contribute to general lipid metabolism (56).

As seen above, multiple pathways are involved in either synthesis or degradation of lysophospholipids; however, these processes are well organized and strictly regulated, through which the concentration of these mediators remains in a narrow range under physiological circumstances.

### 2.3. Lysophospholipid receptors


Both LPA and S1P have extracellular as well as intracellular targets (16, 56). Although, LPA after its discovery quickly emerged as an extracellular bioactive lysophospholipid, its mechanisms of action remained elusive. Several early hypotheses and theories emerged regarding these mechanisms including membrane perturbation (172), calcium chelation (173), and signal transductional pathways involving intracellular- and plasma membrane receptors (174-176). The cloning and identification of the first LPA GPCR in 1996 set a new era in the lysophospholipid field (9). During the past two decades, since the recognition of LPA<sub>1</sub>, five other LPA receptors have been reported (LPA<sub>2-6</sub>); moreover intracellular targets of LPA also have been confirmed (10). In contrast, S1P was already an established intracellular mediator, regulating cell growth (11) and suppressing apoptosis (35), when it has been demonstrated that S1P acts on cell surface receptors (S1P<sub>1-5</sub>). All of these receptors are rhodopsin-like GPCR with seven transmembrane regions (TMs).

#### 2.3.1. G protein-coupled lysophospholipid receptors

Extracellularly LPA can bind to six (LPA<sub>1-6</sub>), whilst S1P to five (S1P<sub>1-5</sub>) subtypes of GPCRs, specific to the corresponding mediator. Recently, new types lysophospholipid receptors have been reported attributed to lysophosphatidyl-inositol (LPI<sub>1</sub>) and lysophosphatidyl-serine (LysoPS<sub>1-3</sub>) (177). However, this thesis focuses only on LPA and S1P GPCR, thus those other receptors will not be discussed here. Three of the six LPA receptors (LPA<sub>1-3</sub>) and all reported S1P GPCRs belong to the EDG family, while the remaining three LPA receptors (LPA<sub>4-6</sub>) are part of the P2Y purinergic cluster (16, 56, 178). The LPA and S1P GPCRs with their respective signal transduction are depicted in figure 6 and 7, respectively.

During the last five years the crystal structures of three lysophospholipid receptors were solved (S1P<sub>1</sub>, LPA<sub>1</sub> and LPA<sub>6</sub>) (179-181), which provided new aspects to our former knowledge of ligand binding and structure-activity properties of these receptors, based on homology studies primarily with rhodopsin and  $\beta$ -adrenergic receptors (182-184). Description of the crystal structure of the first lysophospholipid receptor S1P<sub>1</sub> also gave a boost to homology studies (179), as S1P<sub>1</sub> shared a greater homology with the other EDG-like receptors as rhodopsin or the  $\beta$  receptors, which made possible to

analyze the receptor-agonist/antagonist interaction of the remaining LPA and S1P GPCRs more precisely (185). Although these former experiments lead to the recognition of multiple interactions between receptor and ligand, they have limitations, and thus results gained this way are to be treated with cautiousness (G. Tigyi personal communication).



**Figure 6.** The six confirmed GPCRs of LPA and the signaling pathways they activate; ROCK: Rho kinase, SRF: Serum response factor, PLC: Phospholipase C, IP<sub>3</sub>: Inositol trisphosphate, DAG: Diacylglycerol, PKC: Protein kinase C, MAPK: Mitogen-activated protein kinase, PI3K: Phosphoinositide 3-kinase, AC: Adenylyl cyclase, cAMP: Cyclic adenosine monophosphate; after H. Mirendil, M. E. Lin und J. Chun (186)

### 2.3.1.1. EDG receptors

S1P<sub>1</sub> (formerly EDG1) was the first recognized member of the EDG family by Hla and colleagues in 1990, though at this time unaware of S1P being its cognate ligand, thus being an S1P receptor (13). Hecht and colleagues described LPA<sub>1</sub> (EDG2) as the first lysophospholipid receptor in 1996 (9). Since these early discoveries, all eight members of the EDG gene cluster have been reported and validated to be a receptor specific to either LPA or S1P.

In case of EDG family LPA receptors, three key interactions of ligand binding have been revealed. Cationic amino acids (Arg and Lys) of TM3 and TM7 form ion-pairs with the phosphate group of LPA, while a Gln of TM3 establishes a hydrogen bond with the sn-2 hydroxyl group (33, 183). Further experiments deciphered, that the Arg residue of TM3 is conserved in the whole EDG family and also required for S1P binding of S1P receptors. Based on more in depth investigations of S1P<sub>1</sub>, S1P binding also depends on three amino acid residues; two Arginines, which make an ion-pair with the phosphate group and a Glu of TM3, which corresponds the aforementioned Gln in LPA receptors, and interacts the ammonium moiety of S1P (182). Wang and colleagues reported that the Gln/Glu residue in TM3 determines LPA/S1P specificity respectively. In a range of single-mutation experiments, they showed, if the Gln in LPA<sub>1</sub> is mutated to Glu, LPA<sub>1</sub> is able to bind S1P, on the other hand if Glu of S1P<sub>1</sub> is shifted to Gln, S1P<sub>1</sub> binds only LPA and unable to be activated by its own ligand S1P (183). The defined crystal structures of LPA<sub>1</sub> and S1P<sub>1</sub> also highlighted some intriguing details of ligand docking abilities of both receptors. While the extracellular loops (ECLs) and TMs of LPA<sub>1</sub> are organized in a way that LPA<sub>1</sub> accepts ligands from the extracellular space, in case of S1P<sub>1</sub> the N-terminal with ECL1 and ECL2 forms a cap, which appears to block the entry of ligands, approaching this way. On the other hand, TM1 and TM2 are closer to TM3 than in other GPCRs, which leaves a gap between TM1 and TM7 making it possible for ligands to enter laterally from the outer leaflet of the plasma membrane (179, 180).

**LPA<sub>1</sub>** (EDG2) is the first identified (9) and most thoroughly studied lysophospholipid receptor. In mammalian cells the LPAR1 gene encodes a protein of 364 amino acids, of which one variant has been reported with an 18 amino acid deletion (187). LPA<sub>1</sub> has a broad expression profile, in humans it has been detected in brain, heart, placenta, spleen, kidney, colon, small intestine, prostate, testis, ovary, pancreas, skeletal muscle and thymus (188), while it is highly abundant in murine brain, heart, lung, stomach, small intestine, spleen, thymus, testis and skeletal muscle (189). The murine *Lpar1* gene or formerly ventricular zone gene-1 is highly expressed in the neocortical region called ventricular zone of the developing brain (9). The ventricular zone disappears before birth but *Lpar1* expression persists mainly in cells forming the white matter tracts and seems to play a role in myelination (190). In support of this,

expression of *Lpar1* has been detected in oligodendrocytes and Schwann cells (SC), the myelinating cells of the central and peripheral nervous systems respectively (190, 191).

LPA<sub>1</sub> KO mice exhibit about 50% perinatal lethality, attributed to abnormal suckling behavior, which may be a consequence of impaired olfaction. Besides, KO mice have reduced body and brain sizes, craniofacial dysmorphism with blunted snouts and wide-spaced eyes, and increased apoptosis in sciatic nerve SCs. 2.5% percent of LPA<sub>1</sub> null embryos showed frontal cephalic hematomas (192). It is of interest, that LPA<sub>1</sub> KO mice are significantly protected against bleomycin induced pulmonary fibrosis (193). During breeding of this KO strain a spontaneous variant emerged named MálagaLPA<sub>1</sub> (maLPA<sub>1</sub>) named after the place of its discovery (194). Despite negligible perinatal lethality, maLPA<sub>1</sub> mice show more severe defects in the brain than ordinary LPA<sub>1</sub> KO mice (194) and exhibit multiple behavioral abnormalities including inhibition of fear extinction (195) and aggravation of chronic stress-induced impairment to hippocampal neurogenesis (196).

LPA<sub>1</sub> couples to Gα<sub>i/o</sub>, Gα<sub>q/11</sub> and Gα<sub>12/13</sub>, which can activate a wide range of downstream signaling pathways through phospholipase C (PLC), mitogen-activated protein kinase (MAPK), Akt, Ca<sup>2+</sup> mobilization, Rho and Rho kinase (ROCK). LPA<sub>1</sub> can elicit multiple cellular responses including cell proliferation, migration, survival as well as cytoskeletal changes, and establishment of intercellular connections (189, 197, 198). Uniquely among LPA receptors, LPA<sub>1</sub> is trafficked to early endosomes, which is mediated by C-terminal binding of the GAIP interacting protein (199). LPA has also been implicated to regulate the Hippo-Yes-associated protein pathway, however, the LPA receptor(s) involved in this process remain(s) unidentified (200, 201).

Sequence homology investigations of LPA<sub>1</sub> led to the identification of **LPA<sub>2</sub>** (EDG4), a 351/348 (human/murine) amino acid protein coded by the genes *LPAR2* and *lpar2* in human and mouse respectively, which shows ~60% amino acid identity to LPA<sub>1</sub> (202). Contrary to *LPAR1*, expression of *LPAR2* is quite restricted, showing the highest abundance in testis and leukocytes and lower in the prostate, spleen, thymus, and pancreas (188). In mice, *lpar2* is highly expressed in the kidney, uterus, and testis, while moderate levels of mRNA are detected in the lung, stomach, spleen, thymus, brain, and heart (203). During development, *lpar2* expression has been shown in the limb buds, the craniofacial region, Rathke's pouch, and the embryonic brain (204-207).

LPA<sub>2</sub> KO mice appear lean with no phenotypic alterations (202). LPA<sub>2</sub> null mice were however, protected in a colitis-associated tumor model compared to WT mice (208), while bronchoalveolar lavage fluid of *lpar2* heterozygotes contained reduced number of eosinophil granulocytes and lower levels of prostaglandin (PG) E<sub>2</sub> (209). LPA<sub>2</sub> mice show increased sensitivity to genotoxic stress induced by ionizing radiation and chemotherapeutics (210) and display delayed resolutions of DNA double breaks indicative of impaired DNA damage repair (211).

LPA<sub>1</sub>/LPA<sub>2</sub> double KO mice have also been generated and showed the same phenotype as LPA<sub>1</sub> KOs with an increased incidence of frontal hematomas (26% vs 2.5% for LPA<sub>1</sub>/LPA<sub>2</sub> double KO vs LPA<sub>1</sub> KO respectively) (202). These mice, however highlighted the opposing effects of LPA<sub>1</sub> and LPA<sub>2</sub> on primary VSMCs and injury-induced neointimal hyperplasia, LPA<sub>1</sub> being a negative, whilst LPA<sub>2</sub> a positive regulator of VSMC migration (212).

LPA<sub>2</sub>, similarly to LPA<sub>1</sub>, couples to G $\alpha_{i/o}$ , G $\alpha_{q/11}$ , and G $\alpha_{12/13}$ , through which it can initiate the activation of Ras, Rac, phosphoinositide 3-kinase (PI3K), MAPK, PLC, diacylglycerol, and Rho pathways (197). LPA<sub>2</sub> regulates cell survival and migration. Ligands stimulating LPA<sub>2</sub> provide protection against exposure to genotoxic stressors and protect *Lgr5* marker positive intestinal stem cells and hematopoietic progenitor cell in the bone marrow (213, 214). The LPA<sub>2</sub> PDZ-domain binding motif is unique among LPA receptors and also regulates Na<sup>+</sup>/H<sup>+</sup> exchange regulator factor 2 (NHERF2), which activates PLC $\beta$ 3 and Akt/ERK signaling and inhibits the cystic fibrosis transmembrane conductance regulator (215). Mechanistically, LPA<sub>2</sub> makes physical interaction with the cystic fibrosis transmembrane regulator Cl<sup>-</sup> channel and due to its coupling to the heterotrimeric G<sub>i</sub> protein inhibits cAMP production in the apical compartment of the epithelial cell membrane leading to inhibition of Cl<sup>-</sup> secretion into the lumen (216). This mechanism plays an important role and offer therapeutic intervention in the treatment of secretory diarrhea caused by activation of this regulator protein (217). LPA<sub>2</sub> via its C-terminal PDZ protein interaction motif and another LIM-protein binding motif forms a ligand activation-dependent ternary complex with NHERF2 and the thyroid receptor-interacting protein 6 (TRIP6). This ternary complex is required for the anti-apoptotic effect of LPA<sub>2</sub> that is linked to a robust and long-lasting activation of the PI3K-NF- $\kappa$ B and ERK1/2 pro-survival pathways (218, 219). Cell migration is presumed to be

initiated by the interaction of the receptor C-terminal with TRIP6 (220, 221) and other PDZ-domain and zinc-finger proteins (215). The fact, that LPA<sub>2</sub> signaling is reported to be able to suppress EGF-induced migration and invasion of pancreatic cancer cells, raises the possibility of transactivation/cross-regulation between LPA GPCRs and tyrosine kinase receptors (222, 223).

**LPA<sub>3</sub>** (EDG7) was identified by two research groups independently, conducting homology studies with LPA<sub>1</sub> (224, 225). LPAR3/Lpar3 encodes a 353/354 (human/murine) amino acid protein with ~54% and ~49% homology to LPA<sub>1</sub> and LPA<sub>2</sub> respectively (224). Highest abundance of LPA<sub>3</sub> mRNA was found in human heart, testis, prostate, and pancreas (224, 225) and murine lung, kidney, uterus, and testis (189). Somewhat lower levels were detected in human lung, ovary, and brain (224, 225) as well as in murine small intestine, brain, heart, stomach, placenta, spleen, and thymus (189). Lpar3 is also expressed in heart, mesonephros, and in three spots in the otic vesicle during development (204).

LPA<sub>3</sub> KO mice appear normal; however, KO females show delayed embryo implantation, altered embryo spacing, and reduced litter size (226).

LPA<sub>3</sub> couples with G $\alpha_{i/o}$  and G $\alpha_{q/11}$  through which mediates Ca<sup>2+</sup> mobilization, adenylyl cyclase (AC) inhibition and activation of PLC, and MAPK (227). Uniquely, LPA<sub>3</sub> has been reported to show marked preference for sn2 isoforms of LPA and for those containing unsaturated fatty acids (24, 224).

LPA<sub>3</sub> seems to play a role in determining vertebrate left-right patterning. Downregulation or inhibition of LPA<sub>3</sub> or ATX resulted in disruption of asymmetric gene expression and organ asymmetry in zebrafish (88).

Although **S1P<sub>1</sub>** (EDG1) was the first identified member of the EDG family by Hla and Maciag in 1990, it was designated as an orphan GPCR until 1998, when two research groups independently confirmed S1P as its specific agonist (13-15). The human S1P1R gene encodes a 381 amino acid GPCR (13). High amount of S1P<sub>1</sub> mRNA was detectable in murine brain, heart, lung, liver, and spleen, while lower levels were found in kidney, thymus, and muscle specimens. Murine testis, stomach, and small intestine express S1P<sub>1</sub> in negligible amounts (228, 229). It is of note, that S1P<sub>1</sub> is highly expressed in developing central nervous-, cardiovascular-, and skeletal structures (228, 230).

Classical S1P<sub>1</sub> KO mice show a striking phenotype, as they die in utero between embryonic days 12.5 and 14.5 due to massive intraembryonic hemorrhage and edema throughout the body and limbs. These mice exhibited abnormal vascular maturation despite of normal angio- and vasculogenesis, which can be attributed to a disruption in VSMC and pericyte migration resulting in inadequate ensheathment of endothelial cells in nascent blood vessels (230). Generation of endothelium-specific S1P<sub>1</sub> null mice applying the Tie2 Cre-loxP system highlighted the fact, that the severe alterations seen in classical KOs are caused by the lack of S1P<sub>1</sub> in endothelial rather than VSM cells (231, 232).

Investigation of other tissue-specific KO mice lead to the recognition of the role of S1P<sub>1</sub> in lymphocyte trafficking. Studies of T-cell specific S1P<sub>1</sub> null mice showed, that S1P<sub>1</sub> is crucial for mature T-cells to egress from the thymus, moreover hematopoietic deletion of the receptor caused the same defect of T- as well as B-cell egress (233-235). It is of note, that S1P<sub>1</sub> is the sole lysophospholipid receptor, targeted by an already FDA-administered drug (236).

S1P<sub>1</sub> exclusively couples with G $\alpha_{i/o}$  and can activate ERK, PLC, and can cause Ca<sup>2+</sup> mobilization and inhibit AC (237). Besides S1P<sub>1</sub>-elicited PI3K/Akt and Rac activation have been shown to mediate cell proliferation, survival, migration, and changes in cytoskeletal structure (36, 238, 239). Studies with mouse embryonic fibroblast cells implicated cross-talk between S1P<sub>1</sub> and PDGF signaling, with the latter being upstream, which is also supported by the fact, that PDGF receptor KO mice recapitulate the phenotype of classic S1P<sub>1</sub> KO (240, 241).

**S1P<sub>2</sub>** (EDG5) was first isolated from rat cardiovascular and nervous systems, later confirmed by multiple groups being specific for S1P. The murine S1pr<sub>2</sub> gene encodes a 352 amino acid GPCR (242-244). S1P<sub>2</sub> is ubiquitously expressed, including murine heart, lung, thymus, brain, liver, kidney, spleen, and adipose tissue (229, 245). In the brain, S1P<sub>2</sub> expression is the highest at embryonic age and decreases throughout development, reaching an almost undetectable level at adulthood (229, 243, 246-248).

S1P<sub>2</sub> KO mice exhibit no obvious phenotypical abnormality, however show a slight yet significant decrease in litter size, which was augmented in S1P<sub>2</sub>/S1P<sub>3</sub> double KO animals (249). Studies with these mice revealed progressive vestibule-cochlear loss with aging, including deafness, which proved to be a result of vascular abnormalities in the

inner ear and sensing hair cell loss in the organ of Corti (250). Besides KO mice showed seizure activity (247), disruption in wound healing (251), and in vascular function (252, 253), as well as reduction in inflammatory cell infiltration and pathological neovascularization in ischemia-induced retinopathy (253). Further investigation of S1P<sub>2</sub> KO mice on Apoe<sup>-/-</sup> background demonstrated that S1P<sub>2</sub> signaling is pro-atherogenic (254). Furthermore, the zebrafish homologue of the mammalian S1pr<sub>2</sub> gene proved to be essential for cardiac development, however this phenotype was not observed in mice (249, 255).

S1P<sub>2</sub> couples with Gα<sub>q/11</sub>, Gα<sub>i/o</sub>, and Gα<sub>12/13</sub> through which induces serum response element, ERK, c-Jun N-terminal kinase (JNK), P38, PLC, Rho, and PIP3 phosphatase (PTEN) activation and mediates cell survival, rounding, and proliferation (256). It is noteworthy, that S1P<sub>2</sub> inhibits cell migration through the activation of PTEN, which is in contrast with S1P<sub>1</sub> action (257).

**S1P<sub>3</sub>** (EDG3) was first cloned as a 378 amino acid orphan human GPCR, later proved to be (like S1P<sub>2</sub>) a high affinity S1P and a low-affinity SPC receptor (197, 258). Expression of S1P<sub>3</sub> was detected in murine spleen, heart, lung, thymus, kidney, testis, brain, and skeletal muscle (229, 245) as well as in human heart, placenta, kidney, liver, pancreas, skeletal muscle, and brain (258).

S1P<sub>3</sub> KO mice appear lean, with a small but significant drop in litter size (245). However, deletion of S1P<sub>3</sub> disrupts a certain amount of S1P actions in the cardiovascular system like negative chronotropic and hypertensive effects as well as vasoconstriction in basilar artery and nitric oxide (NO)-dependent vasodilation (245, 259). S1P<sub>3</sub> deficiency also prevented HDL-elicited vasodilation, highlighting the role of S1P<sub>3</sub> in the regulation of the vascular tone (260). Besides, S1P and HDL proved to be protective in myocardial ischemia/reperfusion injury through the activation of both S1P<sub>2</sub> and S1P<sub>3</sub> (261).

Although S1P<sub>3</sub> shows greater homology with S1P<sub>1</sub>, its signaling resembles to that of S1P<sub>2</sub>, as S1P<sub>3</sub> couples with Gα<sub>i/o</sub>, Gα<sub>q/11</sub>, and Gα<sub>12/13</sub> and activates ERK, serum response element, Rho, and Rac through which mediates cell proliferation, survival, migration and rounding (198, 262). It is noteworthy, that in mouse embryonic fibroblast cells S1P<sub>3</sub> is not involved in Rho activation (245).

It is of note that S1P<sub>3</sub> can act as a downstream effector of the protease-activated receptor 1 (PAR1). In this manner, S1P<sub>3</sub> signaling is involved in LPS-induced IL-1 $\beta$  and tissue factor production, which is an essential component in the pathogenesis of sepsis (263).

**S1P<sub>4</sub>** (EDG6) was first isolated from in vitro differentiated human and murine dendritic cells (264). The 384/386 amino acid (human/murine respectively) orphan GPCR later proved to be specific for S1P (265, 266). Expression of S1P<sub>4</sub> is restricted to hematopoietic and lymphatic tissues (264).

S1P<sub>4</sub> KO mice appear without any phenotypical abnormality. However, a significant amount of megakaryocytes in these animals showed aberrant, non-grained cytoplasm with vacuoles. Furthermore, they exhibited delayed recovery after monoclonal antibody-induced thrombocytopenia, without any reactive thrombocytosis compared with wild-type mice. Nonetheless, megakaryocyte count in bone marrow, platelet count in peripheral blood, plasma thrombopoietin level, and bleeding time were normal in S1P<sub>4</sub> null animals, implying a role for S1P<sub>4</sub> in the later phase of megakaryocyte maturation (267). Further studies with these animals suggested a role for S1P<sub>4</sub> in neutrophil trafficking, and pro-inflammatory cytokine release (268) as well as in CD4<sup>+</sup> T cell signaling (269).


S1P<sub>4</sub> couples with G $\alpha_{i/o}$ , G $\alpha_{12/13}$  and possibly G $\alpha_s$ , and can activate ERK, PLC, AC, Rho and small Rho family GTPase Cdc42. S1P<sub>4</sub> influences cell stress fiber formation and migration as well (198, 262).

**S1P<sub>5</sub>** (EDG8) was isolated from rat pheochromocytoma (PC12) cells and identified as an S1P receptor at the beginning of the second millennium (270, 271). The rat variant encodes a 400 amino acid GPCR (270). Expression of S1P<sub>5</sub> is restricted to the brain, spleen, and peripheral leukocytes in humans and the brain, skin, and spleen in mice and rats (245, 270, 271). In rat brain, S1P<sub>5</sub> is localized predominantly to the white matter tracts and cells of oligodendrocyte lineage, suggesting a role in proper myelination (271, 272).

S1P<sub>5</sub> KO mice were generated and appear lean without any phenotypic difference (272). In vivo studies however highlighted the role of S1P<sub>5</sub> in natural killer cell (NK cell) functions. NK cells show high levels of S1P<sub>5</sub> and show abnormal tissue

distribution upon S1P<sub>5</sub> ablation (273). Besides, S1P<sub>5</sub> expression has been shown to be co-mediated with NK cell maturation (274).

S1P<sub>5</sub> couples with G $\alpha_{i/o}$ , and G $\alpha_{12/13}$  through which mediates AC inhibition, Ca<sup>2+</sup> mobilization and, in contrast with other S1P receptors, ERK and cell migration inhibition (245, 271, 275, 276).



**Figure 7.** S1P GPCRs and activated signaling pathways; AC: Adenylyl cyclase, PI3K: Phosphoinositide 3-kinase, PLC: Phospholipase C; after C. O’Sullivan and K. K. Dev (277)

### 2.3.1.2. Non-EDG family LPA receptors

Although description of the EDG LPA receptors clarified a large amount of the extracellular actions of LPA, there are several responses, including platelet aggregation and certain aspects of vascular development that could not be fully explained by the three EDG family LPA GPCRs (278, 279). In 2003, Noguchi and colleagues, using ligand screening by Ca<sup>2+</sup>-mobilization assay, identified a previously known GPCR, P2Y<sub>9</sub> of the purinergic cluster, as an LPA receptor (280). This observation gave new momentum to the lysophospholipid field, and till 2009 two other GPCRs were found to be specific to LPA (281-284). These receptors (LPA<sub>4</sub>, LPA<sub>5</sub> and LPA<sub>6</sub> in order of confirmation) all belong to the P2Y purinergic family, however none of them responds to nucleotide ligands. A recent study in 2017 deciphered the crystal structure and ligand

binding properties of LPA<sub>6</sub> (181). During their research, Taniguchi and colleagues found that LPA<sub>6</sub> possesses a gap between TM4 and TM5, which forms vertical cleft open towards the plasma membrane. Besides, the presence of several hydrophobic amino acids in the cleft indicates its role as a lipid-binding site. They speculate that LPA<sub>6</sub>, in contrast with LPA<sub>1</sub>, can be accessible for its ligands from the extracellular environment as well as laterally from the plasma membrane. Considering the fact, that the ligand-binding pocket of LPA<sub>6</sub>, formed by TM3, TM4 and TM5 is highly conserved in the P2Y family, binding properties of LPA<sub>6</sub> may provide insight into these functions of the other two non-EDG LPA receptors as well (181).

**LPA<sub>4</sub>** (formerly P2Y<sub>9</sub> and GPR23) was the first LPA receptor identified, that does not belong to the EDG family (280). LPAR4 encodes a 370 amino acid GPCR and is located on chromosome X (178). LPA<sub>4</sub> shows high abundance in human ovary, lower abundance in thymus, pancreas, brain, heart, small intestine, testis, prostate, colon, spleen, and platelets (66, 285). Among murine tissues, LPA<sub>4</sub> is present in heart, ovary, skin, thymus, and bone marrow (66). During development, LPA<sub>4</sub> is found in brain, maxillary process, branchial arches, limb buds, liver, and somites (204).

LPA<sub>4</sub> KO mice do not exhibit any obvious phenotypical alteration (286). However, approximately 30% of the embryos do not survive gestation, which can be attributed to hemorrhage and abnormal, dilated blood vessels with abrupt VSM and pericyte recruitment (279). Besides, LPA<sub>4</sub> is also assumed to have a role in lymphatic vessel development, as null mice show dilated lymphatic vessels and lymph sacs (279). Furthermore, LPA<sub>4</sub> KO mice display increased trabecular bone volume, number, and thickness, which are in contrast with what has been seen in LPA<sub>1</sub> KO, suggesting counteracting roles for LPA<sub>1</sub> and LPA<sub>4</sub> in bone formation (287).

LPA<sub>4</sub> couples with G $\alpha$ <sub>12/13</sub>, G $\alpha$ <sub>q/11</sub>, G $\alpha$ <sub>i/o</sub>, and uniquely among LPA receptors G $\alpha$ <sub>s</sub> as well (288). Through these G proteins, LPA<sub>4</sub> can trigger Rho/ROCK activation, intracellular cyclic adenosine monophosphate (cAMP) accumulation, and ERK and PI3K activation (288-290). LPA<sub>4</sub> facilitates cell adhesion via N-cadherin and, in contrast with other LPA GPCRs, e.g. LPA<sub>1</sub>, inhibits cell migration (286, 289).

**LPA<sub>5</sub>** (formerly GPR92) was first identified as an LPA receptor in 2006 (281, 282). LPAR5 encodes a 372 amino acid GPCR, which is highly expressed in human spleen, and mast cells while in a lesser extent in heart, small intestine, placenta, colon, liver,

and platelets (281, 285, 291). In mice LPA<sub>5</sub> mRNA shows high abundance in small intestine, whilst moderately high in lung, heart, stomach, colon, spleen, thymus, skin, liver, platelets, mast cells, gastrointestinal lymphocytes, and dorsal root ganglia (281, 282). LPA<sub>5</sub> expression is high in the early embryonic forebrain, rostral midbrain, and hindbrain; however later on (from embryonic days 9.5-12.5) the expressional pattern becomes more diffuse throughout the whole brain (204).

LPA<sub>5</sub> KO mice appear lean; however, they seem to be protected against neuropathic pain, caused by partial sciatic nerve ligation (PSNL) (292).

LPA<sub>5</sub> couples with G $\alpha_{12/13}$ , and G $\alpha_{q/11}$ , through which elicits neurite retraction, stress fiber formation, receptor internalization and intracellular Ca<sup>2+</sup> mobilization respectively (282). LPA<sub>5</sub> has been reported to increase intracellular cAMP levels in a presumably G $\alpha_s$ -independent manner (281, 282). It is of note, that LPA<sub>5</sub> shows a marked preference for alkyl-LPA analogues (25, 26). Besides LPA<sub>5</sub> can interact with NHERF2, through which it enhances the recruitment of the Na<sup>+</sup>/H<sup>+</sup> exchanger 3 to the microvilli of the colon, and facilitates Na<sup>+</sup>-dependent water resorption (293).

**LPA<sub>6</sub>** (P2Y<sub>5</sub>) is the most recently identified LPA receptor described by Pasternack et colleagues in 2008 (283). Expression of LPA<sub>6</sub> was reported in human intestinal mucosa cells, scalp hair follicles and skin (283, 294). Currently LPA<sub>6</sub> is the only non-EDG LPA receptor with an available crystal structure (181), which was briefly covered in the introduction of this section.

LPA<sub>6</sub> KO mice have been recently reported. Although these mice exhibited normal blood pressure and heart rate, they showed decreased vascular responses to adrenergic stimuli by phenylephrine or noradrenalin. Furthermore, LPA<sub>6</sub> KO mice showed abruption in postnatal retinal vessel formation, indicating that LPA<sub>6</sub> signaling is essential for the development of the normal vasculature (295).

LPA<sub>6</sub> signaling is still obscure, however evidences suggest, that LPA<sub>6</sub> couples with G $\alpha_{12/13}$  and G $\alpha_{i/o}$  and can activate Rho, ROCK, PLC, Ras, and PI3K on the other side inhibits AC (284, 294, 296). LPA<sub>6</sub> has been shown to have marked preference for sn2 regioisomers of LPA (294).

At the time of its characterization, LPA<sub>6</sub> was reported to be a genetic risk factor for an autosomal recessive form for hypotrichosis simplex and woolly hair (283, 297). Besides, mutations of the lipase member H, the human orthologue of PA-PLA<sub>1</sub> enzyme,

that produces sn-2 LPA also proved to cause the same condition (298, 299). These results hint a possible future role for LPA<sub>6</sub> signaling in the therapy of human hair loss. Homozygous inactivation of LPA<sub>6</sub> has been reported in bladder cancer (300).

### **2.3.2. Intracellular lysophospholipid targets**

Besides the GPCRs detailed above, both LPA and S1P can act on intracellular targets (16, 17). Since S1P is generated inside the cells, the biosynthetic pathways of S1P acting intra- and extracellularly do not differ. On the contrary, the bulk of plasma LPA is produced extracellularly primarily by ATX as has been covered in previous sections thus, and since the majority of circulating LPA is albumin-bound (16), and transmembrane migration of albumin-bound LPA is minimal. Thus, intracellular LPA is generated in a different manner compared with extracellular, mainly through the action of Glycerol-3-phosphate acyltransferases (16).

#### **2.3.2.1. Intracellular actions of LPA**

McIntyre and colleagues reported in 2003, that LPA activates **PPAR $\gamma$** , an essential regulator of lipid and glucose homeostasis (10). There are three different PPAR isoforms, labelled as  $\alpha, \beta/\delta$  and  $\gamma$  (301). PPAR $\gamma$  itself has two isoforms PPAR $\gamma_1$  and PPAR $\gamma_2$  (302). PPAR $\gamma_1$  is ubiquitously expressed, whilst PPAR $\gamma_2$  is restricted to adipose tissue (303). Deletion of the  $\gamma_1$  isoform causes embryonic lethality (304), while that of  $\gamma_2$  results in minor alterations in lipid metabolism (305). In case of its activation, PPAR $\gamma$  forms a heterodimer with the retinoid X receptor  $\alpha$  (RXR $\alpha$ ) and together they bind to the peroxisome proliferator response element in the promoter region of the target genes, through which regulate their transcription. In the absence of an agonist, the nuclear receptor co-repressor 1 and silencing mediator of retinoic acid and thyroid hormone receptor bind the heterodimer and repress its action (306-309).

Unlike LPA GPCRs, PPAR $\gamma$  is stereoselective and can only be activated by S-isomers carrying unsaturated acyl chains. Besides, alkyl-LPA analogues are more potent activators of PPAR $\gamma$  than acyl ones, a feature shared with LPA<sub>5</sub> (16, 310, 311).

LPA, activating PPAR $\gamma$ , increases the transcription of enzymes involved in lipogenesis, lipid storage, and adipocyte differentiation. It means, that the accumulation of this intermediate shifts the lipid metabolism of the given cell towards lipogenesis and

storage, instead of  $\beta$ -oxidation. Under pathophysiologic circumstances, this regulation may have a role in the development of non-alcoholic fatty liver disease (16, 312, 313).

It is of note, that synthetic agonists of PPAR $\gamma$ , the thiazolidinediones are applied in the therapy of type 2 diabetes.

CPA, a naturally occurring LPA analogue, on the other side is an antagonist of PPAR $\gamma$  (28).

Yoshida and colleagues described first, that LPA induces neointima formation in a non-injury infusion model of rat carotid artery (314). LPA was injected through the external carotid artery into a segment of the common carotid artery that was previously ligated, rinsed free of blood and maintained at near physiologic pressure. A 1 h exposure to LPA induced neointima formation. This process occurred only if unsaturated species of LPA was applied (314). Others concluded that the effect was PPAR $\gamma$ -dependent, as GW9662, a specific inhibitor of PPAR $\gamma$ , abolished the neointima formation (310).

PPAR $\gamma$  enhances the transcription of the CD36 scavenger receptor as well, which facilitates oxidized LDL uptake of the vessel walls (10).

PPAR $\gamma$ , along with LPA $_1$  and LPA $_3$ , also has a role in mast cell and dendritic cell differentiation. In these cells, LPA (and cardiolipin), through the regulation of CD1 expression, can influence antigen presentation, however this hypothesis needs more evidence to be confirmed (315, 316).

Apart from PPAR $\gamma$ , LPA can attach to multiple actin-binding proteins, like **gelsolin**, **formin**, **adseverin**, and **villin**. These interactions can have a role in the regulation of the cytoskeleton (16).

### 2.3.2.2. Intracellular actions of S1P

Since its discovery, S1P has been known to promote cell survival and inhibit apoptosis (11, 35). Furthermore, studies showed that S1P elicits Ca $^{2+}$ -release from the ER (17). However, the mechanism of these actions remained elusive. Recently, several intracellular targets of S1P have been identified, which highlighted the importance of S1P signaling not only through GPCRs, but via intracellular targets as well.

As discussed formerly, SK2 has nuclear localization and export signals and can be translocated to the nucleus (133, 135). Interestingly, it has been revealed, that SK2 localized in the nucleus forms a repressor complex with the histone H3-histone

deacetylase (**HDAC**) 1/2 bound to the promoter of certain genes. Moreover, S1P generated by SK2 binds to HDAC1/2 and prevents histone deacetylation, thus enhances transcription of genes including the cyclin-dependent kinase inhibitor p21 and the transcriptional master regulator c-Fos (317).

Furthermore, in fibroblasts, nuclear S1P can stabilize the human telomerase reverse transcriptase (**hTERT**), which is the catalytic subunit of the telomerase complex and maintains telomeres, that is often seen in transformed cancer cells. S1P binding of hTERT blocks its interaction with the makorin ring finger protein 1, which itself is an E3 ubiquitin ligase, thus S1P interaction with hTERT prevents the proteasomal degradation of this transcriptase, thus maintaining telomerase activity. Although the exact molecular explanation is still lacking, it appears, that S1P binding of hTERT mimics its phosphorylation at Asp 684 (318).

Intracellular S1P, produced by SK1 can directly target the **TRAF2** (112). This protein is an essential adaptor for the regulatory ubiquitination of receptor interacting protein, which is critical in activation of NF- $\kappa$ B in response to TNF $\alpha$ . It was previously shown, that TNF $\alpha$  stimulates the association of SK1 and TRAF2, which increases the activity of the former (319). Besides, ligase activity of TRAF2 was detectable only in presence of S1P but not that of dihydro-S1P. These findings may also explain the fact, that dihydro-S1P although is equally potent on S1P GPCRs, in contrast with S1P it has no cytoprotective effect (112).

S1P, produced in mitochondria by SK2, can bind to **prohibitin 2**, a protein necessary for mitochondrial assembly and function (320). The importance of this interaction is emphasized by the fact, that mitochondrial respiration is reduced in SK2 KO mice, due to the presence of an abnormal form of cytochrome c oxidase with low activity (320).

In neurons, S1P was shown to modulate the activity of  **$\beta$ -site amyloid precursor protein cleaving enzyme-1**, which is the rate-limiting step in amyloid- $\beta$  peptide (A $\beta$ ) production. SK1 inhibition or downregulation, as well as overexpression of S1P-degrading enzymes decreased the activity of the aforementioned enzyme. Besides, Alzheimer's disease (AD) patients exhibited upregulation of SK2, hinting a possible involvement of S1P in pathogenesis of AD (321).

## **2.4. Roles of lysophospholipids in physiological and pathological responses**

### **2.4.1. Lysophospholipids in the nervous system**

Lysophospholipids have a pivotal role in the nervous system. This is well demonstrated by the fact, that the first identified lysophospholipid receptor, LPA<sub>1</sub>, was isolated from the ventricular zone of the murine brain (9). Since that, both LPA and S1P became well-established regulators in development, physiological function, and pathologies of the nervous system (322-324).

#### **2.4.1.1. Neural development and function**

Neural progenitor cells (NPCs) are located in the ventricular zone of the developing brain and undergo several steps including proliferation, differentiation, maturation, and migration to form nascent neurons (322, 323). LPA<sub>1</sub>, LPA<sub>2</sub>, and LPA<sub>4</sub> show marked expression in NPCs (206). *In vitro* and *ex vivo* studies implicate, that LPA<sub>1</sub> signaling controls cell proliferation and differentiation, playing a key role in development of the cortex of the brain. LPA<sub>1</sub> KO NPCs lack migration, proliferation, differentiation, and morphological changes essential to neurogenesis (192, 325). *Ex vivo* studies show that LPA<sub>2</sub> also has a role in LPA-induced survival and differentiation (326). The importance of LPA<sub>1</sub> is well emphasized by the phenotype of LPA<sub>1</sub> KO and the more severe developmental defects of maLPA<sub>1</sub> KO mice, described in detail in the previous chapter.

Our knowledge of S1P in neurodevelopment is much scarcer. Although all S1P receptors are expressed in NPCs (248), only S1P<sub>1</sub> KO mice exhibit a disruption in neurogenesis with increased cell death and decreased proliferation (101).

In post-mitotic neurons, LPA mediates neurite retraction, and growth cone collapse, however the receptor dependency is still obscure (46). On the other hand, Nerve growth factor can activate S1P production via SK1, which then elicits neurite extension in an S1P<sub>1</sub>-dependent manner; however, overexpression of S1P<sub>2</sub> or S1P<sub>5</sub> inhibited this effect (115, 327). Besides, both LPA and S1P signaling have multiple roles in synaptic transmission, reviewed extensively (322, 324).

Astrocytes express LPA<sub>1-5</sub> and S1P<sub>1,3,4,5</sub> (46). It is of interest, that the injection of either LPA or S1P causes astrogliosis *in vivo* (46). Oligodendrocytes and Schwann cells (SCs) are the myelinating cells of the central and peripheral nervous systems respectively. Oligodendrocytes express LPA<sub>1</sub>, LPA<sub>3</sub>, and low levels of LPA<sub>2</sub> (46). It is

of interest that LPA<sub>1</sub> expression correlates to oligodendrocyte maturation stage. In addition, LPA increases myelin basic protein mRNA levels and myelin formation in vitro (46). On the other hand, S1P, through S1P<sub>5</sub> mediates process retraction, inhibits migration, and promotes survival of mature oligodendrocytes. In SCs, LPA is a well-established survival factor, acting on LPA<sub>1</sub> coupled to G $\alpha_{i/o}$ , PI3K, and Akt. Besides, the same receptor regulates actin cytoskeletal rearrangements and enhances cell-to-cell adhesion via Rho and ROCK. LPA<sub>1</sub> signaling was also demonstrated in SCs in vivo, as LPA<sub>1</sub> KO mice exhibited increased apoptosis of the sciatic nerve SCs (46).

Microglia are the resident macrophages of neural tissues, which, upon stimulation, activate neuro-inflammatory processes. Microglia express LPA<sub>1-3</sub> and S1P<sub>1,2,3,5</sub>, which may alter cell activation. Besides, both S1P and LPA are able to mediate a multitude of cellular responses in microglia, reviewed elsewhere (46, 322).

#### **2.4.1.2. Role of lysophospholipids in neural pathologies**

Both LPA and S1P are involved in multiple processes in neural pathophysiology; however, this thesis does not focus on these responses, hence this chapter highlights only some aspects of lysophospholipid actions in the neural diseases, which are either well-documented or raise the possibility to use lysophospholipid analogs as future drugs.

##### **2.4.1.2.1. Multiple sclerosis**

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized by chronic inflammation, demyelination and axonal loss, as well as damage of the blood-brain-barrier leading to infiltration of lymphocytes and other immune cells (328). Efficacy of FTY720 (Fingolimod) in MS patients shed light on the role of S1P signaling in this disease (329). FTY720 is a sphingosine analogue, that is phosphorylated by SK2 (100, 330) and so is modulator of four of five S1P receptors, S1P<sub>1,3,4,5</sub> (331, 332). Mechanism of Fingolimod action is attributed to its effect on T-lymphocyte S1P<sub>1</sub>, functioning as an antagonist and causing receptor internalization, through which lymphocytes fail to egress from secondary lymphoid organs (333-335). However, compelling amount of data has been presented, which implicates, that lymphocyte-S1P<sub>1</sub> signaling is not the only site of action of FTY720 (336). Fingolimod did not alleviate MS symptoms in astrocyte line S1P<sub>1</sub> KO mice in the widely used MS-model,

experimental autoimmune encephalitis, notwithstanding, the decrease in peripheral leukocyte count was present, showing, that FTY720 had an effect on T-lymphocytes (336). Besides, microglia get activated in experimental autoimmune encephalitis, which was absent in central nervous system-specific S1P<sub>1</sub> KO mice on application of FTY720 (336). It is also assumed, that Fingolimod improves blood-brain-barrier function through a yet unknown mechanism (322, 329). FTY720, under the name Gilenya has been approved in the relapsing-remitting form of MS in 2010 in Europe, US, and several other countries and is still the sole approved drug, targeting a lysophospholipid receptor (337). Unfortunately, it failed in trials with the primary progressive form of MS, which require alternative forms of therapy (329).

#### **2.4.1.2.2. Ischemia**

It is of note, that in case of ischemic stroke, S1P levels in the infarct area, as well as LPA levels in plasma increase (59, 338, 339). SK2 is upregulated in ischemic brains, however not in transient ischemia, where no changes of SK1/2 expression were shown (340-342). Furthermore, a subsequent study established SK2 as a protective factor (342). Interestingly, LPA<sub>1</sub>, and LPA<sub>2</sub> expression is upregulated during retinal ischemia-reperfusion injury (343). FTY720, detailed in the previous part, on the other hand, proved to reduce brain damage in certain models (322). These data highlight the importance of lysophospholipid signaling in ischemic lesions of the central nervous system, however also show, that our knowledge is still quite rudimentary in this area.

#### **2.4.1.2.3. Neuropsychiatric disorders**

The role of lysophospholipids occurred early, as LPA<sub>1</sub> KO mice exhibited multiple traits as olfaction problems, craniofacial dysmorphism, failure in pre-pulse inhibition of the startle reflex, and learning, as well as memory deficiencies, commonly seen in autism and schizophrenia (344). Furthermore, maLPA<sub>1</sub> KOs show several behavioral abnormalities as general anhedonia, anxiety, and stress hypersensitivity (196, 345). Consistent with this, LPA<sub>1</sub> is downregulated in blood lymphocyte of human schizophrenia patients (346).

LPA signaling has been assumed to have a role in several molecular and neurotransmitter pathways, linked to neuropsychiatric functions, including glutamate and serotonin metabolism, regulation of glutamate receptors, and Ca<sup>2+</sup>/calmodulin-

dependent protein kinase II activity (323). Notwithstanding, a study showed, that LPA exposure to the cortex elicited anhedonia, anxiety, and depression-associated immobility in adult mice, traits also seen in LPA<sub>1</sub> KOs (347). Moreover, cortical administration of LPA in high concentrations to embryos in the period of neurogenesis leads to fetal hydrocephalus (see in a later part in detail) (348).

On the other hand, much less is known about S1P in neuropsychiatry. However, S1P<sub>2</sub> KO mice showed anxiety and disruption in spatial memory (349).

#### **2.4.1.2.4. Alzheimer's disease**

AD is a neurodegenerative illness associated with dementia that affects millions of mostly elderly people all around the world (350). AD is a progressive disorder with a loss of specific neuron population and is characterized by senile plaques composed of  $\beta$ -amyloid (A $\beta$ ) and aggregated tau protein (350).

Enzymes of LPA and S1P production ATX and SK2 respectively, have been reported to be upregulated in brain specimens of AD patients (321, 351).

On the contrary, S1P was reported to reduce the activity of BACE, the enzyme responsible for the accumulation of abnormal A $\beta$  in AD (321, 352). In AD patients, decreased levels of S1P and A $\beta$ -induced downregulation of SK1 action were reported (353), and in consistence, SK1-dependent reduction of A $\beta$ -induced cell death (354).

These results imply the role of S1P in AD is far away from being established, further studies hopefully clarify its protective or neurotoxic nature, pointing to possible drug targets in S1P signaling pathways.

#### **2.4.1.2.5. Fetal hydrocephalus**

Fetal hydrocephalus is a common neurological disorder of newborns with prenatal hemorrhagic events, and is associated with dilated ventricles, enlarged head, and third ventricle and aqueduct occlusion (355).

Yung and colleagues reported in 2011, that injection of either blood or LPA into the lateral ventricle of fetal brains induced hydrocephalus, with the clinical characteristics of fetal hydrocephalus in humans (348). Inhibition of LPA<sub>1/3</sub> by Ki16425 or lack of LPA<sub>1&2</sub> prevented the formation of hydrocephalus, which showed the putative role of LPA<sub>1</sub> in this disease (348). The study not only pointed out the potential involvement of

LPA<sub>1</sub> and LPA signaling in fetal hydrocephalus but proposed a new model of the disorder as well.

#### 2.4.1.2.6. Neuropathic pain

Neuropathic pain is a condition, commonly caused by nerve lesion or inflammation, and is often associated with lowered nociceptive threshold and consequent allodynia and hyperalgesia (356). Hypo/dysesthesia is also frequently seen in neuropathic pain (356). Additionally, demyelination can be detected in almost all cases, which presumed to have pathologic role in this disorder (356). Clinically, neuropathic pain can accompany chronic diseases like diabetes or MS; however can occur as a side effect of chemotherapeutical drugs (357).

LPA signaling is involved in multiple levels in the initiation and maintenance of neuropathic pain. This issue has been broadly reviewed (356-358); hereby it is intended to highlight the main aspects of LPA and its receptors in this process.

There are multiple animal models addressing neuropathic pain, including PSNL, intrathecal LPA injection, UVB irradiation, and ischemia induced pain (358). Interestingly, mice lacking LPA<sub>1</sub> or LPA<sub>5</sub> are protected against neuropathic pain induced by PSNL (292, 359). These studies shed light on the role of LPA summarized by the hypothesis of Ueda and colleagues (356, 357). As a result of nerve injury, large amounts of glutamate and substance P (SP) are produced and released by primary afferent neurons, which act on N-methyl-D-aspartate (NMDA) and neurokinin 1 receptors respectively. Activation of neurokinin 1 leads to Ca<sup>2+</sup> mobilization via the conventional G<sub>αq/11</sub> pathway, whilst NMDA promotes Ca<sup>2+</sup> influx. The elevated intracellular Ca<sup>2+</sup> concentration directly activates cPLA2 and indirectly, through calcium influx factor (CIF) iPLA2, which produce LPC from PC in the plasma membrane. As ATX is abundant in the cerebrospinal fluid, the LPC, produced via the aforementioned mechanism, is rapidly converted to LPA (356, 357).

LPA, through LPA<sub>1</sub> is involved in demyelination, as LPA<sub>1</sub> KO exhibit no demyelination in the PSNL model (359). Further studies deciphered, that LPA<sub>1</sub> signaling has multiple roles in this phenomenon. In SC, LPA<sub>1</sub> activates G<sub>αq/11</sub> and enhances intracellular Ca<sup>2+</sup> concentrations. Calpain is a Ca<sup>2+</sup>-dependent protease, that is activated upon LPA<sub>1</sub> agonism and induces the proteolysis of myelin-associated glycoprotein, which is a key component of SC-neuron interactions. Conjointly, LPA<sub>1</sub>,

activating the  $G\alpha_{12/13}$ -Rho-ROCK pathway, elicits JNK activation, which on one hand through PTEN activity, inhibits Akt-mediated myelination, on the other hand, enhances the transcription of c-jun, which downregulates the expression of Egr2 and downstream myelin protein myelin-associated protein, myelin basic protein, myelin protein zero, and peripheral myelin protein 22. LPA-mediated demyelination subsequently leads to induction of axonal sprouting, as axonal surfaces become free of inhibition of the myelin sheath. Sprouting of these axons establish connections between nociceptive and sensory fibers, which may be the pathophysiological basis of the sensory symptoms in neuropathic pain (356, 357).

In dorsal root ganglion neurons, LPA<sub>1</sub> upregulates the levels of several proteins, involved in molecular regulation of pathologic pain, like  $\alpha 2$ - $\delta$  unit of N-type  $Ca^{2+}$  channels, and ephrinB1 (356). EphrinB1, acting on its receptor Eph, mediates function and trafficking of NMDA receptors, influencing synaptic plasticity (356).

LPA, via LPA<sub>3</sub>, also activates astrocytes and microglia; these two cell types seem to be involved in the initial process of neuropathic pain. LPA generation induces further elevation of LPA levels in a feed-forward manner, activating microglia LPA<sub>3</sub> receptors and possibly PLA2 enzymes (356, 357).

It is noteworthy, that LPA<sub>5</sub> KO mice do not exhibit neuropathic pain in the PSNL model (292). Interestingly, there was no difference in demyelination or other protein levels mediated by LPA1, however cAMP response element binding protein showed decreased phosphorylation (292). Further studies will reveal the significance of LPA<sub>5</sub> in this disorder.

As seen from the above, the presence of LPA signaling is well established in the pathogenesis and pathophysiology of neuropathic pain. These studies point out several points of action as possible future drug targets; however, many questions remain to be answered to gain a better understanding of this field.

#### **2.4.2. Lysophospholipids in immune function**

Both LPA and S1P perform several roles in immune cell processes, which are reviewed extensively divided by cell type elsewhere (46, 269, 360). As immunological actions of lysophospholipids are not in the focus of the present thesis, a few well-described roles of S1P and LPA will be listed in the physiological and pathological mechanisms of the immune system.

### 2.4.2.1. Lysophospholipids in immune cell trafficking

As already mentioned previously, S1P through S1P<sub>1</sub> signaling plays a key role in lymphocyte (both T and B) egress from the thymus and secondary lymphoid organs (269). The main driving force behind this is the S1P gradient between plasma, lymph, and the tissues. Plasma S1P is mainly of erythroid origin and is the highest, while the lymph contains S1P in lower concentrations originating almost exclusively from lymphatic endothelial cells. Tissues have usually the lowest levels of S1P, due to high S1PL activity. The gradient is a result of coordinated and strictly regulated function of S1P synthesizing, degrading, and transport proteins, discussed in detail previously (269).

In case of T and B cells, as well as NK T cells, expression of S1P is also required for egress. Therefore, S1P expression is thoroughly regulated in these cells. Krüppel-like factor 2 (KLF2) is a transcriptional factor, that regulates S1P<sub>1</sub> expression, driving its upregulation (269). During T cell maturation, driven by KLF2 S1P<sub>1</sub> expression increases, whilst after T cell activation S1P<sub>1</sub> mRNA levels decrease, which is assumed to be the result of ubiquitination and degradation of KLF2 (269). S1P expression is also regulated through agonist-induced downregulation. High concentrations of S1P elicit internalization and degradation of S1P<sub>1</sub>. It is of note, that Fingolimod is much more effective in inducing this phenomenon than the natural agonist (269). Underlying mechanisms involve the action of GPCR kinase 2, which phosphorylates the receptor at a serine-rich region of the C-terminal and initiates its internalization (361, 362). Modulation of S1P<sub>1</sub> expression also happens through protein-protein interaction. CD69 is a C-type lectin, expressed on lymphoid cells right after their activation. If T cells are activated by type I interferon stimulation, the increase in CD69 expression downregulates S1P<sub>1</sub> (269).

Two hypotheses exist regarding the control of immune cell egress (269). The first one is the so-called lymphocyte-centered hypothesis, which implies, that lymphocytes sense the S1P gradient via S1P<sub>1</sub> expression, which drives them out of the lymph nodes. CCR7 –chemokine receptor-mediated retention signals are counteracting forces against S1P-S1P<sub>1</sub> signaling (269). The other hypothesis emphasizes the role of endothelial S1P<sub>1</sub>. In this model, lymphocyte egress happens constitutively under physiological concentrations of S1P and is blocked by S1P<sub>1</sub> agonism on endothelial cells, closing sites

of egress (269). The evidence in support of both hypotheses is somewhat controversial. S1P<sub>1</sub> agonism-induced block (e.g. FTY720) and the lack of antagonism-induced egress block are in favor of the endothelium-centered hypothesis (363-365). However, the facts, that lymphocytes lacking S1P<sub>1</sub> could not egress from lymph nodes, and decreased S1P<sub>1</sub> expression results in decreased rate of egress, as well as the lack of S1P production through conditional deletion of SK1 and SK2 blocks egress, support the lymphocyte-centered view (154, 233, 235, 366). Further experiments are needed with decisive evidence in favor of one or the other hypothesis, or a new integrated hypothesis should be developed that resolves the above described controversies. It is noteworthy, that S1P also mediates NK cell mobilization, although in an S1P<sub>5</sub>-dependent manner (273).

In contrast to S1P, LPA is assumed to interfere in T cell homing in high endothelial venules (HEVs) (360). Constitutive expression and secretion of LPA-producing enzyme ATX has been confirmed in HEV endothelial cells in 2008 (92, 367). Furthermore, ATX can bind to the plasma membrane of lymphocytes in either an integrin-dependent or independent manner, where it converts membrane LPC to LPA. It is however disputed, if the locally accumulated LPA drives lymphocytes to the lymph nodes or the LPA generated this way acts on the endothelial cells (360). Considering, that HEV endothelium expresses LPA<sub>1</sub> and LPA<sub>4</sub>, LPA induces cytoskeletal redistribution, and inhibition of ATX disrupts extravasation but not lymphocyte accumulation in HEV, the second option seems more plausible (367-369).

Apart from these effects on immune cell trafficking, it is noteworthy, that both mediators have been established in various immunological pathologies as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. For more in depth reviews on this issue see: (178, 361).

### **2.4.3. Lysophospholipids in the reproductive system**

#### **2.4.3.1. Female reproduction**

Involvement of LPA in reproductive functions has been known for almost 30 years (16). Studies in the early 90's identified LPA-mediated oscillatory Cl<sup>-</sup> currents in *Xenopus* oocytes (5, 7). Since then, LPA signaling has been described in almost every organ and tissue of the reproductive tract mediating processes that include oocyte

maturation, acrosome reaction, oviduct contraction, early embryo development, and uterine smooth muscle contraction (370). Besides, LPA concentration in follicular fluid in healthy females is approximately double of that in serum (371). LPA-production is also elevated during pregnancy (32).

The most thoroughly investigated aspect of LPA in reproduction is though the role of LPA<sub>3</sub> in implantation. LPA<sub>3</sub> KO mice have delayed embryo implantation, embryo crowding, and reduced litter size. The fact, that transfer of WT embryos into LPA<sub>3</sub> KO dams reproduced this phenotype argued in favor of a maternal role for LPA<sub>3</sub> (226). Interestingly, mice deficient in COX2 showed the same defects. Moreover, LPA<sub>3</sub> KO mice exhibited low expression of COX2 and suppressed levels of prostaglandin end-products PGE<sub>2</sub> and PGI<sub>2</sub> in embryonic day (E3.5) which is generally the day of preimplantation (226). Exogenously applied PGE<sub>2</sub> and PGI<sub>2</sub> could rescue the delayed implantation and reduced litter size but not the defects in embryo spacing, suggesting the role of different prostaglandins or non-prostaglandin mediators in the process (372). Besides, expression of LPA<sub>3</sub> in the murine uterus was restricted to the luminal epithelium and showed a peak at the preimplantation time point, in contrast to other lysophospholipid receptors, which are constitutively expressed in all layers of the uterus (373). In agreement with the murine data, expression of LPA<sub>3</sub> in human uterus changes with the menstrual cycle showing highest mRNA levels during early and late secretory phase (374). Surprisingly, expression of LPA<sub>3</sub> is upregulated by progesterone and suppressed by estrogen (16, 226, 372). Conversely, deletion of LPA<sub>3</sub> leads to elevated ratio of progesterone signaling/estrogen signaling (375). It is also of interest, that LPA<sub>3</sub> KO mice showed delayed collagen clearance and decreased expression of matrix-degrading metallo- and serine-proteinases in the uterus at E3.5 compared with WT animals. These results demonstrate the involvement of LPA<sub>3</sub> in the dynamic remodeling of uterine extracellular matrix in the peri-implantation period (376).

As described above, disrupted LPA<sub>3</sub> signaling may have a role in the pathogenesis of diseases like non-receptive endometrium, placenta previa, placenta accrete, and certain types of infertilities (16, 370).

Our knowledge of the role of S1P in female reproduction remains incomplete in comparison with that of LPA. S1P was suggested to mediate acrosomal reaction,

ovulation, early embryo development through anti-apoptotic effects, and regulating placental trophoblast differentiation and vascular tone (370).

#### **2.4.3.2. Male reproduction**

Mice deficient in LPA<sub>1/2/3</sub>, which are highly expressed in the murine testis (189), exhibited testosterone-independent decreased germ cell survival, mating activity, and higher prevalence of azoospermia in aging mice (377). As for S1P, it has been reported to be a survival factor for germ cells (378). Besides, it contributes to erectile function, as S1P has been demonstrated to potentiate acetylcholine (ACh)-mediated relaxation in human corpus cavernosum strips, in a Ca<sup>2+</sup>-independent manner, through the Akt-eNOS pathway (379).

As previously demonstrated, both LPA and S1P have well-established roles in reproduction, however this field still requires intensive investigation, in order to assign new points of intervention for managing certain reproductive disorders.

#### **2.4.4. Lysophospholipids in tumor biology**

Both LPA and S1P were implicated in oncology, as the precursor of LPA, LPC was detected in elevated levels in the serum of ovary carcinoma patients (66), and anti-apoptotic functions of S1P were described shortly after its discovery (17).

##### **2.4.4.1. Cell proliferation, tumorigenesis**

Ovarian cancer patients not only exhibited elevated levels of LPC in serum, but markedly increased concentrations of LPA in ascites samples (16). Furthermore, a role of LPA in tumor biology is also implicated by the fact, that aberrantly increased expression of ATX was detected in several tumor types including breast cancer, glioblastoma, renal cell carcinoma, and hepatocellular carcinoma, responsible for the formation of high LPA concentrations locally in the tumor microenvironment (380). In addition, ATX itself was identified first as a motogen factor for melanoma cells in 1992; however, that time its Lyso-PLD activity was unknown (74).

LPA acting on its GPCRs can promote cell proliferation through G $\alpha_1$ -RAS-MAPK, and G $\alpha_{12}$ -JNK pathways and LPA signaling was associated with cyclin D1, c-Myc and  $\beta$ -catenin activation (380). In addition, LPA via PI3K-Akt signaling enhances cell survival, whilst via G $\alpha_{12/13}$ -Rho-ROCK pathway plays a role in cell motility and

migration (380). It is of interest, that in certain Burkitt lymphoma and melanoma cell lines LPA<sub>2</sub> was implied to mediate cell survival via G $\alpha_s$  (380). On the other hand, LPA receptor signaling was shown to inhibit major tumor suppressor p53 (380).

Among LPA GPCRs, LPA<sub>2</sub> is assumed to have a relevant role in tumorigenesis/tumor-progression, as LPA<sub>2</sub> KO mice seem to be protected in DSS-model of colon cancer (208). Wnt/ $\beta$ -catenin is thought to be of grave importance in this type of tumors, in which Wnt-signaling prevents the degradation of  $\beta$ -catenin by the protein complex, formed by adenomatous polyposis coli, axins, casein kinase 1 $\alpha$ , and glycogen synthase kinase 3.  $\beta$ -catenin, if remains intact, can interact with its partner proteins in the nucleus and promote the transcription of genes encoding c-Myc and cyclin D1, thus aiding cell proliferation. LPA<sub>2</sub> takes part in this process by inhibiting glycogen synthase kinase 3, via G $\alpha_q$ -PLC-Ca<sup>2+</sup>-PKC (381). Further evidence supporting the role of LPA<sub>2</sub> in colon cancer is provided by the study, in which deletion of LPA<sub>2</sub> in APC<sup>min/+</sup> mice, a genetic model of human familial adenomatous polyposis, significantly attenuated the initiation and progression of colon cancer (382).

LPA<sub>2</sub> activation also increases the concentration of VEGF locally, which is essential for novel vessel-formation and thus propagation of tumors. VEGF in return induces ATX expression, leading to LPA production, establishing a potential feed-forward loop involving LPA<sub>2</sub>, VEGF, and possibly LPA<sub>4</sub> signaling (16).

LPA<sub>2</sub> was also implicated in regulation of urokinase and MMP expression, enzymes, which are key players in the invasiveness of primary tumors (16).

As already discussed in previous chapters, the effect of S1P on cell proliferation and motility cannot be taken out of context, as the ratio of pro-apoptotic ceramide and anti-apoptotic S1P determines the influence of the sphingolipid rheostat on cell-survival. Alterations of sphingolipid producing and metabolizing enzymes in multiple types of cancer have been widely reviewed elsewhere (383). Here, some direct connections between S1P signal transduction and certain oncological diseases will be highlighted.

Pro-oncogenic S1P signaling happens dependently as well as independently of S1P receptors. The role of S1P<sub>1</sub> occurred in colitis-associated colon cancer, via the NF- $\kappa$ B-IL-6-STAT3 pathway (384). The same receptor acting on PI3K and Rac can have pro-migratory, pro-invasive functions in Wilms' tumor (384). In fibrosarcoma cells, S1P<sub>1</sub> enhances the activity of membrane-type MMP, while in glioblastoma that of urokinase;

thus, it increases invasiveness of these tumors (384). Furthermore, S1P<sub>1</sub> has been associated with neovascularization, as S1P<sub>1</sub> KO mice die in utero between embryonic days 12.5 and 14.5 due to severe vascular malformations (230).

S1P<sub>2</sub> is the only receptor, which has pro- as well as anti-oncogenic roles (384). S1P<sub>2</sub> signaling enhances the transcription of master transcription factors c-Jun and c-Fos, arguing for its proliferative role (384). On the other hand, S1P<sub>2</sub> KO mice show frequent, spontaneous development of diffuse B-cell lymphomas with age (384). The signaling responsible for these pathologies is however still unknown.

S1P<sub>3</sub> is the most abundant of the five S1P receptors in human breast cancer cell lines. Furthermore, it activates Notch to expand the aldehyde dehydrogenase positive cancer stem cell population, which is assumed to be crucial in tumorigenesis (384).

S1P<sub>4</sub> and S1P<sub>5</sub> have less well-established roles in oncology. Although, S1P<sub>5</sub> can activate PI3K-Akt-Polo-like kinase 1, which is generally considered to be pro-oncogenic, inhibitory functions of S1P<sub>5</sub> also occurred (384).

Independently of its receptors, S1P activates intracellularly HDAC1 and 2 and hTERT (17). The relevance of these enzymes has been addressed in the chapter discussing intracellular S1P actions.

#### **2.4.4.2. Metastasis**

Both LPA and S1P have been implicated in metastasis.

Bone metastases are dreaded complication of many types of tumors including breast, prostate, kidney, thyroid, and lung cancers. Bone metastases are categorized as osteolytic and osteoblastic lesions, corresponding for sites with excessive loss or formation of bone tissue respectively (385). Latest evidence suggests that tumor cells do not directly evoke bone loss or formation, but influence the functioning of osteoclasts, osteoblasts, and osteocytes. Several studies pointed out the possible contribution of LPA to osteolytic lesions and some to osteoblastic ones. The knowledge available is excellently reviewed elsewhere (386). Here the hypothesis, based on the results concerning the role of LPA in bone metastasis, will be briefly summarized. LPA, present in a high concentration at the location of metastatic sites, due to platelet activation and/or high ATX expression of metastatic cancer cells, acts on the cancer cells, increasing the production of factors that influence osteoblast and osteoclast activity. Endothelin-1 has been described as a mediator of osteoblastic metastases,

released upon LPA stimuli. It inhibits osteoclasts and simultaneously stimulates osteoblasts. In case of osteolytic lesions, LPA stimulates the production of Dkkopf 1, IL-6, IL-8, GM-CSF, monocyte chemoattractant protein 1 (MCP1) (also known as chemokine ligand 2 CCL2), and Gro $\alpha$  by metastatic cells, which increase phagocytic activity and maturation of osteoclast and inhibit osteoblast activity (386).

LPA has a direct effect on bone cells, promoting osteoclast differentiation, survival, and bone resorption. LPA<sub>1/3</sub> receptors may be involved in this process, as the LPA<sub>1/3</sub> antagonists Ki16425, and VPC32183 inhibited formation and propagation of osteolytic metastases in vitro and in vivo as well (386). Simultaneous inhibition of LPA GPCRs and ATX by BrP-LPA is also a promising approach for future therapies of these types of metastases (386).

The involvement of S1P in metastasis formation is highlighted by the fact that the deletion of Spns2, the ubiquitous S1P transporter reduced the lung metastases of various types of cancer cell lines injected in murine tail vein (387). Deletion of SK1 decreased the occurrence bladder cancer and melanoma metastases. S1P<sub>2</sub> was shown to repress breast cancer metastasis suppressor 1 a suppressing factor of metastases, which was reactivated upon application of sonopizumab, an anti-S1P antibody. Furthermore, S1P activates the ezrin-radixin-moesin proteins, through which increases motility and invasion, features of high importance for metastases. S1P<sub>3</sub> was also shown to promote metastasis in lung cancer, influencing the TGF $\beta$ -SMAD pathway (383).

#### **2.4.4.3. Resistance against chemo- and radiotherapy**

LPA<sub>2</sub> does not only play a role in tumorigenesis of ovary carcinoma, but studies suggest it may also contribute to its resistance against chemotherapeutical drugs. LPA<sub>2</sub>, via its C-terminal, promotes certain anti- and inhibits other pro-apoptotic processes. The LPA<sub>2</sub> C-terminal can bind TRIP6 as well as NHERF2 and these proteins bind each other as well. Additionally, NHERF2 forms a homodimer with another NHERF2 molecule. This complex enhances and prolongs the activation of ERK1/2 and Akt, mediators of cell survival and proliferation. Furthermore, LPA<sub>2</sub> binds the Siva-1 transcription factor through its C-terminal. Siva-1 is a pro-apoptotic factor, downstream of p53 which, when bound to LPA<sub>2</sub> in a ligand-activated mechanism gets polyubiquitinated and thus degraded in the proteasome. By increased impairment of

Siva-1, LPA<sub>2</sub> impedes the pro-apoptotic answer of the cell, triggered by p53, upon DNA-damage, for instance in case of cytotoxic chemotherapeutical agents (16).

Additionally to LPA, S1P may also contribute to the development of chemo- and radioresistance. In case of colorectal cancer, overexpression of SK1 was correlated with intrinsic or acquired cetuximab-resistance. Conversely, inhibition of S1P GPCRs, by FTY720, sensitized this type of cancer to cetuximab (388). Excessive expression of SK1 was also associated with imatinib- and nilotinib-resistance in chronic myeloid leukemia, via inhibition of protein phosphatase 2A by S1P<sub>2</sub>. Interestingly, application of Fingolimod, but not that of Fingolimod-phosphate, restored imatinib-sensitivity in chronic myeloid leukemia (389). The aforementioned phenomenon could be the result of a direct interaction between FTY720 and protein phosphatase 2A, as S1P<sub>2</sub> is the only S1P receptor on which FTY720 has minimal or no effect (337). Likewise, silencing SPP1, an S1P metabolizing enzyme, by miR-95, enhanced resistance against radiation in breast and prostate cancer cells (390). Furthermore, high expression of S1P<sub>3</sub> was correlated with tamoxifen-resistance in human breast cancer cells (391).

This short summary highlights the potential of both lysophospholipid mediators to point out future drug targets, however further intensive research of the field is inevitable to gain a clear view of the roles of certain receptors and their signal transductional pathways.

#### **2.4.5. Lysophospholipids in the cardiovascular system**

The early reports by Tokumura and colleagues in the late seventies already established a role of importance for LPA in the cardiovascular system (3, 4, 392). Since then, LPA emerged as a key player in multiple aspects of vascular pathology. The other lysophospholipid S1P and its receptors also proved to have physiologically relevant interactions with the cells of the circulatory system.

##### **2.4.5.1. Vascular development**

The roles of both mediators in developmental steps of the vasculature have been addressed widely earlier in the chapter discussing ATX and the lysophospholipid receptors.

### 2.4.5.2. Atherosclerosis and atherothrombotic events

The first investigation that associated LPA with atherosclerosis derives from Siess and colleagues back in 1999, when they described the accumulation of LPA in human atherosclerotic plaques (67). Since that time, LPA has been described to affect almost every cell type involved in this process (393).

LPA acts on the endothelium, and so enhances cell migration, and upregulates the expression of adhesion molecules, such as intercellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 (VCAM-1) (393, 394). Secretion of chemokines like CXCL1 and CCL2 also increases (393). LPA is hypothesized to have a biphasic role, as it promotes the secretion as well as transcription of CXCL1 in an LPA<sub>1/3</sub>- and NF- $\kappa$ B-dependent manner, respectively (395). Furthermore, LPA promotes endothelial permeability in an LPA<sub>1</sub>-dependent manner, as mice deficient in LPA<sub>1</sub> showed decreased vascular leakage in a bleomycin-induced lung injury model (193). However, other studies supported the role of LPA in stabilizing the endothelial barrier function (393).

Early stages of atherosclerosis include the migration and dedifferentiation of VSMCs (396). LPA has been shown to promote migration as well as this shift from contractile to pro-inflammatory, secretory phenotype and to enhance SMC proliferation via LPA<sub>1</sub>, including G $\alpha_i$ , G $\alpha_q$ , PKC, ERK1/2, PI3K/Akt and MAPK cascades (393). LPA<sub>1</sub>, G $\alpha_q$ , G $\alpha_i$  and MAPK also mediate the migratory effect of LPA (393). At the same time, the activation of LPA<sub>1</sub> upregulates the expression of pro-inflammatory cytokines IL-6, CCL2 and facilitates the production of NADPH-oxidase-dependent reactive oxygen species (ROS) (393). Besides, downregulation of the contractile proteins occur, in an LPA<sub>3</sub>-dependent pathway (397, 398). On the other hand, activation of the intracellular LPA receptor PPAR $\gamma$  attenuates neointima formation after vascular injury (393), whilst inhibition of LPA<sub>3</sub> by Ki16425 diminished neointimal hyperplasia after carotid wire injury. Unsaturated LPA species mobilized smooth muscle progenitor cells from bone marrow in a pathway linked to CXCL12. This process could be interrupted by silencing either LPA<sub>1</sub> or LPA<sub>3</sub> (399).

LPA also influences monocytes, recruitment of which into the vessel wall is a crucial step in plaque formation (400). It enhances ox-LDL-uptake of monocytes/macrophages, and expression of pro-atherogenic IL-1 $\beta$  in murine

macrophages. Upregulation of the scavenger receptor A via LPA<sub>1/3</sub> intensifies lipid accumulation in these cells. Activation of PPAR $\gamma$  in monocytes increases the expression of other scavenger receptor CD36 (393). While deletion of PPAR $\gamma$  in macrophages promoted atherosclerosis. LPA on one hand evokes monocyte migration, and inhibits reverse transmigration, which results in an entrapment of monocytes in the plaque (393).

It is noteworthy, that LPA may also have a role in acute atherothrombosis on basis of ruptured plaques. Activated platelets bind ATX via  $\beta$ 3 integrins and thus facilitate LPA production from LPC as discussed previously. Although thrombocyte activation has been implicated to be a major source of local LPA production, the exact mechanism is still obscure.

Former studies suggested a multistep process, in which intracellular- and secreted PLA enzymes produce the precursor for ATX (mainly LPC), which binds to the platelets and generates LPA; however, the exact PLA isoenzyme was still lacking (393). Bolen and colleagues described a new PLA, secreted from activated platelets. The enzyme, acyl-protein thioesterase 1, also known as lysophospholipase A-I has PLA<sub>1</sub> activity, thus produces sn2 lysophospholipids, which then undergo acyl-migration as previously mentioned. The sn1 lysophospholipids generated this way are well-known substrates of ATX (401) and explain the dominance of 18:2 and 20:4 molecular species of LPA in serum as these fatty acids are in the sn2 position of phospholipids.

However, the role of two other PLA enzymes also occurred. Group II sPLA<sub>2</sub> and lipoprotein-associated PLA<sub>2</sub> are enzymes implicated in chronic inflammation and produce LPC. Varespladib, an inhibitor of the former as well as darapladib, which inhibits the latter, reduced atherosclerosis in mice (402). These enzymes, however, seem to play a role in the chronic process of plaque building and not in acute thrombotic events.

Furthermore, LPA was not only associated with platelet activation as a product, but itself was also assumed to elicit thrombocyte activation. In accordance, human and cat platelets are activated by LPA, while that of rodents are not (403, 404). Moreover, murine platelets are inhibited by LPA (54). In support of this hypothesis, ATX overexpression in adult mice evokes hemorrhages, whereas mice heterozygote for ATX, that have a plasma concentration of LPA approximately 50% of that in WT, develop

thromboses more often (54). Furthermore, the thrombocytes of 20% of the healthy human population failed to respond upon LPA-stimulation (405). Further studies found, that LPA-induced platelet aggregation was ADP-dependent, which displayed, that LPA itself does not cause thrombocyte activation, but plays a role in the shape-change of platelets in an ADP- or other platelet activator-dependent manner (406). In support of this, LPA has been shown not to act on  $G\alpha_i$  in thrombocytes, which is the initial step in their activation (393). LPA-induced shape-change has been described to be  $G\alpha_{12/13}$ -dependent, through which LPA activates Rho, ROCK, and the actomyosin system on the one hand and the LIM-kinase-1 cascade on the other hand (393). As for the receptors involved, human platelets express all known LPA GPCRs with LPA<sub>4</sub> and LPA<sub>5</sub> in the highest amount (285, 407, 408). First, only indirect evidence suggested a role for either of these receptor, as alkyl-analogues of LPA were more potent than acyl ones, a feature typical for LPA<sub>5</sub> (393). A further investigation by Kandoga and colleagues showed, that knockdown of LPA<sub>5</sub>, but not that of LPA<sub>1-4</sub> or LPA<sub>6</sub> inhibited LPA-mediated shape-change in human megakaryocytic cell lines (278). As for LPA<sub>4</sub>, it is hypothesized, that it would be responsible for the LPA-mediated inhibition in rodents and in that 20% of the human population, whose platelets do not respond to LPA (408).

There are two studies of human subjects from the same group, which bind LPA directly to acute coronary syndrome (ACS), one of the fatal consequences of atherosclerosis (409, 410). In the former paper it was reported, that circulating plasma LPA levels increase in patients with ACS compared to patients with stabile angina pectoris or angiographically normal coronary arteries (409). In the latter publication, a higher LPA level was found at sites in culprit coronary arteries than in the peripheral circulation of patient with ACS (410). Although, these experiments exhibit a potential biomarker role for LPA in ACS, they are difficult to interpret, because no precautions were taken to inhibit in vitro LPA generation during sample handling, and LPA levels in healthy subjects were higher than previously reported by others (393).

The putative role of S1P in atherogenesis was identified early, as plasma S1P is largely bound to HDL, a well-known atheroprotective factor. Although S1P has been extensively studied in this context, it could not be established as either a pro- or an anti-atherogenic mediator till today. S1P also affects nearly all cell types involved in plaque formation (17).

In endothelial cells, S1P was found to suppress IL-8 and CCL2. Furthermore, S1P inhibited VCAM-1, a key adhesion molecule, mediating monocyte invasion into the vessel wall. In contrast, additional studies described enhanced VCAM-1 and E-selectin expression upon S1P-treatment. It is noteworthy, that opposite effects occurred upon application of different concentrations of S1P. While micromolar concentrations increased, nanomolar ones lowered the expression of the aforementioned adhesion molecules (411). Early studies reported, that S1P improves endothelial barrier function by facilitating adherens junction formation via activation of S1P<sub>1</sub> (412). The possible role of S1P<sub>3</sub> has been proposed, however, this issue is still under debate (412). In contrast, S1P<sub>2</sub> proved to increase endothelial permeability, acting on Rho-ROCK and PTEN (411). Nonetheless, the net effect of S1P on vascular permeability is rather an enhancement of its barrier function, as mice deficient in plasma S1P exhibited vascular leakage, a feature could be restored by either transfusion of WT type red blood cells or application of an S1P<sub>1</sub> agonist. Besides, SK1 global KO mice also suffer from vascular leakage, however in a less extent (411). Furthermore, barrier-enhancing functions of activated protein C proved to be at least partially S1P-dependent, and an S1P<sub>1</sub> agonist can rescue mice from PAF-evoked general vascular leaking (411).

Three independent studies investigated the therapeutic potential of FTY720 in atherosclerosis, two of which concluded attenuation in plaque-formation in two distinct established mouse models of the disease (413, 414) and in a third one, Fingolimod had no effect, although evoked hypercholesterinemia (415). The interpretation of these studies is however difficult, considering the wide range of effects FTY720 has on S1P receptors and producing enzymes, addressed previously in detail.

Experiments conducted with S1P receptor KO mice, however, contradict with the former results. S1P<sub>2</sub> KO animals on ApoE KO background showed clearly reduced plaque burden, decreased macrophage density and increased VSMC content of the plaques. Bone-marrow transplantation studies pointed out, that S1P<sub>2</sub> receptor located on macrophages are responsible for the aforementioned effect. Absence of S1P<sub>3</sub> had no direct influence on atherosclerosis, though it alleviated monocyte/macrophage content of the lesions (411).

Finally, S1P also has an ambiguous effect on cytokine production, with S1P<sub>1</sub> on the inhibitory and S1P<sub>2</sub> on the promoting side (411).

As seen from the observations listed above, while LPA actions can be concluded pro-atherogenic, with LPA<sub>1/3</sub> signaling in plaque formation and LPA<sub>5</sub> activation in thrombocyte shape-change, the role of S1P in atherogenesis is far from being clear, as S1P<sub>1</sub> signaling seems to be anti-atherogenic, and S1P<sub>2</sub> is pro-atherogenic on the other hand.

#### **2.4.5.3. Cardiac functions**

In contrast with LPA, the role of S1P in functions of the heart has been extensively studied, hence its effect on this organ should be addressed separated and in more detail than that of LPA. S1P influences heart development, highlighted by the fact, that cardiomyocyte-specific S1P<sub>1</sub> KO mice exhibit ventricular septal defects (416). Besides, S1P was found to be involved in ischemia-reperfusion injury, in which it would be a protective factor. In a porcine ischemia-reperfusion injury model, treatment with FTY720 increased myocardial salvage and reduced adverse post-injury remodeling. Furthermore, cardiomyocytes lacking SK1 proved to be more sensitive to hypoxia than WT ones, manifested in a greater extent of cell-death. Treatment with exogenous S1P could however, increase the survival of KO as well as WT cardiomyocytes. Moreover, hearts of SPL KO mice exhibited higher S1P levels and smaller infarct sizes following myocardial ischemia (417).

Multiple studies point to a cross-talk mechanism between S1P<sub>1</sub> and  $\beta_1$ -adrenergic signaling, in which S1P<sub>1</sub> agonism counteracts  $\beta_1$ -activation, decreasing contractility. At first sight, this effect may seem to be deleterious for the heart in a post-ischemic condition. The level of circulating catecholamines is increased in this set up though, and that would lead to an excessive activation and rapid desensitization of  $\beta_1$  receptors. Hence, this opposing effect of S1P can be beneficial under these circumstances. Moreover, S1P<sub>1</sub> action was reported to be modulated by  $\beta_3$  activation in cardiomyocytes, a mechanism of interest, which may have a role in preventing post-ischemic heart failure (417).

In addition, S1P<sub>1</sub>, S1P<sub>2</sub>, and S1P<sub>3</sub> may also contribute to the protection of the heart. Although S1P<sub>2</sub> and S1P<sub>3</sub> KO animals showed similar sizes of infarcts upon ischemia to WT ones, S1P<sub>2/3</sub> double KO mice exhibited infarct sizes increased more than 50% (261).

Furthermore, the role of S1P also occurred in the regulation of the hearth rate. Studies conducted by Bünemann and colleagues in the mid 90's revealed that in isolated guinea pig atrial myocytes S1P and SPC activate the G protein-coupled inwardly rectifying potassium channel in a GPCR-dependent manner, the channel also targeted by the M<sub>2</sub> ACh receptors upon parasympathetic stimuli. This effect of S1P and SPC is mediated by G $\alpha_i$ , as it can be suppressed by PTX. S1P and SPC showed homologue desensitization, implicating that the two mediators act on the same receptor, which is a distinct one of M<sub>2</sub>, as carbachol could not desensitize their effect (418, 419). In addition, Liliom and colleagues found that guinea pig atrial myocytes express S1P<sub>1-3</sub>, and S1P<sub>5</sub>, and that SPC has a negative chronotropic effect on perfused guinea pig hearts (147). Moreover, bradycardia is a recognized adverse effect of Fingolimod, applied in multiple sclerosis. This effect was lacking in mice deficient in S1P<sub>3</sub> (420). However, data acquired in rats (421) and humans (422) supported a participation of S1P<sub>1</sub> in this process.

Lastly, changes in circulating S1P levels were also investigated in coronary artery disease and acute myocardial infarction. Reduction in S1P levels were reported in humans with acute myocardial infarction (423). The same was observed in case of post-ischemic heart failure in rodents. The bulk of S1P in plasma, is however, bound to HDL, the level of which is also altered in these conditions (417). Algraves and colleagues found that circulating S1P, dihydro-S1P and C24:1-ceramide levels in HDL were inversely correlated with the incidence of ischemic heart disease (424).

#### **2.4.5.4. Regulation of the vascular tone**

The initial report on LPA by Tokumura described, that intravenous administration of LPA elicited hypertension in rats and guinea pigs but the same molecular species proved to be hypotensive in cats and rabbits (4). This hypotensive effect in cats was attributed to a decreased cardiac output, which was a result of pulmonary vasoconstriction upon platelet aggregation (404). Intravenous application of LPA elevated the mean arterial pressure in LPA<sub>1</sub> KO, LPA<sub>2</sub> KO and LPA<sub>1/2</sub> double KO mice as well as in LPA<sub>4</sub> KO and smooth muscle specific PPAR $\gamma$  KO animals. The same effect was also observed in LPA<sub>3</sub> KO animals (425). A recent report by Kano and colleagues described a hypertensive response upon intravenous LPA application in mice. This effect was alleviated in absence of LPA<sub>4</sub> or LPA<sub>6</sub> or upon the application of

the ROCK inhibitor Y-27632. However, LPA<sub>6</sub> KO mice also showed attenuated vasoactive responses upon adrenergic stimuli and exhibited abrupt vessel formation (295).

LPA applied on the extraluminal surface of porcine pial arteries in a cranial window set-up elicited a dose-dependent vasoconstriction (426). This effect was G $\alpha_i$  dependent, because it could be inhibited by PTX. Because LPA receptors were undiscovered that time, the receptor responsible for the effect remained obscure. Furthermore, intrathecal application of autologous blood or Endothelin-1, as a model of subarachnoidal hemorrhage, raised the concentration of LPA in the cerebrospinal fluid into the vasoactive range (427).

The endothelium and eNOS play key roles in regulation of the vascular tone. LPA was shown to activate eNOS and thus elicit NO generation in endothelial cell cultures (428-430), however 24 h incubation of porcine coronary endothel cells with LPA downregulated the transcription of eNOS (431). In bovine aortic endothelial cell (BAEC) culture, LPA-induced eNOS activation was mediated by PI3K (429), nonetheless, in an other study, conducted also on BAEC, inhibition of PI3K had no effect on eNOS activity (430). These investigations, however, should be treated with caution as endothelial cell properties may vary on experimental setup (432, 433). Expressional profile of BAEC changes in a great extent under cultured conditions (434). A report also pointed out the lack of glycocalyx in cultured HUVECs; however, it mediates important physiological interactions (435). Endothelium-dependent flow-stimulated NO production is a key regulator of the tone of resistance arterioles in mammals (436). A recent study reported, that in adipose tissue arterioles of human subjects with coronary artery disease, LPA elicits a shift in the mediator of flow-induced dilation from NO to mitochondria-derived H<sub>2</sub>O<sub>2</sub> in an LPA<sub>1</sub>-dependent manner (437). LPA, on the other hand, was also shown to induce endothelium-dependent vasoconstriction if shear stress was present (438).

The effects of S1P on the vascular tone have been studied broadly. An early report described S1P as a constrictor in basilar artery of dogs in a Rho-ROCK-dependent manner (439). In vivo, injected into the cisterna magna, S1P elicited a contraction of duration lasting for approximately 2 days. Since then, this effect has been confirmed in multiple species in various vascular beds. However, in larger species S1P proved to be

potent only in smaller arteries (cerebral, mesenteric) with moderate (coronary) to no effect (aorta, femoralis) in larger ones (440). In mice, the efficacy was in negative correlation with size (440). Further, in mice S1P caused S1P<sub>3</sub>-dependent contraction of the basilar artery (441). A study, conducted in human chorionic plate arteries, found, that the outcome also depends on the experimental setup (isometric vs. isobar mounting) (442). Pharmacological investigations confirmed the S1P-elicited vasoconstriction to be S1P<sub>3</sub>-dependent in basilar and coronary arteries (411, 440).

Thorough investigations of S1P<sub>2</sub> KO mice revealed interesting results though. These animals exhibited a decreased vascular tone; however, this had no influence on blood pressure. Furthermore, blood flow of the renal and mesenteric areas was elevated with consequent smaller vascular resistance. Additionally, responses of the vessels to  $\alpha$ -adrenergic stimuli were also decreased (252). The subjects also showed a more severe drop in blood pressure in an anaphylactic test (443).

Receptor-independent constrictive actions of S1P were also reported (411). Vessels deficient in SK1 showed reduced contractile responses to KCl, S1P, or the thromboxane receptor agonist U46619 compared to WT, S1P<sub>2</sub> KO or S1P<sub>3</sub> KO arteries (411). Besides, S1P can activate store-operated calcium entry through receptor-dependent and independent pathways (444).

Interestingly, S1P was found to activate eNOS and thus promote NO release in rodent aortic rings, which proved to be mediated via S1P<sub>3</sub> at least in mice (445, 446). A possible contribution of S1P<sub>1</sub> also occurred, however the lack of highly selective antagonists makes these results disputable (440). On the other hand, S1P elicited eNOS activation in COS-7 cells, transfected with eNOS and S1P<sub>1</sub> in an S1P<sub>1</sub>-dependent manner (447). Furthermore, S1P elicited eNOS activation in BAEC (448). Moreover, VEGF was shown to increase S1P<sub>1</sub> expression in aortic endothelial cells, and pretreatment of isolated vessels with VEGF enhanced S1P-dependent vasodilation (449). In rat mesenteric arterioles, S1P-induced dilatation was inhibited by PTX, and the PI3K inhibitor wortmannin. Likewise, S1P can activate eNOS via AMP-activated protein kinase. Nonetheless, the S1P<sub>1</sub> agonist SEW2871 failed to induce any relaxation in basilar, femoral or mesenteric arteries of rats (440).

In summary, LPA as well as S1P have a multitude of actions in the cardiovascular system, which may provide potential drug targets and/or biomarkers for the future,

however in both cases, the receptor-dependency is mostly unsure, which require further investigations of this topic, by which millions of patients are affected worldwide.

### **3. Aims of the study**

The brief summary of the last chapter showed that both LPA and S1P play several, physiologically significant roles in the cardiovascular system. As for the regulation of the vascular tone, a large amount of data is available for both mediators. Constrictor and dilator responses have been reported in case of both lysophospholipids. Nonetheless, these results and especially the receptor-dependency of the described effects are unclear and often inconsequent.

Accordingly, in the present study we addressed the following questions:

1. Are there any EDG LPA receptor-mediated vasoactive actions?
2. If yes, are they endothelium-dependent or independent?
3. Which receptors and underlying signaling pathways may be involved?
4. Does the activation of the S1P GPCRs mediate any vasoactive processes?
5. If yes, are they dependent of the endothelium?
6. Which receptors and downstream pathways participate?

## 4. Materials and Methods

All procedures were carried out according to the guidelines of the Hungarian Law of Animal Protection (28/1998) and were approved by the National Scientific Ethical Committee on Animal Experimentation (PEI/001/2706-13/2014).

### 4.1. Animals

C57BL/6 and eNOS KO mice were obtained from Charles River Laboratories (Isaszeg, Hungary). C57BL/6 mice are referred to as WT in the text and figures. All transgenic mouse lines were on C57BL/6 genetic background. Mice deficient in LPA<sub>1</sub> or LPA<sub>2</sub> receptors (LPA<sub>1</sub> KO and LPA<sub>2</sub> KO, respectively) were generated as previously described (192, 202, 326, 450). Cyclooxygenase-1 KO (COX1 KO) mice were from Dr. Ingvar Bjarnason (Department of Medicine, Guy's, King's College, and St. Thomas' School of Medical Education, London, UK). Thromboxane prostanoid receptor-deficient (TP KO) mice were kindly provided by Dr. Shuh Narumiya (Kyoto University, Kyoto, Japan). The smooth muscle-specific G $\alpha_{q/11}$  and G $\alpha_{12/13}$  deficient mice (G $\alpha_{q/11}$  KO and G $\alpha_{12/13}$  KO respectively) and their respective controls (G $\alpha_{q/11}$  CTRL and G $\alpha_{12/13}$  CTRL), were generated as described (451). Mice deficient in S1P<sub>2</sub>- and S1P<sub>3</sub> receptors (S1P<sub>2</sub> KO, S1P<sub>3</sub> KO) and their controls were kindly provided by Dr. Richard L. Proia (National Institute of Diabetes and Digestive and Kidney Disease, NIH, Bethesda, USA). In experiments performed with LPA<sub>1</sub> KO, LPA<sub>2</sub> KO or COX1 KO mice, wild-type animals from the same strain served as controls and are referred to as LPA<sub>1</sub> CTRL, LPA<sub>2</sub> CTRL and COX1 CTRL, respectively. Because the TP mice have been maintained in our animal facility with KO x KO mating, WT C57BL/6 mice served as controls (TP CTRL). PTX was administered intraperitoneally in some of the animals for 5 days prior to the experiments in a dose of 50  $\mu$ g/kg body weight in order to inhibit G<sub>i</sub> proteins (452, 453).

### 4.2. Preparation of Vessels

Adult male animals were perfused transcardially with 10 mL heparinized (10 IU/mL) Krebs solution under deep ether anesthesia as described previously (454). The aorta was removed and cleaned of fat and connective tissue under a dissection microscope (M3Z, Wild Heerbrugg AG; Gais, Switzerland) and immersed in a Krebs solution of the

following composition (mM): 119 NaCl, 4.7 KCl, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 2.5 CaCl<sub>2</sub>·2 H<sub>2</sub>O, 1.2 MgSO<sub>4</sub>·7 H<sub>2</sub>O, 20 NaHCO<sub>3</sub>, 0.03 EDTA, and 10 glucose at room temperature and pH 7.4. Abdominal and thoracic aortae were cut into ~3 mm-long segments and mounted on stainless steel vessel holders (200 µm in diameter) in a myograph (610 M multiwire myograph system; Danish Myo Technology A/S; Aarhus, Denmark). In certain experiments special care was taken to preserve the endothelium of the segments, in all other cases the endothelium was removed intentionally by gently rotating the segments on the holder pins and mechanical ablation with surgical thread. Integrity or absence of the endothelium was confirmed by the presence or lack of ACh-induced vasorelaxation respectively. Thoracic aortae were also cut into segments and subjected, with the endothelium preserved, to thromboxane B<sub>2</sub> ELISA as described below in detail.

### **4.3. Myography**

Chambers of the myographs were filled with 6 mL gassed (95% O<sub>2</sub>–5% CO<sub>2</sub>) Krebs solution. The vessels were allowed a 30-min resting period, during which the bath solution was warmed up to 37 °C and the passive tension was adjusted to 10 mN in case of abdominal and to 15 mN in case of thoracic segments, which was determined to be optimal in a previous study (454). Subsequently, the tissues were exposed to 124 mM K<sup>+</sup> Krebs solution (made by isoosmolar replacement of Na<sup>+</sup> by K<sup>+</sup>) for 1 min, followed by several washes with normal Krebs solution. A contraction evoked by 10 µM phenylephrine (PE) followed by administration of 0.1 µM ACh served as a test of the reactivity of the smooth muscle and the endothelium, respectively. After repeated washing, during which the vascular tension returned to the resting level, the segments were exposed to 124 mM K<sup>+</sup> Krebs solution for 3 min in order to elicit a reference contraction. Subsequently after a 30-min resting period, increasing concentrations of PE (0.1 nM to 10 µM) and ACh (1 nM to 10 µM) were administered to determine the reactivity of the vessel and to verify the integrity or the proper denudation of the endothelium. We proceeded with a 30-min resting period. Thereafter, we followed three distinct protocols, depending on the aim and setup of the given experiment.

#### **4.3.1. Protocol for testing vasoactive effects in precontracted vessels**

Thoracic vessels were precontracted to 70–90% of the reference contraction by an appropriate concentration of PE, and after reaching a stable plateau, the effect of either

the LPA<sub>1-3</sub> agonist VPC31143 (455) in a concentration of 10  $\mu$ M or that of S1P in 5  $\mu$ M was determined in vessels of different genetic background. Vasoconstrictions were normalized to the reference contraction induced by 124 mM K<sup>+</sup>, whereas vasorelaxations were expressed as percentage of the precontraction produced by PE

#### **4.3.2. Protocol for testing vasoactive effects on resting tone**

In this type of protocols, the vessels were exposed to either 10  $\mu$ M VPC31143 or different concentrations of the LPA<sub>3</sub> agonist T13 (456) or 5  $\mu$ M S1P at the resting tone. In some experiments, the LPA<sub>1&3</sub> receptor antagonist Ki16425 (457) or the selective LPA<sub>3</sub> antagonist diacylglycerol pyrophosphate (DGPP) (458) was applied to the bath chambers at a concentration of 10  $\mu$ M, 30 min prior to the administration of VPC31143. Vasoconstrictions are expressed as percentage of the reference contraction induced by 124 mM K<sup>+</sup>.

#### **4.3.3. Protocol for testing the long-term vasoactive effects of S1P**

In these experiments, we investigated the potentiating effect of S1P on an  $\alpha_1$  agonist-induced contraction in thoracic vessels. Vasoconstrictions were elicited in every 20 minutes by repeated administration of PE. Mean of the first three contractions served as reference and was considered as 100%. After the third administration of PE, we incubated the vessel with either S1P in a concentration of 5  $\mu$ M, or its vehicle 0.3 N sodium hydroxide (NaOH). Subsequently, PE was applied every 20 minutes for three hours after the incubation. Vasoconstrictions are expressed as percentage of the mean of the three contractions, evoked before the incubation.

#### **4.4. Quantification of Vascular Thromboxane A<sub>2</sub> Release**

Thoracic aortae were cut into 5 segments and allowed a 2-h resting period. In some of the experiments, 3  $\mu$ g/mL PTX was applied for 2 h in order to inhibit G<sub>i</sub> (459). Thereafter, the vessels were incubated in 200  $\mu$ L Krebs solution at 37°C for 2 min to obtain a baseline level of TXA<sub>2</sub> release. After the incubation, the supernatant was replaced with 200  $\mu$ L of Krebs solution containing 10  $\mu$ M VPC31143 and incubated for 2 min. Supernatants of the resting and the VPC31143-stimulated vessels were snap-frozen and stored at -80°C until the measurement of thromboxane levels. Concentrations of thromboxane B<sub>2</sub> (TXB<sub>2</sub>), a non-enzymatically produced stable metabolite of TXA<sub>2</sub>,

were determined using a TXB<sub>2</sub> EIA kit, purchased from Cayman Chemical Co. (Ann Arbor, MI, USA; Cat. No.: 501020). TXB<sub>2</sub> production was calculated as pg/min. Vessels with a baseline production of TXB<sub>2</sub> higher than 20 pg/min were considered pre-activated and were excluded from the experiment.

#### 4.5. Expression Analysis of LPA and S1P Receptors in VSM

Endothelium-denuded thoracic and abdominal aortae were isolated, and the adventitia of the vessels was carefully removed under a dissection microscope. Thereafter the vessels were fast-frozen and stored at -80°C until PCR analysis. RNA was isolated from VSM with the RNeasy Micro kit (Qiagen, Valencia, CA, USA; Cat. No. 74004), and RNA concentration and quality were assessed with Nanodrop (Thermo Fischer Scientific; Waltham, MA, USA). Up to 500 ng total RNA was converted to cDNA using a SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen; Carlsbad, CA, USA; Cat. No.: 11754050).

Assessment of mRNA expression was performed by quantitative real-time PCR using cDNA corresponding to 20 ng RNA template. PCR reactions were carried out in triplicate with 300 nmol of each primer in a final volume of 25 µL of 2 x Maxima SYBR Green/ROX qPCR master mix (Thermo Fischer Scientific; Cat. No. K0223). Amplification was performed after one initial step of 10 min at 95°C for 40 cycles at 94°C /15 s and 60°C /60 s with a StepOnePlus real-time PCR system (Applied Biosystems; Carlsbad, CA, USA). Relative gene expression of each mRNA to GAPDH was determined using the dCt method. The primer sequences of LPA GPCR are listed in Table 1. The primers used for expression analysis of S1P receptors were manufacturer designed TaqMan probes (Thermo Fischer Scientific).

**Table 1.** Primers used for quantitative real-time PCR, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, A: Adenine, T: Thymine, G: Guanine, C: Cytosine, LPA<sub>1-6</sub>: LPA<sub>1-6</sub> Receptors

Gene	Primers, 5'-3'	
	Forward	Reverse
GAPDH	CTGCACCACCAACTGCTTAG	GGCCATCCACAGTCTTCT
LPA <sub>1</sub>	CACCATGATGAGCCTTCTGA	GCAGCACACATCCAGCAATA
LPA <sub>2</sub>	CCAGCCTGCTTGCTTCCTA	GGTCCAGCACACCACAAAT
LPA <sub>3</sub>	AGGGCTCCCATGAAGCTAAT	TGCACGTTACACTGCTTGC
LPA <sub>4</sub>	ACAGTGCCTCCCTGTTTGTC	AAATCAGAGAGGGCCAGGTT
LPA <sub>5</sub>	TCATCATCTTCCTGCTGTGC	ATCGCGTCTCTGAATACTGT
LPA <sub>6</sub>	TCGTCATGAGGACACAGAC	CAAAGCAGCAGTTGGAAACA

#### **4.6. Reagents**

LPA (18:1) and VPC31143 were purchased from Avanti Polar Lipids (Alabaster, AL, USA) and dissolved in saline immediately before administration. DGPP was purchased from Avanti Polar Lipids and dissolved in methanol. Ki16425 was purchased from Cayman and dissolved in DMSO to make a 100-fold concentrated stock solution. In these experiments, vehicle treatment served as control. PTX was purchased from List Biological Laboratories, Inc. (Campbell, CA, USA) and dissolved in glycerol. T13 was synthesized as described previously (456) and was dissolved in PBS containing 0.1 % fatty acid free bovine serum albumin. Sphingosine 1-phosphate was purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA) and dissolved in 0.3 N NaOH before administration. All other drugs and chemicals used in the present study were purchased from Sigma-Aldrich (St. Louis, MO, USA). In myography experiments, all concentrations are expressed as the final concentration in the organ bath.


#### **4.7. Data Analysis**

An MP100 system and AcqKnowledge 3.72 software from Biopac System Inc. (Goleta, CA, USA) were used to record and analyze changes in the vascular tone. All data are presented as mean  $\pm$  SE, and *n* indicates either the number of vessels tested in myography experiments or the number of animals tested in the case of TXB<sub>2</sub> EIA or qPCR. Statistical analysis was performed using the GraphPad Prism software v.6.07 from GraphPad Software Inc. (La Jolla, CA, USA). Student's unpaired *t* test was applied when comparing two variables, whereas all other comparisons between the different experimental groups were made by ANOVA followed by either Tukey's or Bonferroni's post hoc test. A *p* value of less than 0.05 was considered statistically significant.

## 5. Results

### 5.1. Activation of EDG-like LPA receptors induce endothelium-dependent and -independent changes of the vascular tension


In order to evaluate the potential vascular effects of LPA EDG-like GPCRs, the LPA<sub>1-3</sub> agonist VPC31143 was administered to WT thoracic aortic segments after PE-induced precontraction. VPC31143 elicited a marked vasorelaxation (Figures 8A and 9A). Dose-response relationship of this effect is shown in Figure 9B. The agonist-induced vasorelaxation has an EC<sub>50</sub> of 15 nM and an E<sub>max</sub> of 51.9% expressed as percentage of the precontraction.



**Figure 8.** Effect of VPC31143 on the tone of precontracted thoracic aortae. Representative recordings of vessels prepared from wild type (WT) mice with intact (A) or denuded (B) endothelium as well as vessels from endothelial nitric oxide synthase (eNOS) KO (C) and cyclooxygenase-1 (COX1) KO (D) mice. VPC31143 was applied at 10  $\mu$ M after phenylephrine (PE)-induced contraction reached a stable plateau. Horizontal and vertical bars indicate 5 min and 5 mN, respectively. PE and VPC denote the application of phenylephrine and VPC31143 respectively, while W stands for washing of the organ chamber with fresh Krebs solution.


In order to analyze the mechanism of VPC31143-evoked relaxation the possible role of endothelium-derived relaxing agents was assessed first. To do so, we tested WT

vessels, mechanically denuded of endothelium, in which the VPC31143-elicited relaxation was not only abolished but was converted to vasoconstriction (Figure 8B) indicating a major role of endothelium-derived vasoactive mediators in the vasoactive effect of VPC31143. In order to identify the mediator(s) involved, vessels of either COX1 KO or eNOS KO mice were tested. Whereas the absence of COX1 did not alter the dilator effect of VPC31143 (Figure 8D), the lack of eNOS, similarly to that of the endothelium, prevented the VPC31143-elicited relaxation and turned it to contraction (Figure 8C). Taken together, these results indicate that the vasorelaxant effect of EDG-like LPA receptor activation is mediated by endothelial NO whereas COX1-derived prostanoid mediators are not involved (Figure 9A).




**Figure 9.** A) Endothelium-derived NO mediates the vasorelaxation induced by VPC31143. Effects of 10  $\mu$ M VPC31143 in wild type (WT) vessels with intact (open bar) or denuded endothelium (solid bar) as well as in vessels of endothelial nitric oxide synthase (eNOS) KO (dark grey bar) and cyclooxygenase-1 (COX1) KO (light gray bar) mice. Absence of endothelium or eNOS but not that of COX1 abolished VPC31143 induced vasorelaxation. \*\*\*\* $P$ <0.0001 vs. WT with intact endothelium; One-way ANOVA with Tukey's post hoc test;  $n = 11-28$  B) Dose-response relationship of vasorelaxation induced by VPC31143 in WT thoracic aortic vessels with intact endothelium. Each dose has been tested in independent aortic segments in order to avoid receptor desensitization.  $E_{max}$  and  $EC_{50}$  values are 51.9% and 15 nM, respectively;  $n=7-29$ .

In the next phase of our study, we sought an in-depth analysis of the VPC31143-evoked vasoconstriction. In order to analyze the potential regional differences between the different parts of the aorta the agonist was applied to WT thoracic and abdominal aortic segments (TA and AA, respectively) at resting tension. In vessels with intact endothelium VPC31143 in a dose of 10  $\mu$ M elicited moderate vasoconstriction compared to the reference contraction induced by 124 mM  $K^+$  (Figures 10A, 10C and 11A).



**Figure 10.** Representative recordings depicting the effect of VPC31143 in murine thoracic (TA) and abdominal aorta (AA) with intact endothelium (A and C respectively) and in TA and AA after endothelium-denudation (B and D, respectively). VPC denotes the application of VPC31143, while W stands for washing of the organ chamber with fresh Krebs solution.

However, removal of the endothelium unmasked the constrictor effect of VPC31143 resulting in an approximately three-fold increase in the AA (Figures 10B, 10D and 11A). Figure 11B shows the dose-response relationship of the contractile effect of VPC31143 in AA. The vasoconstriction has an  $EC_{50}$  of 4.1  $\mu$ M and an  $E_{max}$  of 87.4% as compared to the reference contraction.




**Figure 11.** A) Removal of the endothelium enhances the VPC31143-elicited vasoconstriction in the abdominal aorta (AA). Effect of 10  $\mu$ M VPC31143 in wild type (WT) thoracic aorta (TA) (solid bars) and AA (open bars) \* $P$ <0.01 vs. TA with denuded endothelium; \*\*\* $P$ <0.001 vs. AA with intact endothelium; Two-way ANOVA with Tukey's post hoc test  $n$ =8-37. B) Dose-response relationship of vasoconstriction

elicited by VPC31143 in WT AA vessels after the removal of the endothelium.  $E_{max}$  and  $EC_{50}$  values are 87.4% and 4.1  $\mu$ M, respectively;  $n=4-30$ .

## 5.2. Identification of the LPA receptor(s) mediating VPC31143-induced vasoconstriction


Since removal of the endothelium augmented the vasoconstrictor effect of VPC31143, our attention turned to LPA GPCRs expressed in the vascular smooth muscle (VSM). First, the gene expression profile of LPA receptors was determined in isolated tunica media of the murine TA and AA. LPA<sub>1</sub>, LPA<sub>2</sub>, LPA<sub>4</sub>, and LPA<sub>6</sub> mRNA were most abundantly detectable, with a slightly higher expression of LPA<sub>4</sub> and LPA<sub>6</sub> in the AA as compared to the TA (Figure 12). LPA<sub>3</sub> transcripts had the lowest abundance, nonetheless they found to be expressed in a higher amount in TA than AA. Taken together, these results identified LPA<sub>1</sub> and LPA<sub>2</sub> as likely candidates for mediating EDG-like LPA receptor related vasoconstriction.



**Figure 12.** Expression profile of LPA receptors in freshly isolated tunica media of wild type murine thoracic (TA) and abdominal aortic (AA) segments, determined by quantitative PCR. Murine aortic vascular smooth muscle cells predominantly express LPA<sub>1</sub>, LPA<sub>2</sub>, LPA<sub>4</sub>, and LPA<sub>6</sub>. LPA<sub>4</sub> and LPA<sub>6</sub> proved to be more abundant in the AA whereas LPA<sub>3</sub>, the least abundant subtype, showed higher expression in the TA. \* $P<0.05$  vs. TA; Student's unpaired  $t$  test;  $n=3-9$ . GAPDH: Glyceraldehyde 3-phosphate dehydrogenase


Thereafter, we implemented pharmacological and genetic methodologies to determine the LPA receptor responsible for the vasoconstrictor effect (Figures 13 and 14). Whereas the LPA<sub>1/3</sub> antagonist Ki16425 revoked the 10 $\mu$ M VPC31143-elicited vasoconstriction, the selective LPA<sub>3</sub> antagonist DGPP failed to influence it as compared to vehicle treatment in the AA of WT mice. Aortic rings isolated from LPA<sub>1</sub> KO mice

failed to contract upon VPC31143 application, while the vessels of LPA<sub>2</sub> KO animals showed similar responses to those of WT, indicating that the vasoconstriction is mediated by LPA<sub>1</sub> (Figure 13).



**Figure 13.** LPA<sub>1</sub> receptors mediate VPC31143-elicited vasoconstriction. Ki16425, an LPA<sub>1/3</sub> antagonist, and the lack of LPA<sub>1</sub> but not that of LPA<sub>2</sub> receptors nor the selective LPA<sub>3</sub> antagonist DGPP abolish VPC31143-evoked contraction. Segments of C57Bl/6, LPA<sub>1</sub> control (CTRL), and LPA<sub>2</sub> CTRL exhibited identical responses and are therefore pooled and referred to as WT in the figure. Both Ki16425 and DGPP were applied at 10  $\mu$ M for 30 min before the administration of VPC31143. Vehicle-treated control vessels were exposed to 1% Dimethyl sulfoxide (DMSO) or methanol (MeOH). \*\*\*\*P<0.0001 vs. WT; ##P<0.01 v. WT with DMSO treatment; One-way ANOVA with Tukey’s post hoc test; n=5-23.


To obtain a more detailed evaluation of the possible involvement of LPA<sub>3</sub> in the vasoconstrictor response, the vasoactive effects of T13 were investigated, which had been implied to activate LPA<sub>3</sub> selectively and with high efficiency at 10 nM, however at higher concentrations, it stimulates other LPA GPCRs as well (456). T13, applied in 10 nM concentration, failed to induce vasoconstriction in AA segments of LPA<sub>1</sub> CTRL animals, however at higher concentrations a dose-dependent contractile response developed (Figure 14). This effect was absent in vessels isolated from LPA<sub>1</sub> KO animals, which is consistent with our hypothesis, that the vasoconstrictor response is solely mediated by LPA<sub>1</sub>.



**Figure 14.** LPA<sub>3</sub> has no role in VPC31143-mediated contraction. The selective LPA<sub>3</sub> agonist T13 failed to evoke vasoconstriction in LPA<sub>1</sub> control (CTRL) vessels at 10 nM where it selectively activates LPA<sub>3</sub>. The application of higher concentrations of T13, which are reported to stimulate LPA<sub>1</sub>, resulted in dose-dependent contraction that was completely abolished by the lack of LPA<sub>1</sub>. \*P<0.01, \*\*\*\*P<0.0001 vs. LPA<sub>1</sub> CTRL; <sup>##</sup>P<0.01, <sup>####</sup>P<0.0001 vs. 10 nM LPA<sub>1</sub> CTRL; Two-way ANOVA with Tukey's post hoc test; n= 16-22.


### 5.3. Identification of the signal transduction pathways of LPA<sub>1</sub>-mediated vasoconstriction

LPA signaling has been implicated to interact with the prostanoid system. COX1-mediated effects of LPA (460) and the fact that LPA-evoked contractions of the longitudinal smooth muscle layer of guinea-pig ileum were shown to be indomethacin-sensitive (461), raised our hypothesis, that TXA<sub>2</sub>, a potent vasoconstrictor (462), might have a role in the contractile effect mediated by LPA<sub>1</sub>. In order to investigate this possibility, vessels of WT, COX1 KO and TP KO mice were exposed to 10 μM VPC31143. The absence COX1 and TP markedly decreased the agonist-induced contractions (Fig. 15), implying that COX1-derived TXA<sub>2</sub> could be the mediator, that activates TP, thus elicits (or at least contributes to) vasoconstriction.




**Figure 15.** Prostanoids are involved in VPC31143-mediated contraction. The vasoconstriction evoked by VPC31143 at 10  $\mu$ M was markedly reduced in the abdominal aortic segments of cyclooxygenase-1 (COX1) KO and Thromboxane prostanoid receptor (TP) KO mice as compared with control (CTRL) animals. \*\*\*\* $P$ <0.0001 vs. the corresponding CTRL; One-way ANOVA with Tukey's post hoc test;  $n$ =8-23.

To verify the presence of the constrictor agent TXA<sub>2</sub>, levels of TXB<sub>2</sub>, a metabolite of TXA<sub>2</sub> with a longer life span, were measured from the supernatants of vessels exposed to VPC31143 for 2 min (Figures 16 and 17). VPC31143 treatment enhanced the TXB<sub>2</sub> production of WT specimens more than two-fold, which was also the situation in case of LPA<sub>2</sub> KO aortae. However, the agonist failed to alter the amount of TXB<sub>2</sub>, released from LPA<sub>1</sub> KO vessels (Figure 16).




**Figure 16.** LPA<sub>1</sub> is responsible for VPC31143 mediated vascular Thromboxane A<sub>2</sub> (TXA<sub>2</sub>) release. The lack of LPA<sub>1</sub> but not that of LPA<sub>2</sub> abolished the VPC31143-elicited increase in TXA<sub>2</sub> production in TA segments. LPA<sub>1</sub>- and LPA<sub>2</sub> control mice showed identical responses and are therefore pooled and referred to as control. \* $P$ <0.01, \*\*\*\* $P$ <0.0001 vs. before VPC; #### $P$ <0.0001 vs. control after VPC; Two-way ANOVA with Bonferroni's post hoc test,  $n$ =6-16.

Aortae of COX1 KO mice showed a diminished basal rate of TXB<sub>2</sub> production, which remained unaltered upon VPC31143 application. Nonetheless, absence of the TP receptors had no such effect on either resting or stimulated release of TXB<sub>2</sub> (Figure 17). The above mentioned results are consistent with our hypothesis of LPA<sub>1</sub>-mediated COX1 activation and TXA<sub>2</sub> production, leading to TP activation and consequent contraction of VSM.




**Figure 17.** VPC31143 treatment leads to increased Thromboxane A<sub>2</sub> (TXA<sub>2</sub>) release in cyclooxygenase (COX1) control (CTRL) thoracic aortic segments, whereas COX1 KO vessels exhibited diminished basal rate of TXA<sub>2</sub> production that did not increase upon VPC31143 administration. On the contrary, basal and VPC31143-stimulated TXA<sub>2</sub> release from thromboxane prostanoid receptor (TP) KO vessels showed no difference compared with TP CTRL segments. \*\*P<0.01, \*\*\*\*P<0.0001 vs. before VPC; ###P<0.001, ####P<0.0001 vs. corresponding COX1 CTRL; Two-way ANOVA with Bonferroni's post hoc test, n=3-7.

As LPA<sub>1</sub> is often coupled to G $\alpha_{i/o}$  (66), and G $\alpha_{i/o}$  may activate PLA<sub>2</sub> and TXA<sub>2</sub> production (463-465), we sought evidence of its possible role in LPA<sub>1</sub>-mediated vasoconstriction. In consistence with our hypothesis, PTX pretreatment of WT vessels abolished the VPC31143-induced increase in TXB<sub>2</sub> production (Figure 18A). Moreover, aortic segments of PTX-pretreated WT animals showed diminished vasoconstriction upon VPC31143 administration (Figure 18B).



**Figure 18.**  $G\alpha_i$  mediates VPC31143-mediated thromboxane  $A_2$  (TXA<sub>2</sub>) production and vasoconstriction. A) Pertussis toxin (PTX) pretreatment abolished VPC31143-induced elevation in TXA<sub>2</sub> production in wild type vessels. \*\* $P < 0.01$  vs. before VPC; #### $P < 0.0001$  vs. control after VPC; Two-way ANOVA with Bonferroni's post hoc test;  $n = 5-8$ . B) PTX treatment markedly decreased VPC31143-elicited contraction in wild type vessels. \*\*\* $P < 0.001$  vs. control; Student's unpaired  $t$  test;  $n = 14-19$ .


We also investigated, if the well-established regulators of smooth muscle contraction,  $G\alpha_{q/11}$ , and  $G\alpha_{12/13}$ , could play a role in the VPC31143-induced vasoconstriction. The smooth muscle-specific absence of  $G\alpha_{q/11}$  (Figure 19A) as well as that of  $G\alpha_{12/13}$  (Figure 19B) decreased the contraction, evoked by 10  $\mu$ M VPC31143, however both failed to completely abolish it.



**Figure 19.** Involvement of  $G\alpha_{q/11}$  and  $G\alpha_{12/13}$  in VPC31143-induced vasoconstriction. A) Vessels of smooth muscle-specific  $G\alpha_{q/11}$  KO mice showed diminished contraction upon VPC31143-administration as compared with control (CTRL) segments. \*\*\*\* $P < 0.0001$  vs. CTRL; Student's unpaired  $t$  test;  $n = 48-50$ . B) The lack of  $G\alpha_{12/13}$  in the smooth muscle caused a reduction in VPC31143-evoked vasoconstriction as compared to CTRL vessels. \*\* $P < 0.01$  vs. CTRL; Student's unpaired  $t$  test;  $n = 16-18$ .


#### 5.4. Vasoactive effects of S1P depend on the presence of other constrictors

In the next part of our experiments, we focused on the vasoactive effects of the other thoroughly investigated lipid mediator, S1P. S1P, administered on the basal tone, had negligible effect in either thoracic or abdominal aortic segments of WT animals (Figures 20A, 20B and 21). Removal of the endothelium did not influence this minor effect significantly (Figures 20C, 20D and 21). Nonetheless, after PE-induced precontraction of endothelium-denuded WT vessels S1P elicited a marked vasoconstriction (Figures 20E, 20F and 21). Although, S1P applied alone failed to significantly influence the basal tone, in presence of an other constrictor, elicited vasoconstriction. Considering the fact, that under physiological conditions, several mediators, (e.g. constrictors, dilators) are present in the circulation and actively regulate the tension of the vessels, the above-mentioned effect could play major roles in cardiovascular regulation in vivo.




**Figure 20.** Effect of S1P applied either at the basal tone or after precontraction. Representative recordings of thoracic (A, C and E) or abdominal aortic segments (B, D and F) prepared from wild type mice with intact (A, B) or denuded (C-F) endothelium. S1P was applied at 5  $\mu$ M either at the basal tone (A-D) or after phenylephrine (PE)-induced contraction reached a stable plateau (E and F). Horizontal and vertical bars indicate 2.5 min and 2.5 mN respectively. S1P and PE denote the application of the respective agents, while W stands for washing of the organ chamber with fresh Krebs solution.

In recognition of the imperceptible effect of S1P, applied solely, we investigated if this mediator influences the contractile effect of other constrictors. For this purpose, vasoconstrictions elicited by the  $\alpha_1$  adrenergic receptor agonist PE at 100 nM in WT endothelium-intact TAs were investigated and recorded before and after the administration of S1P.




**Figure 21.** S1P applied at 10 $\mu$ M at the basal tone had negligible effect on the vascular tone in case of intact as well as denuded endothelium. However, after precontraction S1P elicited a pronounced vasoconstriction. \*\*\*\*P<0.0001 vs. intact endothelium, basal tone of the corresponding type of vessel; Two-way ANOVA with Tukey's post hoc test; n=4-6.



**Figure 22.** The effect of S1P on the constrictor effect of the  $\alpha_1$  agonist phenylephrine (PE). Representative recordings show, whilst incubation with S1P for 20 min significantly enhanced PE-induced contraction, the vehicle sodium hydroxide (NaOH) failed to do so. The effect was present even 180 min after the incubation. PE was applied three times before the incubation and the mean of these contractions was considered 100% and served as reference for the evaluation of later effects. S1P and PE were applied at 5  $\mu$ M and 0.1  $\mu$ M respectively.

Incubation with 5  $\mu$ M S1P for 20 min, increased PE-mediated contractions almost 1.5-fold after 40 min and surprisingly the contractions remained enhanced even 180 min


after the incubation (Figures 22 and 23). In contrast, 0.3 N NaOH, the vehicle of S1P, had no effect on PE-elicited vasoconstrictions (Figures 22 and 23).



**Figure 23.** Incubation with S1P for 20 min markedly enhanced phenylephrine (PE)-mediated contractions, whereas the vehicle sodium hydroxide (NaOH) had no effect on it. The potentiation lasted at least for three hours. S1P and PE were applied at 5  $\mu$ M and 0.1  $\mu$ M respectively. \*\*\* $P$ <0.001, \*\*\*\* $P$ <0.0001 vs. 0 min; Two-way ANOVA with Tukey's post hoc test;  $n$ =15-18.


### 5.5. Identification of the S1P receptors, mediating the potentiating effect of S1P

Thereafter, we aimed to identify the S1P receptor responsible for the S1P-mediated augmentation of PE-induced contractions. For this purpose, we first determined the expression profile of S1P GPCRs in VSM of the murine thoracic aorta. In WT specimens, mRNAs of S1P<sub>1</sub>, S1P<sub>2</sub>, S1P<sub>3</sub>, and S1P<sub>4</sub> were detectable, with S1P<sub>1</sub> as the most abundant S1P GPCR (Figure 24).



**Figure 24.** Expression profile of S1P receptors in freshly isolated tunica media of wild type murine thoracic aorta, determined by quantitative PCR. Murine thoracic aortic vascular smooth muscle cells predominantly express S1P<sub>1</sub>, S1P<sub>2</sub>, S1P<sub>3</sub>, and S1P<sub>4</sub>. S1P<sub>1</sub> showed the highest abundance, whereas S1P<sub>5</sub> was barely detectable in our specimens.

In the next phase, we applied a genetic approach, thus we tested vessels prepared from S1P<sub>2</sub> KO and S1P<sub>3</sub> KO mice two of the GPCRs which were detectable in the isolated tunica media of murine thoracic aorta. In segments of S1P<sub>3</sub> KO animals, the S1P-induced potentiation was not different from that observed in WT vessels. Nevertheless, aortae of S1P<sub>2</sub> KO mice failed to develop the above mentioned phenomenon after 20 min incubation with S1P, highlighting the role of this receptor in S1P-induced potentiation of PE-mediated contractions (Figures 25).



**Figure 25.** S1P<sub>2</sub> is responsible for the potentiating effect of S1P. The lack of S1P<sub>2</sub> but not that of S1P<sub>3</sub> abolished the S1P-induced increase in phenylephrine (PE)-mediated vasoconstrictions. S1P and PE were applied at 5 μM and 0.1 μM respectively. \*P<0.05 vs. 0 min; #P<0.05 vs. wild type (WT); Two-way ANOVA with Tukey's post hoc test; n=15-28.

## 6. Discussion

The EDG family of GPCRs contains three of the six confirmed LPA GPCRs (LPA<sub>1-3</sub>) and all of the known S1P receptors (S1P<sub>1-5</sub>). In the present study, we investigated their roles in the regulation of the vascular tone with pharmacological and genetic approaches.

### 6.1. Role of LPA receptors in the regulation of the vascular tone

In our studies, activation of the EDG-like LPA receptors had ambiguous effects in the murine aorta. In precontracted intact vessels, the LPA<sub>1-3</sub> agonist VPC31143 elicited vasorelaxation in an endothelium- and eNOS-dependent manner, moreover, we could rule out the possible role of dilator prostaglandins. Interestingly, mechanical removal of the endothelium did not only abolish the dilator effect, but turned it to vasoconstriction. We presented first, that this contraction is mediated by LPA<sub>1</sub> receptors. The absence of vasoconstriction in LPA<sub>1</sub> KO mice, the inhibitory impact of the LPA<sub>1/3</sub> antagonist Ki16425 but not of the LPA<sub>3</sub> inhibitor DGPP or the lack of LPA<sub>2</sub> receptors emphasized the role of LPA<sub>1</sub> in this process. Furthermore, our former study conducted with the natural ligand LPA concluded, that LPA<sub>1</sub> is also responsible for the eNOS-dependent vasodilation via activation of PLC enzymes (466).

Vasoactive actions of the naturally occurring agonist LPA were described early in the initial reports of Tokumura and colleagues. The effect however, seemed species-dependent, as in vivo administration of LPA elicited hypertension in rats and guinea pigs, whereas hypotension in cats and rabbits (4). Schumacher and colleagues made clear, that the hypotensive effect in cats was a result of excessive pulmonary vasoconstriction upon platelet aggregation and a consequent drop of cardiac output (404). A recent report of Kano and colleagues showed that intravenous application of LPA elicited a hypertensive response in anesthetized mice in an LPA<sub>4</sub>- and Rho-ROCK-dependent manner (295). These in vivo studies were certainly unable to differentiate the role of VSM and endothelium in mediating the responses. It is noteworthy, that LPA had an enhanced pressor impact in spontaneously hypertensive rats compared with Wistar-Kyoto rats (467), which implies an increased effect in case of dysfunctional endothelium. Studies conducted by Tigyi and colleagues in the 90's described an LPA-dependent vasoconstriction in pial arteries of piglets (426, 468). These results are

consistent with ours, because in the cranial window setup they used LPA was applied to the extraluminal surface of pial vessels, in which case the mediator reaches the VSM primarily.

Our quantitative PCR results, obtained from freshly isolated murine thoracic and abdominal aortic VSMC, showed a rank order of LPA receptors subtype transcripts as  $6 > 4 > 1 \geq 2 > 5 > 3$ . Our former expression analysis in murine aortic endothelial cells also confirmed the expression of LPA<sub>1-5</sub> as well as ATX (466). Others showed that LPA<sub>6</sub> is expressed in human pulmonary arterial- and microvascular endothelial cells (469). These observations indicate that LPA may be involved in both endothelium-dependent and -independent regulation of the vascular tone.

Although LPA<sub>1</sub> was first described in the developing brain (9), since that time it has been implicated in a multitude of physiological and pathological processes as described in detail in the introduction of the present thesis. Cardiovascular functions can be found among these roles, which are highlighted by the fact, that 2.5% of LPA<sub>1</sub> KO mice exhibit frontal hematomas (192). Moreover, LPA<sub>1</sub> has a role on atherogenesis and platelet activation; this latter action is however disputed (470).

By seeking to clarify the signal transduction, downstream of LPA<sub>1</sub> in the constrictor effect, we hypothesized the possible involvement of the constrictor prostanoid TXA<sub>2</sub>. Our results are in support of this hypothesis, as we found, that the application of the EDG-agonist VPC31143 elicited increased TXA<sub>2</sub> production in isolated vessels, in an LPA<sub>1</sub>- and COX1- but not LPA<sub>2</sub>- dependent manner. Besides, VPC31143-evoked contractions were alleviated in vessels of mice deficient in either COX1 or TP, which is in favor of this mechanism, in which the LPA<sub>1</sub>-dependent activation of COX1 leads to the release of TXA<sub>2</sub>. Moreover, pretreatment with PTX abolished TXA<sub>2</sub> generation as well as vasoconstriction induced by VPC31143, implying the role of G<sub>i</sub> in COX1 activation. Our further results indicate the involvement of G $\alpha_{q/11}$  and G $\alpha_{12/13}$  in the process. Because the treatment with PTX abolished the VPC31143-elicited elevation in TXA<sub>2</sub> production, we conclude that LPA<sub>1</sub> agonism leads to COX1 activation via G<sub>i</sub> and not G $\alpha_{q/11}$  or G $\alpha_{12/13}$ . Both G $\alpha_{q/11}$  and G $\alpha_{12/13}$  were however associated with TP signaling (471). Therefore, we hypothesize that G $\alpha_{q/11}$  and G $\alpha_{12/13}$  are downstream of TP in this mechanism. Although, it must be taken into consideration, that on one hand, absence of TP and COX1 did not totally abolished the VPC31143-induced contraction,

on the other hand, LPA<sub>1</sub> was found to be linked to PLC in our former study (466), which is associated with G $\alpha_{q/11}$ . In conclusion, the possibility of a direct link between LPA<sub>1</sub> and these G proteins cannot be ruled out, which would result in an LPA<sub>1</sub>-mediated direct VSMC contraction. This signaling may participate in our system, however, considering the remaining contraction in the absence of COX1, TP, or after PTX pretreatment, COX1-dependent TXA<sub>2</sub> production seems to be dominant in this process.


Interaction of the LPA and the COX/TXA<sub>2</sub> pathway has been already described, however only in a shear stress-dependent context. Ohata and colleagues reported, that LPA stimulate Ca<sup>2+</sup>-influx under shear stress in BAEC and murine aortic endothelial cells via mechanosensitive cation channels (472, 473). Furthermore, LPA elicited increased PE-induced vasoconstriction and alleviated ACh-evoked relaxation in rat mesenteric arteries in the presence of shear stress in an endothelium-dependent manner, which was abolished by the non-selective COX inhibitor indomethacin and the TP antagonist SQ29548 (474). Moreover, LPA caused elevation of intracellular Ca<sup>2+</sup>-concentration in VSMCs and contraction of the murine aorta in an endothelial shear stress-dependent way. This latter effect could be prevented by application of the COX blocker aspirin, the TXA<sub>2</sub>-synthase inhibitor OKY-046, or the TP antagonist SQ29548 (438).

Even though the effects discussed above show similarities with our results, it should be emphasized, that in those cases, the process was endothelium- and shear stress-dependent, whereas our experiments have been performed in vessels denuded of endothelium and in absence of shear stress, which indicate a completely different mechanism of action. It is noteworthy however, that under pathological conditions, which are associated with endothelial damage, e.g. hypertension, the amount of shear stress also increases. In such cases, the two mechanisms could be present together. In this scenario, LPA would induce TXA<sub>2</sub> release from the endothelium or VSMCs, leading to vasoconstriction. Upon reduced vascular diameter, shear stress and endothelial damage may escalate further, establishing a vicious cycle.

Further literary data available on the potential interaction of LPA- and prostanoid signaling are scant and controversial. LPA-induced contraction in guinea pig ileum was reported to be blocked by indomethacin (461); however, the same group found that

inhibition of COX signaling had no effect on LPA-induced contraction of the rat colon (475). Ohata et al. described that LPA enhances  $\text{Ca}^{2+}$ -influx upon mechanical stimulation in cultured smooth muscle cells, a similar process they reported earlier in endothelial cells, however this study did not investigate the possible contribution of prostanoids (476, 477). Besides, LPA regulated COX2 expression in the uterus, this effect was mediated by LPA<sub>3</sub> though, and resulted in production of prostaglandins E<sub>2</sub> and I<sub>2</sub> (226). Our findings however imply a direct link between the LPA and thromboxane signaling, as activation of the LPA<sub>1</sub> receptors on VSMC elicits TXA<sub>2</sub> production and consequently induces a vasoconstriction.

The results presented here indicate an ambiguous effect upon activation of EDG-like LPA GPCRs in the vasculature. To evaluate the potential pathophysiological relevance of this process, it must be considered that the production of the natural ligand LPA is linked to activation of the thrombocytes. In this context, upon vascular injury, where platelets activate and interact directly with VSMCs, the LPA produced locally activates LPA<sub>1</sub> on VSMCs that leads to TXA<sub>2</sub> release via G<sub>i</sub> and COX1. TXA<sub>2</sub> on one hand constricts VSM, on the other hand acts on its receptor on platelets, eliciting further activation and aggregation. This interaction between the LPA-LPA<sub>1</sub> and the TXA<sub>2</sub>-TP signaling may initiate a vicious circle, in which production of LPA leads to further production of TXA<sub>2</sub>, which in return promotes further LPA release/production from platelets, and the elevated levels of these mediators promote thrombus growth and sustained vasoconstriction. If the thrombus reaches an intact part of the vessel wall, covered by functional endothelium, activation of the endothelial EDG-like LPA receptors occurs. In this case, NO-production will follow upon LPA GPCR-dependent activation of eNOS as our results illustrate. The NO released prevents further platelet activation and acting on VSM elicits vasorelaxation. Our former study revealed a role of LPA<sub>1</sub> and endothelial PLCs in LPA-dependent eNOS activation (466) (Figure 26).



**Figure 26.** Integrated hypothesis of LPA<sub>1</sub>-mediated vasoactive effects in intact vessels versus damaged endothelium. Under physiological conditions LPA stimulates endothelial nitric oxide production in an LPA<sub>1</sub>/phospholipase C-dependent manner (466), resulting in vasorelaxation and inhibition of platelets. In absence of the endothelium, however, platelet activation initiates LPA production, which in turn acts on LPA<sub>1</sub> in vascular smooth muscle cells and induces thromboxane A<sub>2</sub> (TXA<sub>2</sub>) production. TXA<sub>2</sub> on one hand elicits contraction via the activation of the thromboxane prostanoid receptor (TP) in VSMC, and on the other hand promotes further platelet activation acting on TP in platelets. TP-mediated activation of platelets results in additional LPA production. This mechanism represents a potential positive feed-back loop in which platelet activation promotes contraction and further platelet activation via a vicious circle involving LPA/LPA<sub>1</sub> and TXA<sub>2</sub>/TP receptors resulting in a pathological vasoconstriction or even vasospasm. ATX: Autotaxin, COX1: cyclooxygenase-1, eNOS: endothelial nitric oxide synthase, NO: nitric oxide, PLC: phospholipase C, sGC: soluble guanylate cyclase

LPA accumulation in atherosclerotic plaques has been reported (67). Taking into consideration, that atherosclerosis is associated with endothelial dysfunction, in case of plaque rupture a large amount of LPA can be released into the local circulation, which acts on VSM and launches the aforementioned process. Moreover, accumulation of LPA has been demonstrated, systemically as well as locally in patient with ACS (409, 410). Therefore, this phenomenon may have a role in pathological vasospasm in a post-

ischemic phase. Potentially fatal consequences of this mechanism in cerebral or coronary vessels need not to be emphasized.

Vasoconstrictor effects of LPA<sub>1</sub>-activation may be of importance after hemorrhage, where the natural agonist LPA in blood can also directly contact VSMCs without being engaged by functional endothelium. Studies conducted by Tigyi and colleagues in the 90's showed, that LPA, applied to the subarachnoid space of piglets elicited vasospasm (426, 468). Moreover, in a model of subarachnoid hemorrhage, 4 days after the injection of autologous blood or Endothelin-1, elevated levels of an LPA-like mediator could be detected in the cerebrospinal fluid (426). These results are in consistence with the actions found by the Chun-group in posthemorrhagic hydrocephalus, which was also mediated by LPA<sub>1</sub> (348). Besides, with the same latency (i.e. 3-4 days after subarachnoid hemorrhage), as the LPA-like mediator was detected (426), inhibition of TXA<sub>2</sub> synthesis alleviated the development of postsubarachnoidal vasospasm (478, 479). Our results, together with the aforementioned studies provide a potential mechanism of action in case of vasospasm, a life-threatening complication after subarachnoid hemorrhage. Nonetheless, to verify this process and to point out potential intervening drug targets, further in vivo and clinical studies are essential.

## **6.2. Role of S1P receptors in the regulation of the vascular tone**

In the next phase of our experiments, we focused on the vasoactive actions of S1P and its receptors. S1P applied on the resting tone had no effect on intact murine aortae. Furthermore, mechanical removal of the endothelium did not alter this outcome. However, if the endothelium-denuded vessels were precontracted with PE, S1P elicited marked vasoconstriction.

The literature on this issue is also controversial. Although previous reports described a strong and long-lasting vasoconstriction, induced by S1P in canine basilar artery, in other species S1P proved to be less potent (439, 440). Furthermore, potency of S1P in other species was diverse in different vascular beds (440).

S1P was also found to activate eNOS in rodent aortic rings, mesenteric arteries and various types of cell cultures (440). In these experiments, eNOS-activation was mediated by S1P<sub>3</sub> in mice (441) and S1P<sub>1</sub> in COS-7 cells (447). Involvement of the G<sub>i</sub>-PI3K and AMP-activated-kinase occurred as downstream signaling (440). Although, this appears to be contradictory with our results, it must be emphasized that the eNOS

activation was partly reported in experiments conducted in endothelial cell cultures, which may not fully represent the functionality of the tissues as in vivo and ex vivo studies do. Furthermore, as formerly mentioned the S1P-induced effect may alter upon species and vascular beds (440).

In our further experiments, we investigated the effect of S1P on PE-induced vasoconstriction. We found that 20 min incubation with S1P enhances PE-evoked contractions and this effect was maintained for at least 3 hours.

Afterwards, we determined the expressional profiles of S1P GPCRs in freshly isolated murine thoracic aortic VSMCs. Our results indicate that S1P<sub>1</sub>, S1P<sub>2</sub>, S1P<sub>3</sub>, and S1P<sub>4</sub> are expressed with S1P<sub>1</sub> as most abundant.

Thereafter we repeated the former experiments in vessels prepared from mice deficient in S1P<sub>2</sub>, or S1P<sub>3</sub>. Although, absence of S1P<sub>3</sub> had no effect on S1P-induced potentiation of PE-induced vasoconstriction, the effect was abolished in S1P<sub>2</sub> KO vessels. These results indicate that S1P acting on S1P<sub>2</sub> interferes with  $\alpha_1$ -adrenergic signaling and mediates a long-lasting elevation in  $\alpha_1$ -mediated contractions.

Interactions of S1P<sub>2</sub> and  $\alpha$ -adrenergic signaling have been emerged early at the time of generation of S1P<sub>2</sub> KO mice. These animals showed decreased vascular tone, elevated blood-flow and consequently decreased resistance in the renal and mesenteric areas. Although, vessels of these mice exhibited decreased contractile responsiveness to  $\alpha$ -adrenergic stimulation, this phenotype had no effect on the blood pressure of the animals (252). These results are in consistence with ours, however it must be pointed out, that in our case S1P<sub>2</sub> signaling was not necessary to maintain the basal responsiveness to  $\alpha$ -adrenergic stimuli but elicited further potentiation of it. Considering the fact, that S1P can be released from activated platelets (38, 149), the aforementioned mechanism can contribute to pathological states associated with blood coagulation, such as ischemic stroke or acute myocardial infarction. Hereby, it should be also noted, that the bulk of plasma S1P derives from the erythroid cell line as discussed in the introduction chapter, and that patients with acute myocardial infarction had lower circulating S1P levels than healthy controls (423). However, we hypothesize the effect to be mediated by locally accumulating S1P, which may not change plasma levels significantly.

## 7. Conclusions

In our experiments we sought to answer the question, how the EDG-like lysophospholipid receptors influence the vascular tone. According to our results, we can conclude that:

- Activation of EDG-like lysophosphatidic acid (LPA) receptors elicits dose-dependent vasorelaxation in the intact murine aorta, which is an endothelium dependent process and independent of prostanoids.
- In the absence of endothelium, the EDG-like LPA agonist VPC31143 evoked dose-dependent vasoconstriction, which was more pronounced in the abdominal than in the thoracic aorta. This effect is mediated by LPA<sub>1</sub>, which is relatively highly expressed in murine vascular smooth muscle cells. VPC31143 elicits TXA<sub>2</sub> release in a G<sub>i</sub>- and COX1-dependent manner, which, acting on its receptor (TP), causes vasoconstriction. The G proteins G $\alpha_{q/11}$  and G $\alpha_{12/13}$  are also involved in the signal transduction, probably downstream of the TP receptor.
- Exposition to sphingosine 1-phosphate (S1P) potentiates  $\alpha_1$ -dependent vasoconstriction in murine aorta, in a long-lasting manner. This impact is mediated by S1P<sub>2</sub> receptors, which are expressed in murine vascular smooth muscle.

## 8. Summary

The endothelial differentiation gene (EDG) family is a group of G protein-coupled receptors (GPCR), which contains the first confirmed lysophospholipid receptors, specific for lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), (LPA<sub>1-3</sub>, S1P<sub>1-5</sub>). Both mediators and their receptors have a multitude of regulatory functions in the cardiovascular system, including angiogenesis, platelet shape-change, and ischemia-reperfusion injury. The available literary data is however controversial and sparse on their role in vasoregulation. The aim of this study was to investigate, how the EDG-like lysophospholipid receptors influence the vascular tone.

We showed that activation of the EDG-like LPA GPCRs has an ambiguous role in vasoregulation. In the intact precontracted murine aorta, the LPA<sub>1-3</sub> agonist VPC31143 elicited a dose-dependent vasorelaxation that was dependent of endothelial nitrogen-oxide synthase activation and independent of the prostanoid system. In absence of the endothelium, the relaxation turned into vasoconstriction. Our qPCR results indicate that freshly isolated murine aortic smooth muscle cells (VSMC) express every known LPA GPCR. The vasoconstriction is mediated by LPA<sub>1</sub>, which elicits cyclooxygenase-1 activation and thromboxane A<sub>2</sub> (TXA<sub>2</sub>) release via G<sub>i</sub>. TXA<sub>2</sub> then acts on its receptor TP on VSMCs causing vasoconstriction. G $\alpha_{q/11}$  and G $\alpha_{12/13}$  are also involved in the process; however, the exact role should be further investigated. We hypothesize, that the Janus-faced activity of the EDG-like LPA GPCR may have a role in pathological processes associated with thrombus formation like ischemic stroke or myocardial infarction.

Activation of S1P GPCRs has only negligible influence on the basal tone of the intact murine aorta, and also after removal of the endothelium. In precontracted aortae, S1P evoked vasoconstriction. Furthermore, incubation with S1P potentiated phenylephrine-induced contractions and the effect lasted at least for three hours. Our results indicate that freshly isolated murine aortic VSMCs express S1P<sub>1-4</sub>. Furthermore, we described, that activation of S1P<sub>2</sub> is responsible for the potentiating effect of S1P. As S1P can also be released upon platelet activation, hence we conclude, that this potentiating effect of S1P may have a role under pathological conditions associated with blood coagulation and increased level of naturally occurring vasoconstrictors e.g. ischemic stroke and myocardial infarction.

## 9. Összefoglalás

Az endotheliális differenciációs gén család (EDG) a G protein-kapcsolt receptorok egy csoportja, mely magába foglalja az elsőként leírt lizofosfolipid receptorokat ( $LPA_{1-3}$  és  $S1P_{1-5}$ ), melyek természetes ligandjai a lizofoszfátid sav (LPA) és a szfingozin 1-foszfát (S1P). A kardiovaszkuláris rendszer működésében mindkét mediátor és receptoraik széleskörű szereppel bírnak, résztvevői olyan folyamatoknak, mint az angiogenezis, a trombocyták alakváltozása vagy az iszkémia-reperfüziós károsodás. Ennek ellenére az irodalom szegényes és ellentmondásos e mediátorok és receptorok vazoregulációban betöltött szerepét illetően. Kutatásaink során arra kerestük a választ, befolyásolják-e az EDG családba tartozó LPA és S1P receptorok az értónust.

Eredményeink szerint az  $LPA_{1-3}$  receptort aktiváló VPC31143-nak kettős hatása van az értónusra. Ép, előfeszített egér aortában vazorelaxációt okozott, mely hatás endotheliális nitrogén monoxid szintáz-függő volt, de független volt a prosztanoid rendszertől. Endothél-irtott erekben az agonista vazokonstriktiót okozott. Frissen izolált egér aorta ér simaizom sejtek (VSMC) az összes ismert LPA receptort expresszálják. Továbbá kimutattuk, hogy a kontrakció hátterében az  $LPA_1$  receptor aktivációja áll, mely thromboxán  $A_2$  ( $TXA_2$ ) felszabaduláshoz vezet  $G_i$  és cyclooxygenáz-1 aktiváción keresztül. A  $TXA_2$  saját, TP receptorán hatva vazokonstriktiót okoz. A folyamatban részt vesznek a  $G_{\alpha_{q/11}}$  és  $G_{\alpha_{12/13}}$  fehérjék, pontos szerepük azonban még tisztázásra vár. Eredményeink alapján feltételezhető, hogy az LPA receptorok Janus arcú hatásának szerepe lehet véralvadással összefüggő patológiás folyamatokban, mint az iszkémiás stroke és a szívinfarktus.

Az S1P receptorok aktiválódásának nem volt érdemi hatása az erek alaptónusára és ez nem változott az endothelium eltávolítás után sem. Előfeszített erekben az S1P kontrakciót okozott. Kimutattuk, hogy az S1P-vel való inkubálás fokozza a fenilefrin által kiváltott kontrakciókat egér aortában. Eredményeink szerint frissen izolált egér aorta VSMC-kben az  $S1P_{1-4}$  receptorok fejeződnek ki. Megállapítottuk, hogy az S1P vazokonstriktiót potencírozó hatásáért az  $S1P_2$  receptor felelős. Figyelembe véve, hogy az S1P lokális koncentrációja megnőhet trombocytá aktivációkor, feltételezzük, hogy az itt leírt folyamatoknak szerepük lehet olyan koagulációval összefüggő folyamatokban, ahol a vérben előforduló természetes konstriktorok szintje is emelkedett, mint például a szívinfarktus, vagy az iszkémiás stroke.

## 10. References

1. Lynch, K. R., and Macdonald, T. L. (2001) Structure activity relationships of lysophospholipid mediators. *Prostaglandins & Other Lipid Mediators* **64**, 33-45
2. Vogt, W. (1957) The chemical nature of Darmstoff. *J Physiol* **137**, 154-167
3. Tokumura, A., Fukuzawa, K., Akamatsu, Y., Yamada, S., Suzuki, T., and Tsukatani, H. (1978) Identification of vasopressor phospholipid in crude soybean lecithin. *Lipids* **13**, 468-472
4. Tokumura, A., Fukuzawa, K., and Tsukatani, H. (1978) Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. *Lipids* **13**, 572-574
5. Tigyi, G., Dyer, D., Matute, C., and Miledi, R. (1990) A serum factor that activates the phosphatidylinositol phosphate signaling system in *Xenopus* oocytes. *Proc Natl Acad Sci U S A* **87**, 1521-1525
6. Tigyi, G., Henschen, A., and Miledi, R. (1991) A factor that activates oscillatory chloride currents in *Xenopus* oocytes copurifies with a subfraction of serum albumin. *J Biol Chem* **266**, 20602-20609
7. Tigyi, G., and Miledi, R. (1992) Lysophosphatidates bound to serum albumin activate membrane currents in *Xenopus* oocytes and neurite retraction in PC12 pheochromocytoma cells. *J Biol Chem* **267**, 21360-21367
8. Tigyi, G., Dyer, D. L., and Miledi, R. (1994) Lysophosphatidic acid possesses dual action in cell proliferation. *Proc Natl Acad Sci U S A* **91**, 1908-1912
9. Hecht, J. H., Weiner, J. A., Post, S. R., and Chun, J. (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. *J Cell Biol* **135**, 1071-1083
10. McIntyre, T. M., Pontsler, A. V., Silva, A. R., St Hilaire, A., Xu, Y., Hinshaw, J. C., Zimmerman, G. A., Hama, K., Aoki, J., Arai, H., and Prestwich, G. D. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. *Proc Natl Acad Sci U S A* **100**, 131-136

11. Olivera, A., and Spiegel, S. (1993) Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. *Nature* **365**, 557-560
12. Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. *J Cell Biol* **114**, 155-167
13. Hla, T., and Maciag, T. (1990) An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. *J Biol Chem* **265**, 9308-9313
14. Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science* **279**, 1552-1555
15. Zondag, G. C., Postma, F. R., Etten, I. V., Verlaan, I., and Moolenaar, W. H. (1998) Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. *Biochem J* **330 ( Pt 2)**, 605-609
16. Tigyi, G. (2010) Aiming drug discovery at lysophosphatidic acid targets. *Br J Pharmacol* **161**, 241-270
17. Maceyka, M., Harikumar, K. B., Milstien, S., and Spiegel, S. (2012) Sphingosine-1-phosphate signaling and its role in disease. *Trends Cell Biol* **22**, 50-60
18. Vogt, W. (1957) Pharmacologically active lipidsoluble acids of natural occurrence. *Nature* **179**, 300-304; passim
19. Wang, A., Loo, R., Chen, Z., and Dennis, E. A. (1997) Regiospecificity and catalytic triad of lysophospholipase I. *J Biol Chem* **272**, 22030-22036
20. Croset, M., Brossard, N., Polette, A., and Lagarde, M. (2000) Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. *Biochem J* **345 Pt 1**, 61-67
21. Nakane, S., Tokumura, A., Waku, K., and Sugiura, T. (2001) Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions. *Lipids* **36**, 413-419
22. Sugiura, T., Nakane, S., Kishimoto, S., Waku, K., Yoshioka, Y., Tokumura, A., and Hanahan, D. J. (1999) Occurrence of lysophosphatidic acid and its alkyl

- ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. *Biochim Biophys Acta* **1440**, 194-204
23. Liliom, K. (1998) Identification of a Novel Growth Factor-like Lipid, 1-O-cis-Alk-1'-enyl-2-lyso-sn-glycero-3-phosphate (Alkenyl-GP) That Is Present in Commercial Sphingolipid Preparations. *Journal of Biological Chemistry* **273**, 13461-13468
  24. Bandoh, K., Aoki, J., Taira, A., Tsujimoto, M., Arai, H., and Inoue, K. (2000) Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species - Structure-activity relationship of cloned LPA receptors. *Febs Letters* **478**, 159-165
  25. Fujiwara, Y., Sardar, V., Tokumura, A., Baker, D., Murakami-Murofushi, K., Parrill, A., and Tigyi, G. (2005) Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. *Journal of Biological Chemistry* **280**, 35038-35050
  26. Williams, J. R., Khandoga, A. L., Goyal, P., Fells, J. I., Perygin, D. H., Siess, W., Parrill, A. L., Tigyi, G., and Fujiwara, Y. (2009) Unique Ligand Selectivity of the GPR92/LPA(5) Lysophosphatidate Receptor Indicates Role in Human Platelet Activation. *Journal of Biological Chemistry* **284**, 17304-17319
  27. Kobayashi, T., Tanaka-Ishii, R., Taguchi, R., Ikezawa, H., and Murakami-Murofushi, K. (1999) Existence of a bioactive lipid, cyclic phosphatidic acid, bound to human serum albumin. *Life Sci* **65**, 2185-2191
  28. Tsukahara, T., Tsukahara, R., Fujiwara, Y., Yue, J., Cheng, Y., Guo, H., Bolen, A., Zhang, C., Balazs, L., Re, F., Du, G., Frohman, M. A., Baker, D. L., Parrill, A. L., Uchiyama, A., Kobayashi, T., Murakami-Murofushi, K., and Tigyi, G. (2010) Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. *Mol Cell* **39**, 421-432
  29. Baker, D. L., Desiderio, D. M., Miller, D. D., Tolley, B., and Tigyi, G. J. (2001) Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. *Anal Biochem* **292**, 287-295

30. Hosogaya, S., Yatomi, Y., Nakamura, K., Ohkawa, R., Okubo, S., Yokota, H., Ohta, M., Yamazaki, H., Koike, T., and Ozaki, Y. (2008) Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. *Ann Clin Biochem* **45**, 364-368
31. Sano, T., Baker, D., Virag, T., Wada, A., Yatomi, Y., Kobayashi, T., Igarashi, Y., and Tigyi, G. (2002) Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. *J Biol Chem* **277**, 21197-21206
32. Tokumura, A., Kanaya, Y., Miyake, M., Yamano, S., Irahara, M., and Fukuzawa, K. (2002) Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. *Biol Reprod* **67**, 1386-1392
33. Tigyi, G., and Parrill, A. L. (2003) Molecular mechanisms of lysophosphatidic acid action. *Progress in Lipid Research* **42**, 498-526
34. Lind, S. E., Smith, D. B., Janmey, P. A., and Stossel, T. P. (1988) Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. *Am Rev Respir Dis* **138**, 429-434
35. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S. (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature* **381**, 800-803
36. Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., and Brown, S. (2009) Sphingosine 1-phosphate receptor signaling. *Annu Rev Biochem* **78**, 743-768
37. Adachi, K., and Chiba, K. (2007) FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. *Perspect Medicin Chem* **1**, 11-23
38. Yatomi, Y., Igarashi, Y., Yang, L., Hisano, N., Qi, R., Asazuma, N., Satoh, K., Ozaki, Y., and Kume, S. (1997) Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. *J Biochem* **121**, 969-973
39. Yatomi, Y., Ruan, F., Ohta, J., Welch, R. J., Hakomori, S., and Igarashi, Y. (1995) Quantitative measurement of sphingosine 1-phosphate in biological

- samples by acylation with radioactive acetic anhydride. *Anal Biochem* **230**, 315-320
40. Murata, N., Sato, K., Kon, J., Tomura, H., Yanagita, M., Kuwabara, A., Ui, M., and Okajima, F. (2000) Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. *Biochem J* **352 Pt 3**, 809-815
  41. Murata, N., Sato, K., Kon, J., Tomura, H., and Okajima, F. (2000) Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. *Anal Biochem* **282**, 115-120
  42. Okajima, F. (2002) Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? *Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids* **1582**, 132-137
  43. Aoki, S., Yatomi, Y., Ohta, M., Osada, M., Kazama, F., Satoh, K., Nakahara, K., and Ozaki, Y. (2005) Sphingosine 1-phosphate-related metabolism in the blood vessel. *J Biochem* **138**, 47-55
  44. Blaho, V. A., and Hla, T. (2014) An update on the biology of sphingosine 1-phosphate receptors. *J Lipid Res* **55**, 1596-1608
  45. Christoffersen, C., Obinata, H., Kumaraswamy, S. B., Galvani, S., Ahnstrom, J., Sevvana, M., Egerer-Sieber, C., Muller, Y. A., Hla, T., Nielsen, L. B., and Dahlback, B. (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. *Proc Natl Acad Sci U S A* **108**, 9613-9618
  46. Blaho, V. A., and Hla, T. (2011) Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. *Chem Rev* **111**, 6299-6320
  47. Pyne, S., Adams, D. R., and Pyne, N. J. (2016) Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. *Prog Lipid Res* **62**, 93-106
  48. Lee, M. J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha'afi, R. I., and Hla, T. (1999) Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. *Cell* **99**, 301-312

49. Yatomi, Y. (2008) Plasma sphingosine 1-phosphate metabolism and analysis. *Biochim Biophys Acta* **1780**, 606-611
50. Kimura, T., Sato, K., Kuwabara, A., Tomura, H., Ishiwara, M., Kobayashi, I., Ui, M., and Okajima, F. (2001) Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. *J Biol Chem* **276**, 31780-31785
51. Tamama, K., Kon, J., Sato, K., Tomura, H., Kuwabara, A., Kimura, T., Kanda, T., Ohta, H., Ui, M., Kobayashi, I., and Okajima, F. (2001) Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. *Biochem J* **353**, 139-146
52. Wilkerson, B. A., Grass, G. D., Wing, S. B., Argraves, W. S., and Argraves, K. M. (2012) Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. *J Biol Chem* **287**, 44645-44653
53. Hansson, G. K., Robertson, A. K., and Soderberg-Naucler, C. (2006) Inflammation and atherosclerosis. *Annu Rev Pathol* **1**, 297-329
54. Pamuklar, Z., Federico, L., Liu, S., Umezue-Goto, M., Dong, A., Panchatcharam, M., Fulkerson, Z., Berdyshev, E., Natarajan, V., Fang, X., van Meeteren, L. A., Moolenaar, W. H., Mills, G. B., Morris, A. J., and Smyth, S. S. (2009) Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. *J Biol Chem* **284**, 7385-7394
55. van Meeteren, L. A., and Moolenaar, W. H. (2007) Regulation and biological activities of the autotaxin-LPA axis. *Prog Lipid Res* **46**, 145-160
56. Fyrst, H., and Saba, J. D. (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. *Nat Chem Biol* **6**, 489-497
57. Venkataraman, K., Thangada, S., Michaud, J., Oo, M. L., Ai, Y., Lee, Y. M., Wu, M., Parikh, N. S., Khan, F., Proia, R. L., and Hla, T. (2006) Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. *Biochem J* **397**, 461-471

58. Aoki, J., Taira, A., Takanezawa, Y., Kishi, Y., Hama, K., Kishimoto, T., Mizuno, K., Saku, K., Taguchi, R., and Arai, H. (2002) Serum lysophosphatidic acid is produced through diverse phospholipase pathways. *J Biol Chem* **277**, 48737-48744
59. Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993) The bioactive phospholipid lysophosphatidic acid is released from activated platelets. *Biochem J* **291** ( Pt 3), 677-680
60. Billah, M. M., Lapetina, E. G., and Cuatrecasas, P. (1980) Phospholipase A2 and phospholipase C activities of platelets. Differential substrate specificity, Ca<sup>2+</sup> requirement, pH dependence, and cellular localization. *J Biol Chem* **255**, 10227-10231
61. Sonoda, H., Aoki, J., Hiramatsu, T., Ishida, M., Bandoh, K., Nagai, Y., Taguchi, R., Inoue, K., and Arai, H. (2002) A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. *J Biol Chem* **277**, 34254-34263
62. Inoue, M., and Okuyama, H. (1984) Phospholipase A1 acting on phosphatidic acid in porcine platelet membranes. *J Biol Chem* **259**, 5083-5086
63. Billah, M. M., Lapetina, E. G., and Cuatrecasas, P. (1981) Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. *J Biol Chem* **256**, 5399-5403
64. Dennis, E. A. (1994) Diversity of group types, regulation, and function of phospholipase A2. *J Biol Chem* **269**, 13057-13060
65. Pages, C., Simon, M. F., Valet, P., and Saulnier-Blache, J. S. (2001) Lysophosphatidic acid synthesis and release. *Prostaglandins Other Lipid Mediat* **64**, 1-10
66. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N., and Chun, J. (2010) LPA receptors: subtypes and biological actions. *Annu Rev Pharmacol Toxicol* **50**, 157-186
67. Siess, W., Zangl, K. J., Essler, M., Bauer, M., Brandl, R., Corrinth, C., Bittman, R., Tigyi, G., and Aepfelbacher, M. (1999) Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density

- lipoprotein and accumulates in human atherosclerotic lesions. *Proc Natl Acad Sci U S A* **96**, 6931-6936
68. Weidtmann, A., Scheithe, R., Hrboticky, N., Pietsch, A., Lorenz, R., and Siess, W. (1995) Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. *Arterioscler Thromb Vasc Biol* **15**, 1131-1138
  69. Tokumura, A., Harada, K., Fukuzawa, K., and Tsukatani, H. (1986) Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. *Biochim Biophys Acta* **875**, 31-38
  70. Tokumura, A., Kanaya, Y., Kitahara, M., Miyake, M., Yoshioka, Y., and Fukuzawa, K. (2002) Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits. *J Lipid Res* **43**, 307-315
  71. Tokumura, A., Yamano, S., Aono, T., and Fukuzawa, K. (2000) Lysophosphatidic acids produced by lysophospholipase D in mammalian serum and body fluid. *Ann N Y Acad Sci* **905**, 347-350
  72. Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K., and Fukuzawa, K. (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. *J Biol Chem* **277**, 39436-39442
  73. Umezū-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G. B., Inoue, K., Aoki, J., and Arai, H. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. *J Cell Biol* **158**, 227-233
  74. Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E., and Liotta, L. A. (1992) Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. *J Biol Chem* **267**, 2524-2529
  75. Yukiura, H., and Aoki, J. (2013) Autotaxin: A Unique Ecto-Type Pyrophosphodiesterase with Diverse Functions. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 103-119, Wiley, Hoboken, NJ, USA

76. Kehlen, A., Englert, N., Seifert, A., Klonisch, T., Dralle, H., Langner, J., and Hoang-Vu, C. (2004) Expression, regulation and function of autotaxin in thyroid carcinomas. *Int J Cancer* **109**, 833-838
77. Nam, S. W., Clair, T., Kim, Y. S., McMarlin, A., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. *Cancer Res* **61**, 6938-6944
78. Black, E. J., Clair, T., Delrow, J., Neiman, P., and Gillespie, D. A. (2004) Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. *Oncogene* **23**, 2357-2366
79. Zirn, B., Samans, B., Wittmann, S., Pietsch, T., Leuschner, I., Graf, N., and Gessler, M. (2006) Target genes of the WNT/beta-catenin pathway in Wilms tumors. *Genes Chromosomes Cancer* **45**, 565-574
80. Tice, D. A., Szeto, W., Soloviev, I., Rubinfeld, B., Fong, S. E., Dugger, D. L., Winer, J., Williams, P. M., Wieand, D., Smith, V., Schwall, R. H., Pennica, D., and Polakis, P. (2002) Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. *J Biol Chem* **277**, 14329-14335
81. Chen, M., and O'Connor, K. L. (2005) Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. *Oncogene* **24**, 5125-5130
82. Baumforth, K. R., Flavell, J. R., Reynolds, G. M., Davies, G., Pettit, T. R., Wei, W., Morgan, S., Stankovic, T., Kishi, Y., Arai, H., Nowakova, M., Pratt, G., Aoki, J., Wakelam, M. J., Young, L. S., and Murray, P. G. (2005) Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. *Blood* **106**, 2138-2146
83. van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., Pettit, T. R., Wakelam, M. J., Saulnier-Blache, J. S., Mummery, C. L., Moolenaar, W. H., and Jonkers, J. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. *Mol Cell Biol* **26**, 5015-5022

84. Offermanns, S., Mancino, V., Revel, J. P., and Simon, M. I. (1997) Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. *Science* **275**, 533-536
85. Gu, J. L., Muller, S., Mancino, V., Offermanns, S., and Simon, M. I. (2002) Interaction of G alpha(12) with G alpha(13) and G alpha(q) signaling pathways. *Proc Natl Acad Sci U S A* **99**, 9352-9357
86. Ruppel, K. M., Willison, D., Kataoka, H., Wang, A., Zheng, Y. W., Cornelissen, I., Yin, L., Xu, S. M., and Coughlin, S. R. (2005) Essential role for Galpha13 in endothelial cells during embryonic development. *Proc Natl Acad Sci U S A* **102**, 8281-8286
87. Koike, S., Keino-Masu, K., Ohto, T., Sugiyama, F., Takahashi, S., and Masu, M. (2009) Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. *J Biol Chem* **284**, 33561-33570
88. Lai, S. L., Yao, W. L., Tsao, K. C., Houben, A. J., Albers, H. M., Ovaa, H., Moolenaar, W. H., and Lee, S. J. (2012) Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish. *Development* **139**, 4439-4448
89. Moolenaar, W. H., and Perrakis, A. (2011) Insights into autotaxin: how to produce and present a lipid mediator. *Nat Rev Mol Cell Biol* **12**, 674-679
90. Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., Albers, H. M., van Meeteren, L. A., Houben, A. J., van Zeijl, L., Jansen, S., Andries, M., Hall, T., Pegg, L. E., Benson, T. E., Kasiem, M., Harlos, K., Kooi, C. W., Smyth, S. S., Ovaa, H., Bollen, M., Morris, A. J., Moolenaar, W. H., and Perrakis, A. (2011) Structural basis of substrate discrimination and integrin binding by autotaxin. *Nat Struct Mol Biol* **18**, 198-204
91. Nishimasu, H., Okudaira, S., Hama, K., Mihara, E., Dohmae, N., Inoue, A., Ishitani, R., Takagi, J., Aoki, J., and Nureki, O. (2011) Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. *Nat Struct Mol Biol* **18**, 205-212
92. Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D., and Rosen, S. D. (2008) Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes

- the entry of lymphocytes into secondary lymphoid organs. *Nat Immunol* **9**, 415-423
93. Houben, A. J., van Wijk, X. M., van Meeteren, L. A., van Zeijl, L., van de Westerlo, E. M., Hausmann, J., Fish, A., Perrakis, A., van Kuppevelt, T. H., and Moolenaar, W. H. (2013) The polybasic insertion in autotaxin alpha confers specific binding to heparin and cell surface heparan sulfate proteoglycans. *J Biol Chem* **288**, 510-519
  94. Spiegel, S., and Milstien, S. (2002) Sphingosine 1-phosphate, a key cell signaling molecule. *J Biol Chem* **277**, 25851-25854
  95. Pyne, N. J., and Pyne, S. (2010) Sphingosine 1-phosphate and cancer. *Nat Rev Cancer* **10**, 489-503
  96. Rivera, I. G., Ordonez, M., Presa, N., Gomez-Larrauri, A., Simon, J., Trueba, M., and Gomez-Munoz, A. (2015) Sphingomyelinase D/ceramide 1-phosphate in cell survival and inflammation. *Toxins (Basel)* **7**, 1457-1466
  97. Woodcock, J. (2006) Sphingosine and ceramide signalling in apoptosis. *IUBMB Life* **58**, 462-466
  98. Pitson, S. M. (2011) Regulation of sphingosine kinase and sphingolipid signaling. *Trends Biochem Sci* **36**, 97-107
  99. Allende, M. L., Sasaki, T., Kawai, H., Olivera, A., Mi, Y., van Echten-Deckert, G., Hajdu, R., Rosenbach, M., Keohane, C. A., Mandala, S., Spiegel, S., and Proia, R. L. (2004) Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. *J Biol Chem* **279**, 52487-52492
  100. Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O'Neill, S. L., Morris, M. A., Setiady, Y., Zhu, R., Zigler, M. A., Burcin, T. L., Ley, K., Tung, K. S., Engelhard, V. H., Macdonald, T. L., Pearson-White, S., and Lynch, K. R. (2005) Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. *J Biol Chem* **280**, 36865-36872
  101. Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., and Proia, R. L. (2005) Essential role for sphingosine kinases in neural and vascular development. *Mol Cell Biol* **25**, 11113-11121

102. Billich, A., Bornancin, F., Devay, P., Mechtcheriakova, D., Urtz, N., and Baumruker, T. (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. *J Biol Chem* **278**, 47408-47415
103. Okada, T., Ding, G., Sonoda, H., Kajimoto, T., Haga, Y., Khosrowbeygi, A., Gao, S., Miwa, N., Jahangeer, S., and Nakamura, S. (2005) Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. *J Biol Chem* **280**, 36318-36325
104. Alemany, R., van Koppen, C. J., Danneberg, K., Ter Braak, M., and Meyer Zu Heringdorf, D. (2007) Regulation and functional roles of sphingosine kinases. *Naunyn Schmiedebergs Arch Pharmacol* **374**, 413-428
105. Pitman, M. R., and Pitson, S. M. (2010) Inhibitors of the sphingosine kinase pathway as potential therapeutics. *Curr Cancer Drug Targets* **10**, 354-367
106. Leclercq, T. M., and Pitson, S. M. (2006) Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. *IUBMB Life* **58**, 467-472
107. Yokota, S., Taniguchi, Y., Kihara, A., Mitsutake, S., and Igarashi, Y. (2004) Asp177 in C4 domain of mouse sphingosine kinase 1a is important for the sphingosine recognition. *FEBS Lett* **578**, 106-110
108. Pitman, M. R., Jarman, K. E., Leclercq, T. M., Pham, D. H., and Pitson, S. M. (2013) Sphingosine Kinases: Biochemistry, Regulation, and Roles. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 153-183, Wiley, Hoboken, NJ, USA
109. Pitson, S. M., Moretti, P. A., Zebol, J. R., Lynn, H. E., Xia, P., Vadas, M. A., and Wattenberg, B. W. (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. *Embo j* **22**, 5491-5500
110. Jarman, K. E., Moretti, P. A., Zebol, J. R., and Pitson, S. M. (2010) Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. *J Biol Chem* **285**, 483-492
111. Sutherland, C. M., Moretti, P. A., Hewitt, N. M., Bagley, C. J., Vadas, M. A., and Pitson, S. M. (2006) The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane. *J Biol Chem* **281**, 11693-11701

112. Alvarez, S. E., Harikumar, K. B., Hait, N. C., Allegood, J., Strub, G. M., Kim, E. Y., Maceyka, M., Jiang, H., Luo, C., Kordula, T., Milstien, S., and Spiegel, S. (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. *Nature* **465**, 1084-1088
113. Barr, R. K., Lynn, H. E., Moretti, P. A., Khew-Goodall, Y., and Pitson, S. M. (2008) Deactivation of sphingosine kinase 1 by protein phosphatase 2A. *J Biol Chem* **283**, 34994-35002
114. Rosenfeldt, H. M., Hobson, J. P., Maceyka, M., Olivera, A., Nava, V. E., Milstien, S., and Spiegel, S. (2001) EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. *Faseb j* **15**, 2649-2659
115. Toman, R. E., Payne, S. G., Watterson, K. R., Maceyka, M., Lee, N. H., Milstien, S., Bigbee, J. W., and Spiegel, S. (2004) Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. *J Cell Biol* **166**, 381-392
116. El-Shewy, H. M., Johnson, K. R., Lee, M. H., Jaffa, A. A., Obeid, L. M., and Luttrell, L. M. (2006) Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. *J Biol Chem* **281**, 31399-31407
117. Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinosa, C., Proia, R. L., Rivera, J., Milstien, S., and Spiegel, S. (2004) Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. *J Exp Med* **199**, 959-970
118. Young, K. W., Willets, J. M., Parkinson, M. J., Bartlett, P., Spiegel, S., Nahorski, S. R., and Challiss, R. A. (2003) Ca<sup>2+</sup>/calmodulin-dependent translocation of sphingosine kinase: role in plasma membrane relocation but not activation. *Cell Calcium* **33**, 119-128
119. Johnson, K. R., Becker, K. P., Facchinetti, M. M., Hannun, Y. A., and Obeid, L. M. (2002) PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). *J Biol Chem* **277**, 35257-35262

120. Fujita, T., Okada, T., Hayashi, S., Jahangeer, S., Miwa, N., and Nakamura, S. (2004) Delta-catenin/NPRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1. *Biochem J* **382**, 717-723
121. Urtz, N., Olivera, A., Bofill-Cardona, E., Csonga, R., Billich, A., Mechtcheriakova, D., Bornancin, F., Woisetschlager, M., Rivera, J., and Baumruker, T. (2004) Early activation of sphingosine kinase in mast cells and recruitment to FcepsilonRI are mediated by its interaction with Lyn kinase. *Mol Cell Biol* **24**, 8765-8777
122. Olivera, A., Urtz, N., Mizugishi, K., Yamashita, Y., Gilfillan, A. M., Furumoto, Y., Gu, H., Proia, R. L., Baumruker, T., and Rivera, J. (2006) IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses. *J Biol Chem* **281**, 2515-2525
123. Leclercq, T. M., Moretti, P. A., Vadas, M. A., and Pitson, S. M. (2008) Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. *J Biol Chem* **283**, 9606-9614
124. Lacana, E., Maceyka, M., Milstien, S., and Spiegel, S. (2002) Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. *J Biol Chem* **277**, 32947-32953
125. Maceyka, M., Nava, V. E., Milstien, S., and Spiegel, S. (2004) Aminoacylase 1 is a sphingosine kinase 1-interacting protein. *FEBS Lett* **568**, 30-34
126. Fukuda, Y., Aoyama, Y., Wada, A., and Igarashi, Y. (2004) Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. *Biochim Biophys Acta* **1636**, 12-21
127. Sun, J., Yan, G., Ren, A., You, B., and Liao, J. K. (2006) FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. *Circ Res* **99**, 468-476
128. Hayashi, H., Nakagami, H., Takami, Y., Koriyama, H., Mori, M., Tamai, K., Sun, J., Nagao, K., Morishita, R., and Kaneda, Y. (2009) FHL-2 suppresses

- VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. *Arterioscler Thromb Vasc Biol* **29**, 909-914
129. Mastrandrea, L. D., Sessanna, S. M., and Laychock, S. G. (2005) Sphingosine kinase activity and sphingosine-1 phosphate production in rat pancreatic islets and INS-1 cells: response to cytokines. *Diabetes* **54**, 1429-1436
  130. Hait, N. C., Sarkar, S., Le Stunff, H., Mikami, A., Maceyka, M., Milstien, S., and Spiegel, S. (2005) Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. *J Biol Chem* **280**, 29462-29469
  131. Hait, N. C., Bellamy, A., Milstien, S., Kordula, T., and Spiegel, S. (2007) Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. *J Biol Chem* **282**, 12058-12065
  132. Maceyka, M., Sankala, H., Hait, N. C., Le Stunff, H., Liu, H., Toman, R., Collier, C., Zhang, M., Satin, L. S., Merrill, A. H., Jr., Milstien, S., and Spiegel, S. (2005) SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. *J Biol Chem* **280**, 37118-37129
  133. Ding, G., Sonoda, H., Yu, H., Kajimoto, T., Goparaju, S. K., Jahangeer, S., Okada, T., and Nakamura, S. (2007) Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. *J Biol Chem* **282**, 27493-27502
  134. Don, A. S., and Rosen, H. (2009) A lipid binding domain in sphingosine kinase 2. *Biochem Biophys Res Commun* **380**, 87-92
  135. Igarashi, N., Okada, T., Hayashi, S., Fujita, T., Jahangeer, S., and Nakamura, S. (2003) Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. *J Biol Chem* **278**, 46832-46839
  136. Le Stunff, H., Giussani, P., Maceyka, M., Lepine, S., Milstien, S., and Spiegel, S. (2007) Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2. *J Biol Chem* **282**, 34372-34380
  137. Liu, H., Toman, R. E., Goparaju, S. K., Maceyka, M., Nava, V. E., Sankala, H., Payne, S. G., Bektas, M., Ishii, I., Chun, J., Milstien, S., and Spiegel, S. (2003) Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. *J Biol Chem* **278**, 40330-40336

138. Villen, J., Beausoleil, S. A., Gerber, S. A., and Gygi, S. P. (2007) Large-scale phosphorylation analysis of mouse liver. *Proc Natl Acad Sci U S A* **104**, 1488-1493
139. Dephoure, N., Zhou, C., Villen, J., Beausoleil, S. A., Bakalarski, C. E., Elledge, S. J., and Gygi, S. P. (2008) A quantitative atlas of mitotic phosphorylation. *Proc Natl Acad Sci U S A* **105**, 10762-10767
140. Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S., Korner, R., Greff, Z., Keri, G., Stemmann, O., and Mann, M. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. *Mol Cell* **31**, 438-448
141. Tani, M., Ito, M., and Igarashi, Y. (2007) Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. *Cell Signal* **19**, 229-237
142. Waters, C., Sambhi, B., Kong, K. C., Thompson, D., Pitson, S. M., Pyne, S., and Pyne, N. J. (2003) Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. *J Biol Chem* **278**, 6282-6290
143. Soldi, R., Mandinova, A., Venkataraman, K., Hla, T., Vadas, M., Pitson, S., Duarte, M., Graziani, I., Kolev, V., Kacer, D., Kirov, A., Maciag, T., and Prudovsky, I. (2007) Sphingosine kinase 1 is a critical component of the copper-dependent FGF1 export pathway. *Exp Cell Res* **313**, 3308-3318
144. Hammad, S. M., Taha, T. A., Nareika, A., Johnson, K. R., Lopes-Virella, M. F., and Obeid, L. M. (2006) Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. *Prostaglandins Other Lipid Mediat* **79**, 126-140
145. Weigert, A., Cremer, S., Schmidt, M. V., von Knethen, A., Angioni, C., Geisslinger, G., and Brune, B. (2010) Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. *Blood* **115**, 3531-3540
146. Clair, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003) Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. *Cancer Res* **63**, 5446-5453

147. Liliom, K., Sun, G., Bunemann, M., Virag, T., Nusser, N., Baker, D. L., Wang, D. A., Fabian, M. J., Brandts, B., Bender, K., Eickel, A., Malik, K. U., Miller, D. D., Desiderio, D. M., Tigyi, G., and Pott, L. (2001) Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. *Biochem J* **355**, 189-197
148. Hla, T., Venkataraman, K., and Michaud, J. (2008) The vascular S1P gradient-cellular sources and biological significance. *Biochim Biophys Acta* **1781**, 477-482
149. Yatomi, Y., Ozaki, Y., Ohmori, T., and Igarashi, Y. (2001) Sphingosine 1-phosphate: synthesis and release. *Prostaglandins Other Lipid Mediat* **64**, 107-122
150. Yatomi, Y. (2006) Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. *Curr Pharm Des* **12**, 575-587
151. Yatomi, Y., Yamamura, S., Ruan, F., and Igarashi, Y. (1997) Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. *J Biol Chem* **272**, 5291-5297
152. Aoki, S., Osada, M., Kaneko, M., Ozaki, Y., and Yatomi, Y. (2007) Fluid shear stress enhances the sphingosine 1-phosphate responses in cell-cell interactions between platelets and endothelial cells. *Biochem Biophys Res Commun* **358**, 1054-1057
153. Andrews, N. C. (1998) The NF-E2 transcription factor. *Int J Biochem Cell Biol* **30**, 429-432
154. Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., Camerer, E., Zheng, Y. W., Huang, Y., Cyster, J. G., and Coughlin, S. R. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. *Science* **316**, 295-298
155. Ito, K., Anada, Y., Tani, M., Ikeda, M., Sano, T., Kihara, A., and Igarashi, Y. (2007) Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. *Biochem Biophys Res Commun* **357**, 212-217
156. Hla, T. (2004) Physiological and pathological actions of sphingosine 1-phosphate. *Semin Cell Dev Biol* **15**, 513-520

157. Venkataraman, K., Lee, Y. M., Michaud, J., Thangada, S., Ai, Y., Bonkovsky, H. L., Parikh, N. S., Habrukowich, C., and Hla, T. (2008) Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. *Circ Res* **102**, 669-676
158. Mitra, P., Oskeritzian, C. A., Payne, S. G., Beaven, M. A., Milstien, S., and Spiegel, S. (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. *Proc Natl Acad Sci U S A* **103**, 16394-16399
159. Sato, K., Malchinkhuu, E., Horiuchi, Y., Mogi, C., Tomura, H., Tosaka, M., Yoshimoto, Y., Kuwabara, A., and Okajima, F. (2007) Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. *J Neurochem* **103**, 2610-2619
160. Kihara, A., and Igarashi, Y. (2008) Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. *Biochim Biophys Acta* **1781**, 496-502
161. Kobayashi, N., Nishi, T., Hirata, T., Kihara, A., Sano, T., Igarashi, Y., and Yamaguchi, A. (2006) Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. *J Lipid Res* **47**, 614-621
162. Kobayashi, N., Kobayashi, N., Yamaguchi, A., and Nishi, T. (2009) Characterization of the ATP-dependent sphingosine 1-phosphate transporter in rat erythrocytes. *J Biol Chem* **284**, 21192-21200
163. Lee, Y. M., Venkataraman, K., Hwang, S. I., Han, D. K., and Hla, T. (2007) A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). *Prostaglandins Other Lipid Mediat* **84**, 154-162
164. Osborne, N., Brand-Arzamendi, K., Ober, E. A., Jin, S. W., Verkade, H., Holtzman, N. G., Yelon, D., and Stainier, D. Y. (2008) The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. *Curr Biol* **18**, 1882-1888
165. Kawahara, A., Nishi, T., Hisano, Y., Fukui, H., Yamaguchi, A., and Mochizuki, N. (2009) The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. *Science* **323**, 524-527

166. Tang, X., Benesch, M. G., and Brindley, D. N. (2015) Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. *J Lipid Res* **56**, 2048-2060
167. Panchatcharam, M., Salous, A. K., Brandon, J., Miriyala, S., Wheeler, J., Patil, P., Sunkara, M., Morris, A. J., Escalante-Alcalde, D., and Smyth, S. S. (2014) Mice With Targeted Inactivation of Ppap2b in Endothelial and Hematopoietic Cells Display Enhanced Vascular Inflammation and Permeability. *Arteriosclerosis Thrombosis and Vascular Biology* **34**, 837-845
168. Thompson, F. J., and Clark, M. A. (1994) Purification of a lysophosphatidic acid-hydrolysing lysophospholipase from rat brain. *Biochem J* **300** ( Pt 2), 457-461
169. Chiang, K. P., Niessen, S., Saghatelian, A., and Cravatt, B. F. (2006) An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. *Chem Biol* **13**, 1041-1050
170. Gellett, A. M., Kharel, Y., Sunkara, M., Morris, A. J., and Lynch, K. R. (2012) Biosynthesis of alkyl lysophosphatidic acid by diacylglycerol kinases. *Biochem Biophys Res Commun* **422**, 758-763
171. Ohshima, N., Kudo, T., Yamashita, Y., Mariggio, S., Araki, M., Honda, A., Nagano, T., Isaji, C., Kato, N., Corda, D., Izumi, T., and Yanaka, N. (2015) New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity. *J Biol Chem* **290**, 4260-4271
172. Blankley, C. J., and Kaplan, H. R. (1984) Biologically-Active Phospholipids As Potential Cardiovascular Drugs. *Drug Development Research* **4**, 351-372
173. Pörn, M. I., Akerman, K. E., and Slotte, J. P. (1991) High-density lipoproteins induce a rapid and transient release of Ca<sup>2+</sup> in cultured fibroblasts. *Biochem J* **279** ( Pt 1), 29-33
174. Gerrard, J. M., Kindom, S. E., Peterson, D. A., Peller, J., Krantz, K. E., and White, J. G. (1979) Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux. *Am J Pathol* **96**, 423-438
175. Snyder, F. (1990) Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. *Am J Physiol* **259**, C697-708

176. van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., and Moolenaar, W. H. (1989) Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. *Cell* **59**, 45-54
177. Kihara, Y., Maceyka, M., Spiegel, S., and Chun, J. (2014) Lysophospholipid receptor nomenclature review: IUPHAR Review 8. *Br J Pharmacol* **171**, 3575-3594
178. Yung, Y. C., Stoddard, N. C., and Chun, J. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. *J Lipid Res* **55**, 1192-1214
179. Hanson, M. A., Roth, C. B., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G., Desale, H., Clemons, B., Cahalan, S. M., Schuerer, S. C., Sanna, M. G., Han, G. W., Kuhn, P., Rosen, H., and Stevens, R. C. (2012) Crystal structure of a lipid G protein-coupled receptor. *Science* **335**, 851-855
180. Chrencik, J. E., Roth, C. B., Terakado, M., Kurata, H., Omi, R., Kihara, Y., Warshaviak, D., Nakade, S., Asmar-Rovira, G., Mileni, M., Mizuno, H., Griffith, M. T., Rodgers, C., Han, G. W., Velasquez, J., Chun, J., Stevens, R. C., and Hanson, M. A. (2015) Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. *Cell* **161**, 1633-1643
181. Taniguchi, R., Inoue, A., Sayama, M., Uwamizu, A., Yamashita, K., Hirata, K., Yoshida, M., Tanaka, Y., Kato, H. E., Nakada-Nakura, Y., Otani, Y., Nishizawa, T., Doi, T., Ohwada, T., Ishitani, R., Aoki, J., and Nureki, O. (2017) Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6. *Nature* **548**, 356-360
182. Parrill, A. L., Wang, D., Bautista, D. L., Van Brocklyn, J. R., Lorincz, Z., Fischer, D. J., Baker, D. L., Liliom, K., Spiegel, S., and Tigyi, G. (2000) Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. *J Biol Chem* **275**, 39379-39384
183. Wang, D. A., Lorincz, Z., Bautista, D. L., Liliom, K., Tigyi, G., and Parrill, A. L. (2001) A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. *J Biol Chem* **276**, 49213-49220
184. Li, G., Mosier, P. D., Fang, X., and Zhang, Y. (2009) Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the

- LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study. *J Mol Graph Model* **28**, 70-79
185. Balogh, B., Pazmany, T., and Matyus, P. (2015) Analysis of Edg-Like LPA Receptor-Ligand Interactions. *Curr Pharm Des* **21**, 3533-3547
  186. Mirendil, H., Lin, M. E., and Chun, J. (2013) Lysophosphatidic Acid (LPA) Receptor Signaling. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 1-39, Wiley, Hoboken, NJ, USA
  187. Contos, J. J., and Chun, J. (1998) Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. *Genomics* **51**, 364-378
  188. An, S., Bleu, T., Hallmark, O. G., and Goetzl, E. J. (1998) Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. *J Biol Chem* **273**, 7906-7910
  189. Contos, J. J., Ishii, I., and Chun, J. (2000) Lysophosphatidic acid receptors. *Mol Pharmacol* **58**, 1188-1196
  190. Weiner, J. A., Hecht, J. H., and Chun, J. (1998) Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. *J Comp Neurol* **398**, 587-598
  191. Weiner, J. A., and Chun, J. (1999) Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. *Proc Natl Acad Sci U S A* **96**, 5233-5238
  192. Contos, J. J., Fukushima, N., Weiner, J. A., Kaushal, D., and Chun, J. (2000) Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. *Proc Natl Acad Sci U S A* **97**, 13384-13389
  193. Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., and Luster, A. D. (2008) The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. *Nat Med* **14**, 45-54
  194. Estivill-Torrus, G., Llebrez-Zayas, P., Matas-Rico, E., Santin, L., Pedraza, C., De Diego, I., Del Arco, I., Fernandez-Llebrez, P., Chun, J., and De Fonseca, F.

- R. (2008) Absence of LPA1 signaling results in defective cortical development. *Cereb Cortex* **18**, 938-950
195. Pedraza, C., Sanchez-Lopez, J., Castilla-Ortega, E., Rosell-Valle, C., Zambrana-Infantes, E., Garcia-Fernandez, M., Rodriguez de Fonseca, F., Chun, J., Santin, L. J., and Estivill-Torrus, G. (2014) Fear extinction and acute stress reactivity reveal a role of LPA(1) receptor in regulating emotional-like behaviors. *Brain Struct Funct* **219**, 1659-1672
196. Castilla-Ortega, E., Hoyo-Becerra, C., Pedraza, C., Chun, J., Rodriguez De Fonseca, F., Estivill-Torrus, G., and Santin, L. J. (2011) Aggravation of chronic stress effects on hippocampal neurogenesis and spatial memory in LPA(1) receptor knockout mice. *PLoS One* **6**, e25522
197. Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A., and Chun, J. (2001) Lysophospholipid receptors. *Annu Rev Pharmacol Toxicol* **41**, 507-534
198. Ishii, I., Fukushima, N., Ye, X., and Chun, J. (2004) Lysophospholipid receptors: signaling and biology. *Annu Rev Biochem* **73**, 321-354
199. Varsano, T., Taupin, V., Guo, L., Baterina, O. Y., Jr., and Farquhar, M. G. (2012) The PDZ protein GIPC regulates trafficking of the LPA1 receptor from APPL signaling endosomes and attenuates the cell's response to LPA. *PLoS One* **7**, e49227
200. Yu, F. X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., Fu, X. D., Mills, G. B., and Guan, K. L. (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* **150**, 780-791
201. Cai, H., and Xu, Y. (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. *Cell Commun Signal* **11**, 31
202. Contos, J. J. A., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., Brown, J. H., and Chun, J. (2002) Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2. *Molecular and Cellular Biology* **22**, 6921-6929

203. Contos, J. J., and Chun, J. (2000) Genomic characterization of the lysophosphatidic acid receptor gene, *lp(A2)/Edg4*, and identification of a frameshift mutation in a previously characterized cDNA. *Genomics* **64**, 155-169
204. Ohuchi, H., Hamada, A., Matsuda, H., Takagi, A., Tanaka, M., Aoki, J., Arai, H., and Noji, S. (2008) Expression patterns of the lysophospholipid receptor genes during mouse early development. *Dev Dyn* **237**, 3280-3294
205. Diez-Roux, G., Banfi, S., Sultan, M., Geffers, L., Anand, S., Rozado, D., Magen, A., Canidio, E., Pagani, M., Peluso, I., Lin-Marq, N., Koch, M., Bilio, M., Cantiello, I., Verde, R., De Masi, C., Bianchi, S. A., Cicchini, J., Perroud, E., Mehmeti, S., Dagand, E., Schrunner, S., Nurnberger, A., Schmidt, K., Metz, K., Zwingmann, C., Brieske, N., Springer, C., Hernandez, A. M., Herzog, S., Grabbe, F., Sieverding, C., Fischer, B., Schrader, K., Brockmeyer, M., Dettmer, S., Helbig, C., Alunni, V., Battaini, M. A., Mura, C., Henrichsen, C. N., Garcia-Lopez, R., Echevarria, D., Puelles, E., Garcia-Calero, E., Kruse, S., Uhr, M., Kauck, C., Feng, G., Milyaev, N., Ong, C. K., Kumar, L., Lam, M., Semple, C. A., Gyenesei, A., Mundlos, S., Radelof, U., Lehrach, H., Sarmientos, P., Reymond, A., Davidson, D. R., Dolle, P., Antonarakis, S. E., Yaspo, M. L., Martinez, S., Baldock, R. A., Eichele, G., and Ballabio, A. (2011) A high-resolution anatomical atlas of the transcriptome in the mouse embryo. *PLoS Biol* **9**, e1000582
206. Dubin, A. E., Herr, D. R., and Chun, J. (2010) Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. *J Neurosci* **30**, 7300-7309
207. Magdaleno, S., Jensen, P., Brumwell, C. L., Seal, A., Lehman, K., Asbury, A., Cheung, T., Cornelius, T., Batten, D. M., Eden, C., Norland, S. M., Rice, D. S., Dosooye, N., Shakya, S., Mehta, P., and Curran, T. (2006) BGEM: an in situ hybridization database of gene expression in the embryonic and adult mouse nervous system. *PLoS Biol* **4**, e86
208. Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., Chun, J., and Yun, C. C. (2009) The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. *Gastroenterology* **136**, 1711-1720

209. Zhao, Y., Tong, J., He, D., Pendyala, S., Evgeny, B., Chun, J., Sperling, A. I., and Natarajan, V. (2009) Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. *Respir Res* **10**, 114
210. Deng, W., Shuyu, E., Tsukahara, R., Valentine, W. J., Durgam, G., Gududuru, V., Balazs, L., Manickam, V., Arsura, M., VanMiddlesworth, L., Johnson, L. R., Parrill, A. L., Miller, D. D., and Tigyi, G. (2007) The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. *Gastroenterology* **132**, 1834-1851
211. Balogh, A., Shimizu, Y., Lee, S. C., Norman, D. D., Gangwar, R., Bavaria, M., Moon, C., Shukla, P., Rao, R., Ray, R., Naren, A. P., Banerjee, S., Miller, D. D., Balazs, L., Pelus, L., and Tigyi, G. (2015) The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair. *Cell Signal* **27**, 1751-1762
212. Panchatcharam, M., Miriyala, S., Yang, F., Rojas, M., End, C., Vallant, C., Dong, A., Lynch, K., Chun, J., Morris, A. J., and Smyth, S. S. (2008) Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. *Circ Res* **103**, 662-670
213. Patil, R., Szabo, E., Fells, J. I., Balogh, A., Lim, K. G., Fujiwara, Y., Norman, D. D., Lee, S. C., Balazs, L., Thomas, F., Patil, S., Emmons-Thompson, K., Boler, A., Strobos, J., McCool, S. W., Yates, C. R., Stabenow, J., Byrne, G. I., Miller, D. D., and Tigyi, G. J. (2015) Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist. *Chem Biol* **22**, 206-216
214. Kuo, B., Szabo, E., Lee, S. C., Balogh, A., Norman, D., Inoue, A., Ono, Y., Aoki, J., and Tigyi, G. (2018) The LPA2 receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids. *Cell Signal* **51**, 23-33
215. Lin, F. T., and Lai, Y. J. (2008) Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions. *Biochim Biophys Acta* **1781**, 558-562

216. Li, C., Dandridge, K. S., Di, A., Marrs, K. L., Harris, E. L., Roy, K., Jackson, J. S., Makarova, N. V., Fujiwara, Y., Farrar, P. L., Nelson, D. J., Tigyi, G. J., and Naren, A. P. (2005) Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. *J Exp Med* **202**, 975-986
217. Thompson, K. E., Ray, R. M., Alli, S., Ge, W., Boler, A., Shannon McCool, W., Meena, A. S., Shukla, P. K., Rao, R., Johnson, L. R., Miller, M. A., and Tigyi, G. J. (2018) Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100. *Exp Biol Med (Maywood)* **243**, 1056-1065
218. Lin, F. T., Lai, Y. J., Makarova, N., Tigyi, G., and Lin, W. C. (2007) The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. *J Biol Chem* **282**, 37759-37769
219. E, S., Lai, Y. J., Tsukahara, R., Chen, C. S., Fujiwara, Y., Yue, J., Yu, J. H., Guo, H., Kihara, A., Tigyi, G., and Lin, F. T. (2009) Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. *J Biol Chem* **284**, 14558-14571
220. Lai, Y. J., Chen, C. S., Lin, W. C., and Lin, F. T. (2005) c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. *Mol Cell Biol* **25**, 5859-5868
221. Lai, Y. J., Lin, W. C., and Lin, F. T. (2007) PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. *J Biol Chem* **282**, 24381-24387
222. Komachi, M., Tomura, H., Malchinkhuu, E., Tobo, M., Mogi, C., Yamada, T., Kimura, T., Kuwabara, A., Ohta, H., Im, D. S., Kurose, H., Takeyoshi, I., Sato, K., and Okajima, F. (2009) LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. *Carcinogenesis* **30**, 457-465
223. Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., and Ullrich, A. (2001) Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. *Oncogene* **20**, 1594-1600
224. Bandoh, K., Aoki, J., Hosono, H., Kobayashi, S., Kobayashi, T., Murakami-Murofushi, K., Tsujimoto, M., Arai, H., and Inoue, K. (1999) Molecular cloning

- and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. *J Biol Chem* **274**, 27776-27785
225. Im, D. S., Heise, C. E., Harding, M. A., George, S. R., O'Dowd, B. F., Theodorescu, D., and Lynch, K. R. (2000) Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. *Mol Pharmacol* **57**, 753-759
226. Ye, X., Hama, K., Contos, J. J., Anliker, B., Inoue, A., Skinner, M. K., Suzuki, H., Amano, T., Kennedy, G., Arai, H., Aoki, J., and Chun, J. (2005) LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. *Nature* **435**, 104-108
227. Ishii, I., Contos, J. J., Fukushima, N., and Chun, J. (2000) Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. *Mol Pharmacol* **58**, 895-902
228. Liu, C. H., and Hla, T. (1997) The mouse gene for the inducible G-protein-coupled receptor edg-1. *Genomics* **43**, 15-24
229. Zhang, G., Contos, J. J., Weiner, J. A., Fukushima, N., and Chun, J. (1999) Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. *Gene* **227**, 89-99
230. Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C. X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S. S., Lee, M. J., Liu, C. H., Hla, T., Spiegel, S., and Proia, R. L. (2000) Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. *J Clin Invest* **106**, 951-961
231. Allende, M. L., and Proia, R. L. (2002) Sphingosine-1-phosphate receptors and the development of the vascular system. *Biochim Biophys Acta* **1582**, 222-227
232. Allende, M. L., Yamashita, T., and Proia, R. L. (2003) G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. *Blood* **102**, 3665-3667
233. Allende, M. L., Dreier, J. L., Mandala, S., and Proia, R. L. (2004) Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. *J Biol Chem* **279**, 15396-15401

234. Kabashima, K., Haynes, N. M., Xu, Y., Nutt, S. L., Allende, M. L., Proia, R. L., and Cyster, J. G. (2006) Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. *J Exp Med* **203**, 2683-2690
235. Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature* **427**, 355-360
236. Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., and Burtin, P. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. *Nat Rev Drug Discov* **9**, 883-897
237. Rivera, R., and Chun, J. (2008) Biological effects of lysophospholipids. *Rev Physiol Biochem Pharmacol* **160**, 25-46
238. Kono, M., Allende, M. L., and Proia, R. L. (2008) Sphingosine-1-phosphate regulation of mammalian development. *Biochim Biophys Acta* **1781**, 435-441
239. Lee, M. J., Thangada, S., Paik, J. H., Sapkota, G. P., Ancellin, N., Chae, S. S., Wu, M., Morales-Ruiz, M., Sessa, W. C., Alessi, D. R., and Hla, T. (2001) Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. *Mol Cell* **8**, 693-704
240. Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., and Betsholtz, C. (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. *Development* **126**, 3047-3055
241. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* **277**, 242-245
242. Okazaki, H., Ishizaka, N., Sakurai, T., Kurokawa, K., Goto, K., Kumada, M., and Takuwa, Y. (1993) Molecular cloning of a novel putative G protein-coupled receptor expressed in the cardiovascular system. *Biochem Biophys Res Commun* **190**, 1104-1109

243. MacLennan, A. J., Browe, C. S., Gaskin, A. A., Lado, D. C., and Shaw, G. (1994) Cloning and characterization of a putative G-protein coupled receptor potentially involved in development. *Mol Cell Neurosci* **5**, 201-209
244. Gonda, K., Okamoto, H., Takuwa, N., Yatomi, Y., Okazaki, H., Sakurai, T., Kimura, S., Sillard, R., Harii, K., and Takuwa, Y. (1999) The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and -insensitive G-proteins to multiple signalling pathways. *Biochem J* **337** ( Pt 1), 67-75
245. Ishii, I., Friedman, B., Ye, X., Kawamura, S., McGiffert, C., Contos, J. J., Kingsbury, M. A., Zhang, G., Brown, J. H., and Chun, J. (2001) Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. *J Biol Chem* **276**, 33697-33704
246. MacLennan, A. J., Marks, L., Gaskin, A. A., and Lee, N. (1997) Embryonic expression pattern of H218, a G-protein coupled receptor homolog, suggests roles in early mammalian nervous system development. *Neuroscience* **79**, 217-224
247. MacLennan, A. J., Carney, P. R., Zhu, W. J., Chaves, A. H., Garcia, J., Grimes, J. R., Anderson, K. J., Roper, S. N., and Lee, N. (2001) An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. *Eur J Neurosci* **14**, 203-209
248. McGiffert, C., Contos, J. J., Friedman, B., and Chun, J. (2002) Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. *FEBS Lett* **531**, 103-108
249. Ishii, I., Ye, X., Friedman, B., Kawamura, S., Contos, J. J., Kingsbury, M. A., Yang, A. H., Zhang, G., Brown, J. H., and Chun, J. (2002) Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. *J Biol Chem* **277**, 25152-25159
250. Kono, M., Belyantseva, I. A., Skoura, A., Frolenkov, G. I., Starost, M. F., Dreier, J. L., Lidington, D., Bolz, S. S., Friedman, T. B., Hla, T., and Proia, R.

- L. (2007) Deafness and stria vascularis defects in S1P2 receptor-null mice. *J Biol Chem* **282**, 10690-10696
251. Serriere-Lanneau, V., Teixeira-Clerc, F., Li, L., Schippers, M., de Wries, W., Julien, B., Tran-Van-Nhieu, J., Manin, S., Poelstra, K., Chun, J., Carpentier, S., Levade, T., Mallat, A., and Lotersztajn, S. (2007) The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. *Faseb j* **21**, 2005-2013
252. Lorenz, J. N., Arend, L. J., Robitz, R., Paul, R. J., and MacLennan, A. J. (2007) Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. *Am J Physiol Regul Integr Comp Physiol* **292**, R440-446
253. Skoura, A., Sanchez, T., Claffey, K., Mandala, S. M., Proia, R. L., and Hla, T. (2007) Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. *J Clin Invest* **117**, 2506-2516
254. Skoura, A., Michaud, J., Im, D. S., Thangada, S., Xiong, Y., Smith, J. D., and Hla, T. (2011) Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. *Arterioscler Thromb Vasc Biol* **31**, 81-85
255. Kupperman, E., An, S., Osborne, N., Waldron, S., and Stainier, D. Y. (2000) A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. *Nature* **406**, 192-195
256. Jung, B., and Hla, T. (2013) Sphingosine 1-Phosphate (S1P) Receptors. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 41-60, Wiley, Hoboken, NJ, USA
257. Estrada, R., Zeng, Q., Lu, H., Sarojini, H., Lee, J. F., Mathis, S. P., Sanchez, T., Wang, E., Kontos, C. D., Lin, C. Y., Hla, T., Haribabu, B., and Lee, M. J. (2008) Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. *J Biol Chem* **283**, 30363-30375
258. Yamaguchi, F., Yamaguchi, K., Tokuda, M., and Brenner, S. (1999) Molecular cloning of EDG-3 and N-Shc genes from the puffer fish, *Fugu rubripes*, and conservation of synteny with the human genome. *FEBS Lett* **459**, 105-110

259. Takuwa, Y., Okamoto, Y., Yoshioka, K., and Takuwa, N. (2008) Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. *Biochim Biophys Acta* **1781**, 483-488
260. Levkau, B., Hermann, S., Theilmeyer, G., van der Giet, M., Chun, J., Schober, O., and Schafers, M. (2004) High-density lipoprotein stimulates myocardial perfusion in vivo. *Circulation* **110**, 3355-3359
261. Means, C. K., Xiao, C. Y., Li, Z., Zhang, T., Omens, J. H., Ishii, I., Chun, J., and Brown, J. H. (2007) Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* **292**, H2944-2951
262. Sanchez, T., and Hla, T. (2004) Structural and functional characteristics of S1P receptors. *J Cell Biochem* **92**, 913-922
263. Niessen, F., Schaffner, F., Furlan-Freguia, C., Pawlinski, R., Bhattacharjee, G., Chun, J., Derian, C. K., Andrade-Gordon, P., Rosen, H., and Ruf, W. (2008) Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. *Nature* **452**, 654-658
264. Graler, M. H., Bernhardt, G., and Lipp, M. (1998) EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. *Genomics* **53**, 164-169
265. Yamazaki, Y., Kon, J., Sato, K., Tomura, H., Sato, M., Yoneya, T., Okazaki, H., Okajima, F., and Ohta, H. (2000) Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway. *Biochem Biophys Res Commun* **268**, 583-589
266. Van Brocklyn, J. R., Graler, M. H., Bernhardt, G., Hobson, J. P., Lipp, M., and Spiegel, S. (2000) Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. *Blood* **95**, 2624-2629
267. Golfier, S., Kondo, S., Schulze, T., Takeuchi, T., Vassileva, G., Achtman, A. H., Graler, M. H., Abbondanzo, S. J., Wiekowski, M., Kremmer, E., Endo, Y., Lira, S. A., Bacon, K. B., and Lipp, M. (2010) Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4. *Faseb j* **24**, 4701-4710

268. Allende, M. L., Bektas, M., Lee, B. G., Bonifacino, E., Kang, J., Tuymetova, G., Chen, W., Saba, J. D., and Proia, R. L. (2011) Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. *J Biol Chem* **286**, 7348-7358
269. Rivera, J., Proia, R. L., and Olivera, A. (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. *Nat Rev Immunol* **8**, 753-763
270. Glickman, M., Malek, R. L., Kwitek-Black, A. E., Jacob, H. J., and Lee, N. H. (1999) Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein-coupled receptor, nrg-1. *Mol Cell Neurosci* **14**, 141-152
271. Im, D. S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G. J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., George, S. R., and Lynch, K. R. (2000) Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *J Biol Chem* **275**, 14281-14286
272. Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M. S., Calver, A. R., Duddy, G., Walsh, F. S., Pangalos, M. N., Arimura, N., Kaibuchi, K., Zalc, B., and Lubetzki, C. (2005) Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. *J Neurosci* **25**, 1459-1469
273. Walzer, T., Chiossone, L., Chaix, J., Calver, A., Carozzo, C., Garrigue-Antar, L., Jacques, Y., Baratin, M., Tomasello, E., and Vivier, E. (2007) Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. *Nat Immunol* **8**, 1337-1344
274. Jenne, C. N., Enders, A., Rivera, R., Watson, S. R., Bankovich, A. J., Pereira, J. P., Xu, Y., Roots, C. M., Beilke, J. N., Banerjee, A., Reiner, S. L., Miller, S. A., Weinmann, A. S., Goodnow, C. C., Lanier, L. L., Cyster, J. G., and Chun, J. (2009) T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. *J Exp Med* **206**, 2469-2481
275. Malek, R. L., Toman, R. E., Edsall, L. C., Wong, S., Chiu, J., Letterle, C. A., Van Brocklyn, J. R., Milstien, S., Spiegel, S., and Lee, N. H. (2001) Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. *J Biol Chem* **276**, 5692-5699

276. Niedernberg, A., Scherer, C. R., Busch, A. E., and Kostenis, E. (2002) Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists. *Biochem Pharmacol* **64**, 1243-1250
277. O'Sullivan, C., and Dev, K. K. (2013) The structure and function of the S1P1 receptor. *Trends Pharmacol Sci* **34**, 401-412
278. Khandoga, A. L., Pandey, D., Welsch, U., Brandl, R., and Siess, W. (2011) GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques. *Cardiovasc Res* **90**, 157-164
279. Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., Iwata, C., Miyazono, K., Sakimura, K., Shimizu, T., and Ishii, S. (2010) LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. *Blood* **116**, 5060-5070
280. Noguchi, K., Ishii, S., and Shimizu, T. (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. *J Biol Chem* **278**, 25600-25606
281. Kotarsky, K., Boketoft, A., Bristulf, J., Nilsson, N. E., Norberg, A., Hansson, S., Owman, C., Sillard, R., Leeb-Lundberg, L. M., and Olde, B. (2006) Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. *J Pharmacol Exp Ther* **318**, 619-628
282. Lee, C. W., Rivera, R., Gardell, S., Dubin, A. E., and Chun, J. (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. *J Biol Chem* **281**, 23589-23597
283. Pasternack, S. M., von Kugelgen, I., Al Aboud, K., Lee, Y. A., Ruschendorf, F., Voss, K., Hillmer, A. M., Molderings, G. J., Franz, T., Ramirez, A., Nurnberg, P., Nothen, M. M., and Betz, R. C. (2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. *Nat Genet* **40**, 329-334
284. Yanagida, K., Masago, K., Nakanishi, H., Kihara, Y., Hamano, F., Tajima, Y., Taguchi, R., Shimizu, T., and Ishii, S. (2009) Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6\*. *J Biol Chem* **284**, 17731-17741

285. Amisten, S., Braun, O. O., Bengtsson, A., and Erlinge, D. (2008) Gene expression profiling for the identification of G-protein coupled receptors in human platelets. *Thromb Res* **122**, 47-57
286. Lee, Z., Cheng, C. T., Zhang, H., Subler, M. A., Wu, J., Mukherjee, A., Windle, J. J., Chen, C. K., and Fang, X. (2008) Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. *Mol Biol Cell* **19**, 5435-5445
287. Liu, Y. B., Kharode, Y., Bodine, P. V., Yaworsky, P. J., Robinson, J. A., and Billiard, J. (2010) LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. *J Cell Biochem* **109**, 794-800
288. Lee, C. W., Rivera, R., Dubin, A. E., and Chun, J. (2007) LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. *J Biol Chem* **282**, 4310-4317
289. Yanagida, K., Ishii, S., Hamano, F., Noguchi, K., and Shimizu, T. (2007) LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. *J Biol Chem* **282**, 5814-5824
290. Taghavi, P., Verhoeven, E., Jacobs, J. J., Lambooi, J. P., Stortelers, C., Tanger, E., Moolenaar, W. H., and van Lohuizen, M. (2008) In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. *Oncogene* **27**, 6806-6816
291. Lundequist, A., and Boyce, J. A. (2011) LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release. *PLoS One* **6**, e18192
292. Lin, M. E., Rivera, R. R., and Chun, J. (2012) Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. *J Biol Chem* **287**, 17608-17617
293. Lin, S., Yeruva, S., He, P., Singh, A. K., Zhang, H., Chen, M., Lamprecht, G., de Jonge, H. R., Tse, M., Donowitz, M., Hogema, B. M., Chun, J., Seidler, U., and Yun, C. C. (2010) Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. *Gastroenterology* **138**, 649-658

294. Lee, M., Choi, S., Hallden, G., Yo, S. J., Schichnes, D., and Aponte, G. W. (2009) P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. *Am J Physiol Gastrointest Liver Physiol* **297**, G641-654
295. Kano, K., Matsumoto, H., Inoue, A., Yukiura, H., Kanai, M., Chun, J., Ishii, S., Shimizu, T., and Aoki, J. (2019) Molecular mechanism of lysophosphatidic acid-induced hypertensive response. *Sci Rep* **9**, 2662
296. Mutoh, T., Rivera, R., and Chun, J. (2012) Insights into the pharmacological relevance of lysophospholipid receptors. *Br J Pharmacol* **165**, 829-844
297. Shimomura, Y., Garzon, M. C., Kristal, L., Shapiro, L., and Christiano, A. M. (2009) Autosomal recessive woolly hair with hypotrichosis caused by a novel homozygous mutation in the P2RY5 gene. *Exp Dermatol* **18**, 218-221
298. Pasternack, S. M., von Kugelgen, I., Muller, M., Oji, V., Traupe, H., Sprecher, E., Nothen, M. M., Janecke, A. R., and Betz, R. C. (2009) In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confirming the role of lipase H and lysophosphatidic acid in hair growth. *J Invest Dermatol* **129**, 2772-2776
299. Shinkuma, S., Akiyama, M., Inoue, A., Aoki, J., Natsuga, K., Nomura, T., Arita, K., Abe, R., Ito, K., Nakamura, H., Ujiie, H., Shibaki, A., Suga, H., Tsunemi, Y., Nishie, W., and Shimizu, H. (2010) Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA-PLA1alpha in autosomal recessive hypotrichosis. *Hum Mutat* **31**, 602-610
300. Lee, S., Jeong, J., Majewski, T., Scherer, S. E., Kim, M. S., Tuziak, T., Tang, K. S., Baggerly, K., Grossman, H. B., Zhou, J. H., Shen, L., Bondaruk, J., Ahmed, S. S., Samanta, S., Spiess, P., Wu, X., Filipek, S., McConkey, D., Bar-Eli, M., Issa, J. P., Benedict, W. F., and Czerniak, B. (2007) Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. *Proc Natl Acad Sci U S A* **104**, 13732-13737
301. Evans, R. M. (2005) The nuclear receptor superfamily: a rosetta stone for physiology. *Mol Endocrinol* **19**, 1429-1438
302. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruchart, J. C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs,

- M. R., Staels, B., Vidal, H., and Auwerx, J. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. *J Biol Chem* **272**, 18779-18789
303. Lehrke, M., and Lazar, M. A. (2005) The many faces of PPARgamma. *Cell* **123**, 993-999
304. Asami-Miyagishi, R., Iseki, S., Usui, M., Uchida, K., Kubo, H., and Morita, I. (2004) Expression and function of PPARgamma in rat placental development. *Biochem Biophys Res Commun* **315**, 497-501
305. Medina-Gomez, G., Virtue, S., Lelliott, C., Boiani, R., Campbell, M., Christodoulides, C., Perrin, C., Jimenez-Linan, M., Blount, M., Dixon, J., Zahn, D., Thresher, R. R., Aparicio, S., Carlton, M., Colledge, W. H., Kettunen, M. I., Seppanen-Laakso, T., Sethi, J. K., O'Rahilly, S., Brindle, K., Cinti, S., Oresic, M., Burcelin, R., and Vidal-Puig, A. (2005) The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. *Diabetes* **54**, 1706-1716
306. Weatherman, R. V., Fletterick, R. J., and Scanlan, T. S. (1999) Nuclear-receptor ligands and ligand-binding domains. *Annu Rev Biochem* **68**, 559-581
307. Yu, C., Markan, K., Temple, K. A., Deplewski, D., Brady, M. J., and Cohen, R. N. (2005) The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. *J Biol Chem* **280**, 13600-13605
308. Dowell, P., Ishmael, J. E., Avram, D., Peterson, V. J., Nevriy, D. J., and Leid, M. (1999) Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. *J Biol Chem* **274**, 15901-15907
309. Chen, J. D., and Evans, R. M. (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* **377**, 454-457
310. Zhang, C., Baker, D. L., Yasuda, S., Makarova, N., Balazs, L., Johnson, L. R., Marathe, G. K., McIntyre, T. M., Xu, Y., Prestwich, G. D., Byun, H. S., Bittman, R., and Tigyi, G. (2004) Lysophosphatidic acid induces neointima formation through PPARgamma activation. *J Exp Med* **199**, 763-774

311. Tsukahara, T., Tsukahara, R., Yasuda, S., Makarova, N., Valentine, W. J., Allison, P., Yuan, H., Baker, D. L., Li, Z., Bittman, R., Parrill, A., and Tigyi, G. (2006) Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. *J Biol Chem* **281**, 3398-3407
312. Nagle, C. A., Klett, E. L., and Coleman, R. A. (2009) Hepatic triacylglycerol accumulation and insulin resistance. *J Lipid Res* **50 Suppl**, S74-79
313. Wendel, A. A., Lewin, T. M., and Coleman, R. A. (2009) Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. *Biochim Biophys Acta* **1791**, 501-506
314. Yoshida, K., Nishida, W., Hayashi, K., Ohkawa, Y., Ogawa, A., Aoki, J., Arai, H., and Sobue, K. (2003) Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. *Circulation* **108**, 1746-1752
315. Bagga, S., Price, K. S., Lin, D. A., Friend, D. S., Austen, K. F., and Boyce, J. A. (2004) Lysophosphatidic acid accelerates the development of human mast cells. *Blood* **104**, 4080-4087
316. Leslie, D. S., Dascher, C. C., Cembrola, K., Townes, M. A., Hava, D. L., Hugendubler, L. C., Mueller, E., Fox, L., Roura-Mir, C., Moody, D. B., Vincent, M. S., Gumperz, J. E., Illarionov, P. A., Besra, G. S., Reynolds, C. G., and Brenner, M. B. (2008) Serum lipids regulate dendritic cell CD1 expression and function. *Immunology* **125**, 289-301
317. Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., and Spiegel, S. (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. *Science* **325**, 1254-1257
318. Panneer Selvam, S., De Palma, R. M., Oaks, J. J., Oleinik, N., Peterson, Y. K., Stahelin, R. V., Skordalakes, E., Ponnusamy, S., Garrett-Mayer, E., Smith, C. D., and Ogretmen, B. (2015) Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. *Sci Signal* **8**, ra58
319. Xia, P., Wang, L., Moretti, P. A., Albanese, N., Chai, F., Pitson, S. M., D'Andrea, R. J., Gamble, J. R., and Vadas, M. A. (2002) Sphingosine kinase

- interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. *J Biol Chem* **277**, 7996-8003
320. Strub, G. M., Paillard, M., Liang, J., Gomez, L., Allegood, J. C., Hait, N. C., Maceyka, M., Price, M. M., Chen, Q., Simpson, D. C., Kordula, T., Milstien, S., Lesnefsky, E. J., and Spiegel, S. (2011) Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. *Faseb j* **25**, 600-612
  321. Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., Shimada, N., Higo, T., Yokoshima, S., Fukuyama, T., Lee, V. M., Trojanowski, J. Q., Tomita, T., and Iwatsubo, T. (2011) BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. *J Neurosci* **31**, 6850-6857
  322. Choi, J. W., and Chun, J. (2013) Lysophospholipids and their receptors in the central nervous system. *Biochim Biophys Acta* **1831**, 20-32
  323. Yung, Y. C., Stoddard, N. C., Mirendil, H., and Chun, J. (2015) Lysophosphatidic Acid signaling in the nervous system. *Neuron* **85**, 669-682
  324. Karunakaran, I., and van Echten-Deckert, G. (2017) Sphingosine 1-phosphate - A double edged sword in the brain. *Biochim Biophys Acta* **1859**, 1573-1582
  325. Fukushima, N., Shano, S., Moriyama, R., and Chun, J. (2007) Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway. *Neurochem Int* **50**, 302-307
  326. Kingsbury, M. A., Rehen, S. K., Contos, J. J., Higgins, C. M., and Chun, J. (2003) Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. *Nat Neurosci* **6**, 1292-1299
  327. MacLennan, A. J., Devlin, B. K., Marks, L., Gaskin, A. A., Neitzel, K. L., and Lee, N. (2000) Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth. *Dev Neurosci* **22**, 283-295
  328. Broux, B., Stinissen, P., and Hellings, N. (2013) Which immune cells matter? The immunopathogenesis of multiple sclerosis. *Crit Rev Immunol* **33**, 283-306
  329. O'Sullivan, S., and Dev, K. K. (2017) Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases. *Neuropharmacology* **113**, 597-607

330. Zemann, B., Kinzel, B., Muller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., and Billich, A. (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. *Blood* **107**, 1454-1458
331. Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J Biol Chem* **277**, 21453-21457
332. Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science* **296**, 346-349
333. Chun, J., and Brinkmann, V. (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). *Discov Med* **12**, 213-228
334. Cohen, J. A., and Chun, J. (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. *Ann Neurol* **69**, 759-777
335. Lee, C. W., Choi, J. W., and Chun, J. (2010) Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. *Arch Pharm Res* **33**, 1567-1574
336. Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C. W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., and Chun, J. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. *Proc Natl Acad Sci U S A* **108**, 751-756
337. Sanford, M. (2014) Fingolimod: a review of its use in relapsing-remitting multiple sclerosis. *Drugs* **74**, 1411-1433
338. Li, Z. G., Yu, Z. C., Wang, D. Z., Ju, W. P., Zhan, X., Wu, Q. Z., Wu, X. J., Cong, H. M., and Man, H. H. (2008) Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. *Neurol Res* **30**, 366-369

339. Kimura, A., Ohmori, T., Kashiwakura, Y., Ohkawa, R., Madoiwa, S., Mimuro, J., Shimazaki, K., Hoshino, Y., Yatomi, Y., and Sakata, Y. (2008) Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. *Stroke* **39**, 3411-3417
340. Blondeau, N., Lai, Y., Tyndall, S., Popolo, M., Topalkara, K., Pru, J. K., Zhang, L., Kim, H., Liao, J. K., Ding, K., and Waeber, C. (2007) Distribution of sphingosine kinase activity and mRNA in rodent brain. *J Neurochem* **103**, 509-517
341. Wacker, B. K., Park, T. S., and Gidday, J. M. (2009) Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. *Stroke* **40**, 3342-3348
342. Pfeilschifter, W., Czech-Zechmeister, B., Sujak, M., Mirceska, A., Koch, A., Rami, A., Steinmetz, H., Foerch, C., Huwiler, A., and Pfeilschifter, J. (2011) Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia. *Biochem Biophys Res Commun* **413**, 212-217
343. Savitz, S. I., Dhallu, M. S., Malhotra, S., Mammis, A., Ocava, L. C., Rosenbaum, P. S., and Rosenbaum, D. M. (2006) EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. *Brain Res* **1118**, 168-175
344. Harrison, S. M., Reavill, C., Brown, G., Brown, J. T., Cluderay, J. E., Crook, B., Davies, C. H., Dawson, L. A., Grau, E., Heidbreder, C., Hemmati, P., Hervieu, G., Howarth, A., Hughes, Z. A., Hunter, A. J., Latcham, J., Pickering, S., Pugh, P., Rogers, D. C., Shilliam, C. S., and Maycox, P. R. (2003) LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. *Mol Cell Neurosci* **24**, 1170-1179
345. Santin, L. J., Bilbao, A., Pedraza, C., Matas-Rico, E., Lopez-Barroso, D., Castilla-Ortega, E., Sanchez-Lopez, J., Riquelme, R., Varela-Nieto, I., de la Villa, P., Suardiaz, M., Chun, J., De Fonseca, F. R., and Estivill-Torres, G. (2009) Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. *Genes Brain Behav* **8**, 772-784

346. Bowden, N. A., Weidenhofer, J., Scott, R. J., Schall, U., Todd, J., Michie, P. T., and Tooney, P. A. (2006) Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. *Schizophr Res* **82**, 175-183
347. Castilla-Ortega, E., Escuredo, L., Bilbao, A., Pedraza, C., Orio, L., Estivill-Torres, G., Santin, L. J., de Fonseca, F. R., and Pavon, F. J. (2014) 1-Oleoyl lysophosphatidic acid: a new mediator of emotional behavior in rats. *PLoS One* **9**, e85348
348. Yung, Y. C., Mutoh, T., Lin, M. E., Noguchi, K., Rivera, R. R., Choi, J. W., Kingsbury, M. A., and Chun, J. (2011) Lysophosphatidic acid signaling may initiate fetal hydrocephalus. *Sci Transl Med* **3**, 99ra87
349. Akahoshi, N., Ishizaki, Y., Yasuda, H., Murashima, Y. L., Shinba, T., Goto, K., Himi, T., Chun, J., and Ishii, I. (2011) Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2. *Epilepsy Behav* **22**, 659-665
350. Kumar, K., Kumar, A., Keegan, R. M., and Deshmukh, R. (2017) Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease. *Biomed Pharmacother* **98**, 297-307
351. Umemura, K., Yamashita, N., Yu, X., Arima, K., Asada, T., Makifuchi, T., Murayama, S., Saito, Y., Kanamaru, K., Goto, Y., Kohsaka, S., Kanazawa, I., and Kimura, H. (2006) Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. *Neurosci Lett* **400**, 97-100
352. Yi, H., Lee, S. J., Lee, J., Myung, C. S., Park, W. K., Lim, H. J., Lee, G. H., Kong, J. Y., and Cho, H. (2011) Sphingosylphosphorylcholine attenuated beta-amyloid production by reducing BACE1 expression and catalysis in PC12 cells. *Neurochem Res* **36**, 2083-2090
353. He, X., Huang, Y., Li, B., Gong, C. X., and Schuchman, E. H. (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. *Neurobiol Aging* **31**, 398-408
354. Gomez-Brouchet, A., Pchejetski, D., Brizuela, L., Garcia, V., Altie, M. F., Maddelein, M. L., Delisle, M. B., and Cuvillier, O. (2007) Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. *Mol Pharmacol* **72**, 341-349

355. Persson, E. K., Anderson, S., Wiklund, L. M., and Uvebrant, P. (2007) Hydrocephalus in children born in 1999-2002: epidemiology, outcome and ophthalmological findings. *Childs Nerv Syst* **23**, 1111-1118
356. Ueda, H. (2013) Lysophosphatidic Acid and Neuropathic Pain: Demyelination and LPA Biosynthesis. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 433-449, Wiley, Hoboken, NJ, USA
357. Ueda, H., Matsunaga, H., Olaposi, O. I., and Nagai, J. (2013) Lysophosphatidic acid: chemical signature of neuropathic pain. *Biochim Biophys Acta* **1831**, 61-73
358. Velasco, M., O'Sullivan, C., and Sheridan, G. K. (2017) Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain. *Neuropharmacology* **113**, 608-617
359. Inoue, M., Rashid, M. H., Fujita, R., Contos, J. J., Chun, J., and Ueda, H. (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. *Nat Med* **10**, 712-718
360. Knowlden, S., and Georas, S. N. (2014) The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. *J Immunol* **192**, 851-857
361. Tsai, H. C., and Han, M. H. (2016) Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation. *Drugs* **76**, 1067-1079
362. Arnon, T. I., Xu, Y., Lo, C., Pham, T., An, J., Coughlin, S., Dorn, G. W., and Cyster, J. G. (2011) GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. *Science* **333**, 1898-1903
363. Sanna, M. G., Wang, S. K., Gonzalez-Cabrera, P. J., Don, A., Marsolais, D., Matheu, M. P., Wei, S. H., Parker, I., Jo, E., Cheng, W. C., Cahalan, M. D., Wong, C. H., and Rosen, H. (2006) Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. *Nat Chem Biol* **2**, 434-441
364. Wei, S. H., Rosen, H., Matheu, M. P., Sanna, M. G., Wang, S. K., Jo, E., Wong, C. H., Parker, I., and Cahalan, M. D. (2005) Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. *Nat Immunol* **6**, 1228-1235

365. Foss, F. W., Jr., Snyder, A. H., Davis, M. D., Rouse, M., Okusa, M. D., Lynch, K. R., and Macdonald, T. L. (2007) Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. *Bioorg Med Chem* **15**, 663-677
366. Lo, C. G., Xu, Y., Proia, R. L., and Cyster, J. G. (2005) Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. *J Exp Med* **201**, 291-301
367. Nakasaki, T., Tanaka, T., Okudaira, S., Hirosawa, M., Umemoto, E., Otani, K., Jin, S., Bai, Z., Hayasaka, H., Fukui, Y., Aozasa, K., Fujita, N., Tsuruo, T., Ozono, K., Aoki, J., and Miyasaka, M. (2008) Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. *Am J Pathol* **173**, 1566-1576
368. Zhang, Y., Chen, Y. C., Krummel, M. F., and Rosen, S. D. (2012) Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. *J Immunol* **189**, 3914-3924
369. Bai, Z., Cai, L., Umemoto, E., Takeda, A., Tohya, K., Komai, Y., Veeraveedu, P. T., Hata, E., Sugiura, Y., Kubo, A., Suematsu, M., Hayasaka, H., Okudaira, S., Aoki, J., Tanaka, T., Albers, H. M., Ovaa, H., and Miyasaka, M. (2013) Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. *J Immunol* **190**, 2036-2048
370. Ye, X. (2008) Lysophospholipid signaling in the function and pathology of the reproductive system. *Hum Reprod Update* **14**, 519-536
371. Tokumura, A., Miyake, M., Nishioka, Y., Yamano, S., Aono, T., and Fukuzawa, K. (1999) Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of In vitro fertilization patients. *Biol Reprod* **61**, 195-199
372. Hama, K., Aoki, J., Inoue, A., Endo, T., Amano, T., Motoki, R., Kanai, M., Ye, X., Chun, J., Matsuki, N., Suzuki, H., Shibasaki, M., and Arai, H. (2007) Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. *Biol Reprod* **77**, 954-959

373. Ye, X., Herr, D. R., Diao, H., Rivera, R., and Chun, J. (2011) Unique uterine localization and regulation may differentiate LPA3 from other lysophospholipid receptors for its role in embryo implantation. *Fertil Steril* **95**, 2107-2113, 2113.e2101-2104
374. Guo, H., Gong, F., Luo, K. L., and Lu, G. X. (2013) Cyclic regulation of LPA3 in human endometrium. *Arch Gynecol Obstet* **287**, 131-138
375. Diao, H., Li, R., El Zowalaty, A. E., Xiao, S., Zhao, F., Dudley, E. A., and Ye, X. (2015) Deletion of Lysophosphatidic Acid Receptor 3 (Lpar3) Disrupts Fine Local Balance of Progesterone and Estrogen Signaling in Mouse Uterus During Implantation. *Biol Reprod* **93**, 123
376. Diao, H., Aplin, J. D., Xiao, S., Chun, J., Li, Z., Chen, S., and Ye, X. (2011) Altered spatiotemporal expression of collagen types I, III, IV, and VI in Lpar3-deficient peri-implantation mouse uterus. *Biol Reprod* **84**, 255-265
377. Ye, X., Skinner, M. K., Kennedy, G., and Chun, J. (2008) Age-dependent loss of sperm production in mice via impaired lysophosphatidic acid signaling. *Biol Reprod* **79**, 328-336
378. Ojala, M., Suomalainen, L., Pentikainen, M. O., Kovanen, P., Tenhunen, M., Erkkila, K., Toppari, J., and Dunkel, L. (2004) Protection from radiation-induced male germ cell loss by sphingosine-1-phosphate. *Biol Reprod* **70**, 759-767
379. di Villa Bianca, R., Sorrentino, R., Sorrentino, R., Imbimbo, C., Palmieri, A., Fusco, F., Maggi, M., De Palma, R., Cirino, G., and Mirone, V. (2006) Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. *J Pharmacol Exp Ther* **316**, 703-708
380. Nattapon, P., and Mills, G. B. (2013) Understanding the Functions of Lysophosphatidic Acid Receptors in Cancer In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 641-660, Wiley, Hoboken, NJ, USA
381. Yang, M., Zhong, W. W., Srivastava, N., Slavin, A., Yang, J., Hoey, T., and An, S. (2005) G protein-coupled lysophosphatidic acid receptors stimulate

- proliferation of colon cancer cells through the {beta}-catenin pathway. *Proc Natl Acad Sci U S A* **102**, 6027-6032
382. Lin, S., Lee, S. J., Shim, H., Chun, J., and Yun, C. C. (2010) The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine. *Am J Physiol Gastrointest Liver Physiol* **299**, G1128-1138
383. Ogretmen, B. (2018) Sphingolipid metabolism in cancer signalling and therapy. *Nat Rev Cancer* **18**, 33-50
384. Patmanathan, S. N., Wang, W., Yap, L. F., Herr, D. R., and Paterson, I. C. (2017) Mechanisms of sphingosine 1-phosphate receptor signalling in cancer. *Cell Signal* **34**, 66-75
385. Roodman, G. D. (2004) Mechanisms of bone metastasis. *Discov Med* **4**, 144-148
386. Peyruchaud, O., David, M., Macdonald, T. L., and Lynch, K. R. (2013) Lysophosphatidic Acid (LPA) Signaling in Bone Cancer. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 627-640, Wiley, Hoboken, NJ, USA
387. van der Weyden, L., Arends, M. J., Campbell, A. D., Bald, T., Wardle-Jones, H., Griggs, N., Velasco-Herrera, M. D., Tuting, T., Sansom, O. J., Karp, N. A., Clare, S., Gleeson, D., Ryder, E., Galli, A., Tuck, E., Cambridge, E. L., Voet, T., Macaulay, I. C., Wong, K., Spiegel, S., Speak, A. O., and Adams, D. J. (2017) Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. *Nature* **541**, 233-236
388. Rosa, R., Marciano, R., Malapelle, U., Formisano, L., Nappi, L., D'Amato, C., D'Amato, V., Damiano, V., Marfe, G., Del Vecchio, S., Zannetti, A., Greco, A., De Stefano, A., Carlomagno, C., Veneziani, B. M., Troncone, G., De Placido, S., and Bianco, R. (2013) Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. *Clin Cancer Res* **19**, 138-147
389. Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R., Walker, C. J., Ellis, J. J., Ferenchak, G., Dorrance, A. M., Paisie, C. A., Eiring, A. M., Ma, Y., Mao, H. C., Zhang, B., Wunderlich, M., May, P. C., Sun, C., Saddoughi, S. A., Bielawski, J., Blum, W., Klisovic, R. B., Solt, J. A., Byrd, J. C., Volinia, S., Cortes, J., Huettner, C. S., Koschmieder, S., Holyoake, T. L., Devine, S.,

- Caligiuri, M. A., Croce, C. M., Garzon, R., Ogretmen, B., Arlinghaus, R. B., Chen, C. S., Bittman, R., Hokland, P., Roy, D. C., Milojkovic, D., Apperley, J., Goldman, J. M., Reid, A., Mulloy, J. C., Bhatia, R., Marcucci, G., and Perrotti, D. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. *J Clin Invest* **123**, 4144-4157
390. Huang, X., Taeb, S., Jahangiri, S., Emmenegger, U., Tran, E., Bruce, J., Mesci, A., Korpela, E., Vesprini, D., Wong, C. S., Bristow, R. G., Liu, F. F., and Liu, S. K. (2013) miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. *Cancer Res* **73**, 6972-6986
391. Watson, C., Long, J. S., Orange, C., Tannahill, C. L., Mallon, E., McGlynn, L. M., Pyne, S., Pyne, N. J., and Edwards, J. (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. *Am J Pathol* **177**, 2205-2215
392. Tokumura, A., Akamatsu, Y., Yamada, S., and Tsukatani, H. (1978) Chemical and pharmacological properties of vasopressor phospholipid in crude soybean lecithin. *Agric. Biol. Chem.* **42**, 515–521
393. Schober, A., and Siess, W. (2012) Lysophosphatidic acid in atherosclerotic diseases. *Br J Pharmacol* **167**, 465-482
394. Rizza, C., Leitinger, N., Yue, J., Fischer, D. J., Wang, D. A., Shih, P. T., Lee, H., Tigyi, G., and Berliner, J. A. (1999) Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. *Lab Invest* **79**, 1227-1235
395. Zhou, Z., Subramanian, P., Sevilimis, G., Globke, B., Soehnlein, O., Karshovska, E., Megens, R., Heyll, K., Chun, J., Saulnier-Blache, J. S., Reinholz, M., van Zandvoort, M., Weber, C., and Schober, A. (2011) Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. *Cell Metab* **13**, 592-600
396. Li, M., Qian, M., Kyler, K., and Xu, J. (2018) Endothelial-Vascular Smooth Muscle Cells Interactions in Atherosclerosis. *Front Cardiovasc Med* **5**, 151
397. Hayashi, K., Takahashi, M., Nishida, W., Yoshida, K., Ohkawa, Y., Kitabatake, A., Aoki, J., Arai, H., and Sobue, K. (2001) Phenotypic modulation of vascular

- smooth muscle cells induced by unsaturated lysophosphatidic acids. *Circ Res* **89**, 251-258
398. Zhou, Z., Niu, J., and Zhang, Z. (2010) The role of lysophosphatidic acid receptors in phenotypic modulation of vascular smooth muscle cells. *Mol Biol Rep* **37**, 2675-2686
399. Subramanian, P., Karshovska, E., Reinhard, P., Megens, R. T. A., Zhou, Z., Akhtar, S., Schumann, U., Li, X. F., van Zandvoort, M., Ludin, C., Weber, C., and Schober, A. (2010) Lysophosphatidic Acid Receptors LPA1 and LPA3 Promote CXCL12-Mediated Smooth Muscle Progenitor Cell Recruitment in Neointima Formation. *Circulation Research* **107**, 96-U197
400. Swirski, F. K., Pittet, M. J., Kircher, M. F., Aikawa, E., Jaffer, F. A., Libby, P., and Weissleder, R. (2006) Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. *Proc Natl Acad Sci U S A* **103**, 10340-10345
401. Bolen, A. L., Naren, A. P., Yarlagadda, S., Beranova-Giorgianni, S., Chen, L., Norman, D., Baker, D. L., Rowland, M. M., Best, M. D., Sano, T., Tsukahara, T., Liliom, K., Igarashi, Y., and Tigyi, G. (2011) The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation. *J Lipid Res* **52**, 958-970
402. Charo, I. F., and Taub, R. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. *Nat Rev Drug Discov* **10**, 365-376
403. Tokumura, A., Fukuzawa, K., Isobe, J., and Tsukatani, H. (1981) Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. *Biochem Biophys Res Commun* **99**, 391-398
404. Schumacher, K. A., Classen, H. G., and Spath, M. (1979) Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). *Thromb Haemost* **42**, 631-640
405. Tokumura, A., Sinomiya, J., Kishimoto, S., Tanaka, T., Kogure, K., Sugiura, T., Satouchi, K., Waku, K., and Fukuzawa, K. (2002) Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. *Biochem J* **365**, 617-628

406. Haseruck, N., Erl, W., Pandey, D., Tigyi, G., Ohlmann, P., Ravanat, C., Gachet, C., and Siess, W. (2004) The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y(1) and P2Y(12) receptors. *Blood* **103**, 2585-2592
407. Khandoga, A. L., Fujiwara, Y., Goyal, P., Pandey, D., Tsukahara, R., Bolen, A., Guo, H., Wilke, N., Liu, J., Valentine, W. J., Durgam, G. G., Miller, D. D., Jiang, G., Prestwich, G. D., Tigyi, G., and Siess, W. (2008) Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin. *Platelets* **19**, 415-427
408. Pamuklar, Z., Lee, J. S., Cheng, H. Y., Panchatcharam, M., Steinhubl, S., Morris, A. J., Charnigo, R., and Smyth, S. S. (2008) Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. *Arterioscler Thromb Vasc Biol* **28**, 555-561
409. Dohi, T., Miyauchi, K., Ohkawa, R., Nakamura, K., Kishimoto, T., Miyazaki, T., Nishino, A., Nakajima, N., Yaginuma, K., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., Shimada, K., Yatomi, Y., and Daida, H. (2012) Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. *Clin Chim Acta* **413**, 207-212
410. Dohi, T., Miyauchi, K., Ohkawa, R., Nakamura, K., Kurano, M., Kishimoto, T., Yanagisawa, N., Ogita, M., Miyazaki, T., Nishino, A., Yaginuma, K., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., Shimada, K., Daida, H., and Yatomi, Y. (2013) Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. *Atherosclerosis* **229**, 192-197
411. Levkau, B. (2013) Sphingosine 1-Phosphate (S1P) Signaling in Cardiovascular Physiology and Disease. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 283-312, Wiley, Hoboken, NJ, USA
412. Avraham-Davidi, I., Grunspan, M., and Yaniv, K. (2013) Lipid signaling in the endothelium. *Exp Cell Res* **319**, 1298-1305
413. Keul, P., Sattler, K., and Levkau, B. (2007) HDL and its sphingosine-1-phosphate content in cardioprotection. *Heart Fail Rev* **12**, 301-306
414. Nofer, J. R., Bot, M., Brodde, M., Taylor, P. J., Salm, P., Brinkmann, V., van Berkel, T., Assmann, G., and Biessen, E. A. (2007) FTY720, a synthetic

- sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. *Circulation* **115**, 501-508
415. Klingenberg, R., Nofer, J. R., Rudling, M., Bea, F., Blessing, E., Preusch, M., Grone, H. J., Katus, H. A., Hansson, G. K., and Dengler, T. J. (2007) Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. *Arterioscler Thromb Vasc Biol* **27**, 2392-2399
416. Clay, H., Wilsbacher, L. D., Wilson, S. J., Duong, D. N., McDonald, M., Lam, I., Park, K. E., Chun, J., and Coughlin, S. R. (2016) Sphingosine 1-phosphate receptor-1 in cardiomyocytes is required for normal cardiac development. *Dev Biol* **418**, 157-165
417. Cannavo, A., Liccardo, D., Komici, K., Corbi, G., de Lucia, C., Femminella, G. D., Elia, A., Bencivenga, L., Ferrara, N., Koch, W. J., Paolocci, N., and Rengo, G. (2017) Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. *Front Pharmacol* **8**, 556
418. Bunemann, M., Brandts, B., zu Heringdorf, D. M., van Koppen, C. J., Jakobs, K. H., and Pott, L. (1995) Activation of muscarinic K<sup>+</sup> current in guinea-pig atrial myocytes by sphingosine-1-phosphate. *J Physiol* **489** ( Pt 3), 701-707
419. Bunemann, M., Liliom, K., Brandts, B. K., Pott, L., Tseng, J. L., Desiderio, D. M., Sun, G., Miller, D., and Tigyi, G. (1996) A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1-phosphate in atrial myocytes. *Embo j* **15**, 5527-5534
420. Sanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M. Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., and Rosen, H. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. *J Biol Chem* **279**, 13839-13848
421. Fryer, R. M., Muthukumarana, A., Harrison, P. C., Nodop Mazurek, S., Chen, R. R., Harrington, K. E., Dinallo, R. M., Horan, J. C., Patnaude, L., Modis, L. K., and Reinhart, G. A. (2012) The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat. *PLoS One* **7**, e52985

422. Gergely, P., Nuesslein-Hildesheim, B., Guerini, D., Brinkmann, V., Traebert, M., Bruns, C., Pan, S., Gray, N. S., Hinterding, K., Cooke, N. G., Groenewegen, A., Vitaliti, A., Sing, T., Luttringer, O., Yang, J., Gardin, A., Wang, N., Crumb, W. J., Jr., Saltzman, M., Rosenberg, M., and Wallstrom, E. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. *Br J Pharmacol* **167**, 1035-1047
423. Knapp, M., Lisowska, A., Zabielski, P., Musial, W., and Baranowski, M. (2013) Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. *Prostaglandins Other Lipid Mediat* **106**, 53-61
424. Argraves, K. M., Sethi, A. A., Gazzolo, P. J., Wilkerson, B. A., Remaley, A. T., Tybjaerg-Hansen, A., Nordestgaard, B. G., Yeatts, S. D., Nicholas, K. S., Barth, J. L., and Argraves, W. S. (2011) S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. *Lipids Health Dis* **10**, 70
425. Smyth, S. S., Dong, A., Wheeler, J., Panchatcharam, M., and Morris, A. J. (2013) Lysophosphatidic Acid (LPA) Signaling and Cardiovascular Pathology. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 265-281, Wiley, Hoboken, NJ, USA
426. Tigyi, G., Hong, L., Yakubu, M., Parfenova, H., Shibata, M., and Leffler, C. W. (1995) Lysophosphatidic acid alters cerebrovascular reactivity in piglets. *Am J Physiol* **268**, H2048-2055
427. Yakubu, M. A., Liliom, K., Tigyi, G., and Leffler, C. W. (1996) Role of lysophosphatidic acid in endothelin-1- and hematoma-induced alteration of cerebral microcirculation. *Am. J. Physiol. (Comp. & Integrative Physiol.)* **42**, R703-R709
428. Montagnani, M., Chen, H., Barr, V. A., and Quon, M. J. (2001) Insulin-stimulated activation of eNOS is independent of Ca<sup>2+</sup> but requires phosphorylation by Akt at Ser(1179). *J Biol Chem* **276**, 30392-30398

429. Kou, R., Igarashi, J., and Michel, T. (2002) Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase. *Biochemistry* **41**, 4982-4988
430. Chen, H., Montagnani, M., Funahashi, T., Shimomura, I., and Quon, M. J. (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *J Biol Chem* **278**, 45021-45026
431. Chen, C., Ochoa, L. N., Kagan, A., Chai, H., Liang, Z., Lin, P. H., and Yao, Q. (2012) Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. *Atherosclerosis* **222**, 74-83
432. Aird, W. C. (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. *Circ Res* **100**, 158-173
433. Sandow, S. L., and Grayson, T. H. (2009) Limits of isolation and culture: intact vascular endothelium and BKCa. *Am J Physiol Heart Circ Physiol* **297**, H1-7
434. Liaw, L., and Schwartz, S. M. (1993) Comparison of gene expression in bovine aortic endothelium in vivo versus in vitro. Differences in growth regulatory molecules. *Arteriosclerosis, Thrombosis, and Vascular Biology* **13**, 985-993
435. Chappell, D., Jacob, M., Paul, O., Rehm, M., Welsch, U., Stoeckelhuber, M., Conzen, P., and Becker, B. F. (2009) The glycocalyx of the human umbilical vein endothelial cell: an impressive structure ex vivo but not in culture. *Circ Res* **104**, 1313-1317
436. Davies, P. F. (1995) Flow-mediated endothelial mechanotransduction. *Physiol Rev* **75**, 519-560
437. Chabowski, D. S., Kadlec, A. O., Ait-Aissa, K., Hockenberry, J. C., Pearson, P. J., Beyer, A. M., and Gutterman, D. D. (2018) Lysophosphatidic acid acts on LPA1 receptor to increase H<sub>2</sub> O<sub>2</sub> during flow-induced dilation in human adipose arterioles. *Br J Pharmacol* **175**, 4266-4280
438. Niioka, T., Ohata, H., Momose, K., and Honda, K. (2013) Lysophosphatidic acid induces shear stress-dependent contraction in mouse aortic strip in situ. *J Cardiovasc Pharmacol* **62**, 530-538
439. Tosaka, M., Okajima, F., Hashiba, Y., Saito, N., Nagano, T., Watanabe, T., Kimura, T., and Sasaki, T. (2001) Sphingosine 1-phosphate contracts canine

- basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. *Stroke* **32**, 2913-2919
440. Waeber, C. (2013) Sphingosine 1-Phosphate (S1P) Signaling and the Vasculature. In *Lysophospholipid Receptors Signaling and Biochemistry* (Chun, J., ed) pp. 313-347, Wiley, Hoboken, NJ, USA
441. Salomone, S., Potts, E. M., Tyndall, S., Ip, P. C., Chun, J., Brinkmann, V., and Waeber, C. (2008) Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. *Br J Pharmacol* **153**, 140-147
442. Hemmings, D. G., Hudson, N. K., Halliday, D., O'Hara, M., Baker, P. N., Davidge, S. T., and Taggart, M. J. (2006) Sphingosine-1-phosphate acts via rho-associated kinase and nitric oxide to regulate human placental vascular tone. *Biol Reprod* **74**, 88-94
443. Olivera, A., Eisner, C., Kitamura, Y., Dillahunt, S., Allende, L., Tuymetova, G., Watford, W., Meylan, F., Diesner, S. C., Li, L., Schnermann, J., Proia, R. L., and Rivera, J. (2010) Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice. *J Clin Invest* **120**, 1429-1440
444. Hopson, K. P., Truelove, J., Chun, J., Wang, Y., and Waeber, C. (2011) S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells. *Am J Physiol Cell Physiol* **300**, C919-926
445. Nofer, J. R., van der Giet, M., Tolle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H. A., Tietge, U. J., Godecke, A., Ishii, I., Kleuser, B., Schafers, M., Fobker, M., Zidek, W., Assmann, G., Chun, J., and Levkau, B. (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J Clin Invest* **113**, 569-581
446. Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., von Wnuck Lipinski, K., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., and Van der Giet, M. (2005) Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. *Circ Res* **96**, 913-920

447. Igarashi, J., and Michel, T. (2000) Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. *J Biol Chem* **275**, 32363-32370
448. Igarashi, J., Miyoshi, M., Hashimoto, T., Kubota, Y., and Kosaka, H. (2007) Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. *Br J Pharmacol* **150**, 470-479
449. Igarashi, J., Erwin, P. A., Dantas, A. P., Chen, H., and Michel, T. (2003) VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. *Proc Natl Acad Sci U S A* **100**, 10664-10669
450. Yang, A. H., Ishii, I., and Chun, J. (2002) In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. *Biochim Biophys Acta* **1582**, 197-203
451. Wirth, A., Benyo, Z., Lukasova, M., Leutgeb, B., Wettschureck, N., Gorbey, S., Orsy, P., Horvath, B., Maser-Gluth, C., Greiner, E., Lemmer, B., Schutz, G., Gutkind, J. S., and Offermanns, S. (2008) G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nat Med* **14**, 64-68
452. Mallem, Y., Holopherne, D., Reculeau, O., Le Coz, O., Desfontis, J. C., and Gogny, M. (2005) beta-adrenoceptor-mediated vascular relaxation in spontaneously hypertensive rats. *Autonomic Neuroscience-Basic & Clinical* **118**, 61-67
453. van Meijeren, C. E., Vleeming, W., van de Kuil, T., Manni, J., Kegler, D., Hendriksen, C. F. M., and de Wildt, D. J. (2004) In vivo pertussis toxin treatment reduces contraction of rat resistance arteries but not that of mouse trachea. *European Journal of Pharmacology* **488**, 127-135
454. Horvath, B., Orsy, P., and Benyo, Z. (2005) Endothelial NOS-mediated relaxations of isolated thoracic aorta of the C57BL/6J mouse: a methodological study. *J Cardiovasc Pharmacol* **45**, 225-231
455. Heise, C. E., Santos, W. L., Schreihof, A. M., Heasley, B. H., Mukhin, Y. V., Macdonald, T. L., and Lynch, K. R. (2001) Activity of 2-substituted

- lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. *Mol Pharmacol* **60**, 1173-1180
456. Tamaruya, Y., Suzuki, M., Kamura, G., Kanai, M., Hama, K., Shimizu, K., Aoki, J., Arai, H., and Shibasaki, M. (2004) Identifying specific conformations by using a carbohydrate scaffold: discovery of subtype-selective LPA-receptor agonists and an antagonist. *Angew Chem Int Ed Engl* **43**, 2834-2837
457. Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., Yagi, M., Sato, M., Suzuki, R., Murooka, H., Sakai, T., Nishitoba, T., Im, D. S., Nochi, H., Tamoto, K., Tomura, H., and Okajima, F. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. *Mol Pharmacol* **64**, 994-1005
458. Fischer, D. J., Nusser, N., Virag, T., Yokoyama, K., Wang, D., Baker, D. L., Bautista, D., Parrill, A. L., and Tigyi, G. (2001) Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. *Mol Pharmacol* **60**, 776-784
459. Petitcolin, M. A., Vandeputte, C., Spitzbarth-Regrigny, E., Bueb, J. L., Capdeville-Atkinson, C., and Tschirhart, E. (2001) Lack of involvement of pertussis toxin-sensitive G-proteins in norepinephrine-induced vasoconstriction of rat aorta smooth muscle. *Biochemical Pharmacology* **61**, 485-491
460. Li, H., Wang, D., Zhang, H., Kirmani, K., Zhao, Z., Steinmetz, R., and Xu, Y. (2009) Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. *Mol Cancer Ther* **8**, 1692-1701
461. Tokumura, A., Fukuzawa, K., and Tsukatani, H. (1982) Contractile actions of lysophosphatidic acids with a chemically-defined fatty acyl group on longitudinal muscle from guinea-pig ileum. *J Pharm Pharmacol* **34**, 514-516
462. Sellers, M. M., and Stallone, J. N. (2008) Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. *American Journal of Physiology-Heart and Circulatory Physiology* **294**, H1978-H1986
463. Nebigil, C., and Malik, K. U. (1993) Alpha adrenergic receptor subtypes involved in prostaglandin synthesis are coupled to Ca<sup>++</sup> channels through a

- pertussis toxin-sensitive guanine nucleotide-binding protein. *J Pharmacol Exp Ther* **266**, 1113-1124
464. LaBelle, E. F., and Polyak, E. (1998) Norepinephrine stimulates arachidonic acid release from vascular smooth muscle via activation of cPLA2. *Am J Physiol* **274**, C1129-1137
465. Mong, S., Wu, H. L., Clark, M. A., Gleason, J. G., and Crooke, S. T. (1986) Leukotriene D4 receptor-mediated synthesis and release of arachidonic acid metabolites in guinea pig lung: induction of thromboxane and prostacyclin biosynthesis by leukotriene D4. *J Pharmacol Exp Ther* **239**, 63-70
466. Ruisanchez, É., Dancs, P., Kerék, M., Németh, T., Faragó, B., Balogh, A., Patil, R., Jennings, B. L., Liliom, K., Malik, K. U., Smrcka, A. V., Tigyi, G., and Benyó, Z. (2014) Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. *FASEB J* **28**, 880-890
467. Tokumura, A., Yotsumoto, T., Masuda, Y., and Tanaka, S. (1995) Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats. *Res Commun Mol Pathol Pharmacol* **90**, 96-102
468. Yakubu, M. A., Liliom, K., Tigyi, G. J., and Leffler, C. W. (1997) Role of lysophosphatidic acid in endothelin-1- and hematoma-induced alteration of cerebral microcirculation. *Am J Physiol* **273**, R703-709
469. Ren, Y., Guo, L., Tang, X., Apparsundaram, S., Kitson, C., Deguzman, J., Fuentes, M. E., Coyle, L., Majmudar, R., Allard, J., Truitt, T., Hamid, R., Chen, Y., Qian, Y., and Budd, D. C. (2013) Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. *Microvasc Res* **85**, 59-67
470. Rother, E., Brandl, R., Baker, D. L., Goyal, P., Gebhard, H., Tigyi, G., and Siess, W. (2003) Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. *Circulation* **108**, 741-747
471. Chen, H. (2018) Role of thromboxane A2 signaling in endothelium-dependent contractions of arteries. *Prostaglandins Other Lipid Mediat* **134**, 32-37

472. Ohata, H., Ikeuchi, T., Kamada, A., Yamamoto, M., and Momose, K. (2001) Lysophosphatidic Acid Positively Regulates the Fluid Flow-Induced Local Ca<sup>2+</sup> Influx in Bovine Aortic Endothelial Cells. *Circulation Research* **88**, 925-932
473. Ohata, H., Yamada, H., and Momose, K. (2011) Lysophosphatidic acid induces shear stress-dependent Ca<sup>2+</sup> influx in mouse aortic endothelial cells in situ. *Experimental Physiology* **96**, 468-475
474. Shibata, K., Miyazaki, T., Ohata, H., and Honda, K. (2011) Shear Stress-dependent Effects of Lysophosphatidic Acid on Agonist-induced Vasomotor Responses in Rat Mesenteric Artery. *Journal of Cardiovascular Pharmacology* **57**, 604-610
475. Tokumura, A., Yube, N., Fujimoto, H., and Tsukatani, H. (1991) Lysophosphatidic acids induce contraction of rat isolated colon by two different mechanisms. *J Pharm Pharmacol* **43**, 774-778
476. Ohata, H., Seito, N., Aizawa, H., Nobe, K., and Momose, K. (1995) Sensitizing effect of lysophosphatidic acid on mechanoreceptor-linked response in cytosolic free Ca<sup>2+</sup> concentration in cultured smooth muscle cells. *Biochem Biophys Res Commun* **208**, 19-25
477. Ohata, H., Aizawa, H., and Momose, K. (1996) Mechanisms of mechanical stress-induced Ca<sup>(2+)</sup>-mobilization sensitized by lysophosphatidic acid in cultured smooth muscle cells. *Life Sci* **58**, 2217-2223
478. Sasaki, T., Wakai, S., Asano, T., Takakura, K., and Sano, K. (1982) Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. *J Neurosurg* **57**, 74-82
479. Chan, R. C., Durity, F. A., Thompson, G. B., Nugent, R. A., and Kendall, M. (1984) The role of the prostacyclin-thromboxane system in cerebral vasospasm following induced subarachnoid hemorrhage in the rabbit. *J Neurosurg* **61**, 1120-1128

## 11. Publications

### 11.1. Publication directly related to this thesis

Ruisanchez, E., **Dancs, P.**, Kerek, M., Nemeth, T., Farago, B., Balogh, A., Patil, R., Jennings, B. L., Liliom, K., Malik, K. U., Smrcka, A. V., Tigyi, G., and Benyo, Z.: Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. *FASEB J.* 2014 Feb; 28(2): 880-90

**Dancs, P. T.**, Ruisanchez, E., Balogh, A., Panta, C. R., Miklos, Z., Nusing, R. M., Aoki, J., Chun, J., Offermanns, S., Tigyi, G., and Benyo, Z.: LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction. *FASEB J.* 2017 Apr; 31(4): 1547-1555

### 11.2. Publications not related to this thesis

Iring, A., Jin, Y.-J., Albarrán-Juárez, J., Siragusa, M., Wang, S., **Dancs, P. T.**, Nakayama, A., Tonack, S., Chen, M., Künne, C., Sokol, A. M., Günther, S., Martínez, A., Fleming, I., Wettschurek, N., Graumann, J., Weinstein, L. S., and Offermanns, S.: Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure. *J Clin Invest.* 2019 Jun; 129(7): 2775-2791

## 12. Acknowledgement

First of all, I am deeply indebted to my supervisor Prof. Dr. Zoltán Benyó, for letting me join his group as a medical student in 2011 and for introducing and guiding me in the scientific world. His enthusiasm and knowledge inspired me during the whole time we worked together for which I am thankful.

I would like to express my gratitude to Prof. Dr. Gábor Tigyi who, as one of the pioneers of the field, introduced our group to the leading scientists of the lysophospholipid biology. Furthermore, his instructions, remarks and advices forged my way of thinking not only in the field of lysophospholipids but in general scientific and medical issues as well.

I would like to thank Prof. Dr. Stefan Offermanns for letting me join his laboratory for a half year, through which I had the privilege to gain insight into the work of one of the leading labs in Europe.

I am grateful to Dr. András Iring for his friendship, instructions, guidance and patience while teaching me during my time in Germany.

I would like to extend my thanks to the former and present colleagues of our laboratory, Dr. Éva Ruisanchez, Dr. Cecília Rita Panta, Margit Kerék, Dr. Andrea Balogh, Nóra Kerkovits, László Hricisák, Ágnes Fülöp and Dr. Bernadett Faragó for their friendship, help and the time we spent together in the lab. I thank Dr. András Kucsa for graphic artwork of figure 26.

I thank all the co-authors in our publications for their contribution.

The scientific work presented in this thesis was supported by the grants K-112964, K-125174 and NVKP\_16-1-2016-0042 provided by the National Office for Research, Improvement and Innovation (NKFIH).

Finally yet importantly, I would like to thank my parents for their love, help and continuous support throughout my medical and PhD studies.